Compounds and their use in treating cancer
Patent Information
- Application Number
- EP2023702752
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-01-21
- Filing Date
- 2023-01-20
- Publication Date
- 2024-11-27
AI Technical Summary
Current treatments for prostate cancer, particularly castrate-resistant prostate cancer (CRPC), face challenges due to resistance mechanisms such as AR amplification, mutation, or the generation of splice variants that limit the effectiveness of existing antiandrogen therapies, and there is a need for alternative AR inhibitors that can target both wild-type and clinically relevant mutated forms of the androgen receptor (AR) while minimizing off-target activity.
Development of Proteolysis Targeting Chimera (PROTAC) compounds that bind to the androgen receptor (AR) and recruit an E3 ubiquitin ligase like cereblon for targeted degradation, specifically designed to incorporate AR binding units effective against both wild-type and mutated AR forms, with a linker connecting the binding units to ensure selective AR degradation and minimize off-target effects.
The PROTAC compounds demonstrate enhanced selectivity and efficacy in degrading both wild-type and clinically relevant mutated AR forms, potentially offering a therapeutic benefit for prostate cancer, including metastatic CRPC, by reducing mitotoxicity and improving the treatment's safety profile.
Smart Images

Figure 1.1
Abstract
Description
[0001] Compounds and Their Use in Treating Cancer
[0002] FIELD
[0003] This specification relates to certain Proteolysis Targeting Chimera (PROTAC) compounds and, as a minimum, their ability to degrade the Androgen Receptor (AR) and therefore their use for the treatment of diseases or disorders dependent on the androgen receptor in mammals. Degradation of androgen receptors may provide, for example, an anti-tumour effect and accordingly this specification relates in part to the use of such compounds for the treatment of cancer and to pharmaceutical compositions containing them. It also relates to intermediate compounds that may be useful in the preparation of such PROTACs.
[0004] BACKGROUND
[0005] Traditional small molecule drugs reversibly (or sometimes irreversibly) bind to a target protein as a means of modulating a given biological activity. In contrast, PROTACs bind to their target proteins, but then bring about the target protein’s degradation. Having achieved this effect, the PROTAC is in theory able to repeat this process with another target protein. Accordingly, unlike with “traditional small molecule” inhibitors, the PROT AC-driven degradation mechanism can in theory operate in a sub- stoichiometric manner - meaning that more modest exposures of a PROTAC compound could still achieve a desired level of efficacy in vivo. In practice this can mean that the degradation power (DC50 and Dmax) of a PROTAC can have an improved effect than that reflected only by its binding affinity.
[0006] At a simplistic level, PROTAC molecules are often described as having three parts - (1) a part that is capable of binding to the target protein to be degraded, (2) a second part that is capable of binding to an E3 ubiquitin ligase, and finally, a linker that connects (1) and (2) together.
[0007] In use, the PROTAC binds to both the target protein and E3 ubiquitin ligase simultaneously to form a ternary complex. The E3 ligase then recruits an E2 conjugating enzyme to the ternary complex, which ubiquitinates the target protein. This has the effect of labelling the target protein for degradation by the cell’ s proteasome machinery. A PROTAC can then dissociate from the target protein and initiate another cycle of this process in a catalytic manner. Meanwhile, the ubiquitinated target proteins are recognized and degraded by the cell’s proteasome machinery.
[0008] This PROTAC-mediated approach may be valuable as a method of treating certain diseases where the targeted degradation of specific bodily proteins may be beneficial, for example in the treatment of cancer. One such cancer-related target is the androgen receptor.
[0009] The androgen receptor (AR) belongs to the steroid hormone group of nuclear receptors and is a ligand-dependent transcription factor which controls the expression of a range of genes involved in growth and survival of prostate cells. AR is composed of four distinct domains: the N-terminal domain (NTD), DNA binding domain (DBD), a hinge region which allows the N- and C-termini to interact and a C-terminal ligand binding domain (LBD). Androgens such as testosterone and its derivative dihydrotestosterone (DHT) bind to the AR ligand binding domain which releases AR chaperone proteins allowing AR to dimerise and translocate from the cytoplasm into the nucleus. Within the nucleus receptor dimers bind to androgen response elements (AREs) in the promoters of androgen responsive genes such as PSA and FKBP5. The AR signalling pathway is critical for normal prostate development and male sexual differentiation fails to occur in the absence of androgens or without a functioning AR.
[0010] The relationship between androgens and prostate cancer was first discovered in a seminal study by Huggins and Hodges in 1941 and subsequent work has shown that androgen deprivation therapy is highly effective in the treatment of recurrent prostate cancer. However, despite good responses initially most tumour cells adapt to low androgen levels and patients relapse within a few years developing a disease state known as castrate resistant prostate cancer (CRPC). Several second generation antiandrogens have been approved by the US FDA for the treatment of CRPC. These include enzalutamide, apalutamide and darolutamide, which all compete with androgens for binding to the ligand binding domain. As well as antagonising the AR, preventing its activation, they also inhibit nuclear translocation and DNA binding thus effectively shutting down AR signalling. In contrast abiraterone acetate is an androgen biosynthesis inhibitor which targets cytochrome p450 enzyme 17R-hydroxlase-17,20-lyase (CYP17). Testosterone is processed in the testes and adrenal glands by CYP17 and therefore inhibition of this enzyme inhibits prostate tumour growth by decreasing circulating androgen levels.
[0011] Whilst the above-mentioned drugs significantly prolong survival of patients with late stage prostate cancer they are not curative and resistance inevitably occurs. However, it is clear that the AR remains central to the progression of CRPC meaning there is still a need to develop alternative AR inhibitors. Several resistance mechanisms have been identified including AR amplification, mutation or the generation of splice variants that lack the ligand binding domain. Mutations in the ligand binding domain, for example F877L or L702H, can convert antagonists into agonists or allow the receptor to utilise alternative steroid hormones such as glucocorticoids or progesterone. Agents that degrade AR, removing it from the cell could therefore help tackle these forms of resistance. As such, AR PROTACs, which bind the ligand binding domain of the androgen receptor and simultaneously recruit an E3 ligase such as cereblon leading to ubiquitination and degradation of AR via the proteasome, could offer therapeutic benefit to patients with prostate cancer, particularly metastatic CRPC. AR PROTACs may also be useful against AR+ breast cancer.
[0012] Given that the above-mentioned resistance mutations that can occur in the ligand binding domain and may limit the effectiveness of known CRPC treatments, it would be beneficial to develop AR degrading PROTACs that do not just target the “wild-type” AR, but which are also effective in degrading clinically relevant mutated forms of AR too.
[0013] Whichever target protein binding unit (1) is used at one end of a PROTAC’s linker unit, a fundamental element that must always be present at the other end of a PROTAC molecule is a unit (2) that helps to direct the tagging of the target protein for degradation, for example an E3 ubiquitin ligase cereblon binder unit. Scientific endeavours have already provided a number of such E3 ubiquitin ligase cereblon binder units and further examples are demonstrated hereinafter by the present researchers.
[0014] WO2018 / 071606 describes certain PROTAC compounds said to be AR degraders.
[0015] As with “traditional small molecule” binders and PROTACs alike, there is always the issue of “off- target” activity in vivo which can be important to avoid in the development of safe and effective drug treatments. In other words, a given binding unit may be very potent against the intended target, but if it is inadvertently potent against other unintended biological targets in the human body, it may cause unacceptable toxicities, side effects and so on.
[0016] It is therefore an ongoing challenge to develop potent molecules for pharmaceutical use that are also suitably selective - i.e. avoiding inhibition / binding / degradation of unintended biological targets in vivo.
[0017] For example, the present researchers have surprisingly found that certain compounds of this specification show beneficial selectivity that is expected to avoid or reduce the risk of mitotoxicity in vivo.
[0018] As part of developing current and future PROTAC drug treatments for medicinal use (e.g. cancer), there is still a need to develop androgen receptor PROTAC compounds that have a combination of beneficial / improved properties. As mentioned above, development of PROTACs that target both wild-type AR and one or more clinically relevant mutated forms of AR is an example of such a combination effect.
[0019] Furthermore, there is a need to develop androgen receptor binder units that can be incorporated into a PROTAC, regardless of which an E3 ubiquitin ligase cereblon binder unit is selected for use at the other end of the molecule.
[0020] Other properties of interest during pharmaceutical discovery and development of such PROTACs may relate to selectivity profile, absorption / bioavailability, distribution, metabolism, elimination, toxicity and side-effect profile, stability, manufacturability and so on.
[0021] SUMMARY
[0022] The compounds of this specification provide, as a minimum, potent AR binding units suitable for incorporation into PROTAC compounds, and to PROTAC compounds containing such AR binding units together with an E3 ubiquitin ligase cereblon binder unit at the other end of the PROTAC molecule. Certain AR binding units are advantageously configured to degrade not only the wild-type AR, but also one or more clinically relevant mutant forms of AR too, for example L702H. Certain PROTAC compounds of this specification also have a surprisingly beneficial combination of properties, e.g. relating to AR degradation and selectivity / safety profile in combination.
[0023] This specification relates to the above-mentioned AR-binding units and to PROTAC compounds (and pharmaceutically acceptable salts thereof) that incorporate such AR binding units together with an E3 ubiquitin ligase cereblon binder unit (the two units being linked by a linker).
[0024] This specification also relates to pharmaceutical compositions containing such PROTACs (and pharmaceutically acceptable salts thereof) and their use in methods of treatment in the human or animal body, for example in the treatment or prevention of cancer. This specification also relates to processes and intermediate compounds (and salts thereof) involved in the preparation of said PROTACs.
[0025] According to the first aspect of this specification there is provided a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein:
[0026] X1is C & 0, 1 or 2 of X2, X3& X4is / are N, and are otherwise C: or
[0027] X3& X4are both C and are substituted by -X5=X6-X7=XS- with Xsattached to X3and with Xsattached to Xs, where 1 or 2 of X1, X2, Xs, X6, X7& Xsis / are N, and are otherwise C: p is 1 or 2 and X1is C attached to R1when X3& X4are not substituted by
[0028] -X5=X6-X7=X8-: and otherwise p is 0. I or 2: where: each R1is a substituent on any C atom at X1, X2, X3& X4, (or at X1, X2, Xs, X6, X7
[0029] & Xswhen X3& X4are substituted by -X5=X6-X7=X8-), and is / are independently selected from F, Cl, Ci-aalkyl and Ci-aalkoxy, wherein said Ci-aalkyl and C i-aalkoxy may be independently optionally substituted by one or more F; n is 0, 1 or 2; m is 0 or 1 ;
[0030] Q is CH or N when n & m are both other than 0 and otherwise Q is CH;
[0031] R2aand R2bare substituents on the same or different C atoms other than at Q, each independently selected from H, F and Ci-aalkyl, or R2a& R2btogether form a -(CH2)r- group where r is 1 , 2 or 3 ;
[0032] 0, 1 or 2 of Y1, Y2, Y3& Y4is / are N, and are otherwise C; each R3is a substituent on any C atom at Y1, Y2, Y3& Y4, and is / are independently selected from F, Cl, CN, C i-aalkyl and Ci-aalkoxy, wherein said C i-aalkyl and C i-aalkoxy may be independently optionally substituted by one or more F ; q is 0, 1 or 2;
[0033] Linker is a saturated or a partially or fully unsaturated framework comprising C and H atoms and at least one heteroatom, wherein said framework has end points of attachment ‘a’ and ‘b’ and a minimum length of from 6 to 26 atoms between ‘a’ and ‘b’; wherein said framework may include one or more straight and / or branched chains and / or rings and is optionally substituted on any available C atom(s) by one or more F; and
[0034] W is an E3 ubiquitin ligase cereblon binder unit.
[0035] This specification also describes, in part, a pharmaceutical composition which comprises a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
[0036] This specification also describes, in part, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in therapy. This specification also describes, in part, a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer.
[0037] This specification also describes, in part, a method for treating cancer in a warm-blooded animal in need of such treatment, which comprises administering to the warm-blooded animal a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
[0038] As shown in the experimental section hereinafter, the present researchers have not just developed a range of beneficial AR binding units, but gained an understanding about where such binding units can incorporate a linker (leading to an E3 ubiquitin ligase cereblon binder unit) without it interfering with their AR binding capability. Accordingly the present researchers understand that when incorporating their AR binding units into a PROTAC, the linker of said PROTAC should not attach at the left or central rings in Formula (I) shown hereinabove, but may suitably attach at the specified position on the right-hand ring in the compound of Formula (I) as shown herein.
[0039] Therefore, in a further aspect of this specification there is provided a PROTAC compound or a pharmaceutically acceptable salt thereof, containing an E3 ubiquitin ligase cereblon binder unit and an AR binding unit of Formula (la): where R1, p, X1, X2, X3, X4, n, m, R2a, R2b, Q, Y1, Y2, Y3, Y4, R3and q may take any of the values defined herein for each of these integers respectively.
[0040] For avoidance of doubt in Formula (la) indicates a point of connection via a single covalent bond to the remainder of the PROTAC compound.
[0041] In one embodiment there is provided a PROTAC compound or a pharmaceutically acceptable salt thereof, containing an E3 ubiquitin ligase cereblon binder unit linked to an AR binding unit of Formula (la) as described herein.
[0042] As described herein, the link between an E3 ubiquitin ligase cereblon binder unit and an AR binding unit of Formula (la) as shown hereinabove preferably has a length corresponding to the length of a linear chain of from 6 to 26 atoms, said atoms being linked by single covalent bonds and each selected from carbon or a heteroatom (i.e. O, N or S).
[0043] As described herein, the link between an E3 ubiquitin ligase cereblon binder unit and an AR binding unit of Formula (la) as shown hereinabove preferably has a length corresponding to the length of a linear chain of from 7 to 14 atoms, said atoms being linked by single covalent bonds and each selected from carbon or a heteroatom (i.e. O, N or S). In one embodiment, the link between an E3 ubiquitin ligase cereblon binder unit and an AR binding unit of Formula (la) as shown hereinabove preferably has a length corresponding to the length of a linear chain of from 6 to 26 atoms, said atoms being linked by single covalent bonds and each selected from C, N or O.
[0044] In one embodiment, the link between an E3 ubiquitin ligase cereblon binder unit and an AR binding unit of Formula (la) as shown hereinabove preferably has a length corresponding to the length of a linear chain of from 7 to 14 atoms, said atoms being linked by single covalent bonds and each selected from C, N or O.
[0045] It is to be understood that although a link length “corresponding to the length of [certain atoms in a chain]” it is not to be interpreted that this limits said link to said atoms, and for example sulfur atom(s) may also be present in the link even if S atoms are not included in the length descriptor.
[0046] As described herein, the link between an E3 ubiquitin ligase cereblon binder unit and an AR binding unit of Formula (la) as shown hereinabove preferably has a length of from 0.9 nm to 4 nm.
[0047] As described herein, the link between an E3 ubiquitin ligase cereblon binder unit and an AR binding unit of Formula (la) as shown hereinabove preferably has a length of from 1.0 nm to 2.2 nm.
[0048] In a further aspect of the specification there is provided an androgen receptor binding unit of Formula (la), as described herein, for use in a PROTAC compound (or pharmaceutically acceptable salt thereof) that also contains an E3 ubiquitin ligase cereblon binder unit.
[0049] In a further aspect of the specification there is provided an androgen receptor binding unit of Formula (la), as described herein, for use in a PROTAC compound (or pharmaceutically acceptable salt thereof) that is linked to an E3 ubiquitin ligase cereblon binder unit.
[0050] Accordingly, there is provided an androgen receptor binding unit of Formula (la), as described herein, for use in a PROTAC compound (or pharmaceutically acceptable salt thereof) where said PROTAC compound also contains an E3 ubiquitin ligase cereblon binder unit.
[0051] Accordingly, there is provided an androgen receptor binding unit of Formula (la), as described herein, for use in a PROTAC compound (or pharmaceutically acceptable salt thereof) where said PROTAC compound also contains an E3 ubiquitin ligase cereblon binder unit that is linked to said androgen receptor binding unit.
[0052] Accordingly, there is provided an androgen receptor binding unit of Formula (la), as described herein, for incorporation into a PROTAC compound (or pharmaceutically acceptable salt thereof) where said PROTAC compound also contains an E3 ubiquitin ligase cereblon binder unit.
[0053] Accordingly, there is provided an androgen receptor binding unit of Formula (la), as described herein, for incorporation into a PROTAC compound (or pharmaceutically acceptable salt thereof) where said PROTAC compound also contains an E3 ubiquitin ligase cereblon binder unit that is linked to said androgen receptor binding unit.
[0054] Therefore, there is provided an androgen receptor binding unit of Formula (la), as described herein, contained within a PROTAC compound (or a pharmaceutically acceptable salt thereof) where said PROTAC compound also contains an E3 ubiquitin ligase cereblon binder unit.
[0055] Therefore, there is provided an androgen receptor binding unit of Formula (la), as described herein, contained within a PROTAC compound (or a pharmaceutically acceptable salt thereof) where said PROTAC compound also contains an E3 ubiquitin ligase cereblon binder unit that is linked to said androgen receptor binding unit.
[0056] In one embodiment the link between androgen receptor binding unit of Formula (la) [as described above] and an E3 ubiquitin ligase cereblon binder unit is a Linker as defined according to any embodiment or claim herein, where the point of attachment shown in Formula (la) above connects to the ‘a’ point of connection on any Linker as defined herein.
[0057] DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
[0058] Many embodiments of this disclosure are detailed throughout the specification and will be apparent to a reader skilled in the art.
[0059] A pharmaceutically acceptable salt of a compound of Formula (I) or PROTAC compound described herein may be, for example, an acid-addition salt when said compound contains a basic functional group, such as an amine. An acid-addition salt may be formed using an inorganic acid or an organic acid. A pharmaceutically acceptable salt of said compound may be, for example, a base-addition salt when said compound contains an acidic functional group, such as a carboxylic acid. An acid-addition salt may be formed using an inorganic base or an organic base. “Pharmaceutically acceptable salt” is used to specify that the salt is suitable for use in the human or animal body. An example list of pharmaceutically acceptable salts can be found in the Handbook of Pharmaceutical Salts: Properties, Selection and Use, P. H. Stahl and C. G. Wermuth, editors, Weinheim / Zurich:Wiley-VCH / VHCA, 2002. A pharmaceutically acceptable salt of a compound of Formula (I) or PROTAC compound includes such salts that may be formed within the human or animal body after administration of said compound to said human or animal body.
[0060] As used herein the term “alkyl” includes straight chain, branched chain and cyclic alkyl groups and combinations thereof having the specified number of carbon atoms. Therefore, C i.vilkvl includes methyl, ethyl, w-propyl, isopropyl and cyclopropyl; and Ci.galkyl would include (4-isopropylcyclohexyl)methyl. The same principles apply to the term “alkoxy”. Similarly, as used herein the term “alkoxy” includes straight chain, branched chain and / or cyclic alkoxy groups having the specified number of carbon atoms. Therefore, Ci-aalkoxy includes methoxy, ethoxy, w-propoxy, isopropoxy and cyclopropoxy.
[0061] In this specification chemical abbreviations familiar to the skilled person may be used including for example “Me” = methyl, “Ef ’ = ethyl, “Pr” = propyl, “Bu” = butyl and “Ph” = phenyl.
[0062] Where the term “optionally” is used, it is intended that the subsequent feature may occur or may not occur. As such, use of the term “optionally” includes instances where the feature is present, and also instances where the feature is not present. For example, “methyl optionally substituted by one or more F” includes -CI L. -CH2F, -CHF2and -CF3.
[0063] The term “substituted” means that one or more hydrogens on the designated atom or group is replaced by the indicated substituent(s) provided that any atom(s) bearing such substituent(s) maintains its permitted valency where the skilled person understands that the standard valencies of carbon, nitrogen and oxygen are 4, 3 and 2 respectively. Therefore, “substituted on any available C atom(s)” is to be understood to mean that the substituent(s) is / are limited in their positioning (and / or potentially in their number) according to whether there are any hydrogen atoms remaining on the designated atom or group which could be replaced by said substituent(s).
[0064] The dashed bonds included in Z , " ", indicate the possibility that the bond may in each case be a single covalent bond or a double covalent bond - in accordance with the atom (or group of atoms) present at each of the XE, XE, XG, XHand XJpositions. The skilled person understands that the standard valencies of carbon, nitrogen and oxygen are as mentioned above, and as such they can understand whether each dashed bond should be interpreted as a single bond or a double bond in any given Z group in the compound of Formula (I). The same applies to the XE2, XE2, XG2, XH2and XJ2positions in ZA.
[0065] The term “adjacent” or “adjacent position” - for example in reference to XG, XHand XJof Z refers to the next closest position in the molecular chain / ring system. Accordingly, in the context of Z: XGand XHare adjacent each other, XHand XJare also adjacent each other, but XGis not adjacent XJ.
[0066] The term “saturated” means that the atoms of the specified framework or group are linked only by single covalent bonds. Accordingly, the term “unsaturated” means that the specified framework or group contains double and / or triple covalent bonds. Examples of unsaturated molecular fragments that may be present within a partly or fully unsaturated group or framework are C=C, C=N, C=O, N=N, C=C or C=N in cases where nitrogen and oxygen heteroatoms are permitted / present, and may also include S=O in cases where sulfur heteroatoms are also permitted / present.
[0067] It is to be understood that “heteroatom” may represent an oxygen, nitrogen or sulfur atom unless explicitly further limited in a given context.
[0068] The term “minimum length of [... ] atoms between ‘a’ and ‘b’” refers to the shortest chain of atoms in the chain between ‘a’ and ‘b’. Therefore, if the chain consisted of -CH2CH2CH2-, the number of atoms in the chain is 3 (the hydrogen atoms are regarded as not being in the chain). Alternatively if the chain consisted of 1,3-phenylene, where the shorter route around the phenyl ring contains 3 C atoms and the long route around the phenyl ring contains 5 C atoms, the minimum length of such a chain would be counted as 3 atoms.
[0069] It is to be understood that the points of attachment ‘a’ and ‘b’ each represent single covalent bonds to the relevant adjacent groups / atoms.
[0070] It is to be understood that in this specification “rings” or “heterocyclic groups” may include single rings, fused rings, spirocyclic rings and bridged rings.
[0071] In reference to the Linker, as described herein, it is to be understood that the branching, where present may be present on a chain (even a chain of 1 atom length) and / or on a ring. The skilled person would generally interpret in this manner, but for the avoidance of doubt, it is to be understood that the “branching” that occurs inherently in order to form a ring is not considered “branching” in the context of the Linker embodiments described herein. It is to be understood that said branches may occur on the same or different atoms of the Linker framework. For example it is possible to have two “=O” branches on a sulfur heteroatom in order to form a SO2 group within the Linker framework. Linker #22 described hereinafter is an example where there is one branch (-Me) coming from a chain within the Linker.
[0072] It is further to be understood that ‘branches’ (and definitions for branches provided herein) refer to branches that branch off the main chain of atoms between ‘a’ and ‘b’, leading to a ‘dead end’ in the molecular structure. In this specification it is to be understood that the point of attachment of a given group to some other group (via a single covalent bond) may be represented by a line meeting a bond substantially at right angles to said bond, for example as shown on the far right-hand side of Formula (la) herein, and for example at either end of Linkers 1 to 46 depicted hereinafter.
[0073] In this specification when “0, 1 or 2 of XA, XB, Xc, XD, XE& XFis / are N where XE& XEare not both N, and are otherwise C” - certain of the C atoms are to be understood to implicitly possess a hydrogen atom where necessary in order to satisfy the standard valency (4) for carbon atoms. The skilled person will understand that such H atom cannot be present on a C at XEor XEor on a C at XA, XB, Xcor XDwhen a substituent or Linker is attached to said carbon. The same principle applies in respect of X1, X2, X3, X4(and with Xs, X6, X7& Xswhere present), and also with Y1, Y2, Y3& Y4. The same applies to XA2, XB2, XC2, XD2, XE2, XE2, XG2, XH2& X32.
[0074] In this specification a reference to a secondary or tertiary amine is intended to have the normal meaning in the art and therefore a nitrogen atom that is part of an amide group or a sulphonamide group, for example, is not to be regarded as a secondary or tertiary amine.
[0075] In this specification a saturated heterocyclic group refers to at least one ring of atoms (including bridged rings, spiro rings, fused rings, and single rings) containing carbon atoms and at least one heteroatom, where the heteroatom(s) is / are each independently selected from N, O and S, and where each atom in the ring is linked to its adjacent atoms by single covalent bonds. Therefore, an example of a heterocyclic group is a spiro heterocyclic group having two rings and a total of one heteroatom such as 9-azasprio[5.5]undecane. Typically, a saturated heterocyclic group will have at least two carbon atoms separating each of the heteroatom(s) present in said group to ensure a suitable level of chemical stability for use in a pharmaceutical context. Where reference is made to a “nitrogen-containing saturated (or partially unsaturated) heterocyclic group” this requires the presence of at least one nitrogen heteroatom but does not limit the possibility of one or more non-nitrogen heteroatoms (i.e. S, O) being present in addition. In this specification a partially unsaturated heterocyclic group refers to at least one ring of atoms (including bridged rings, spiro rings, fused rings, and single rings) containing carbon atoms and at least one heteroatom, where the heteroatom(s) is / are each independently selected from N, O and S, and where at least two atoms within the heterocyclic group are connected to each other via a double covalent bond. As the skilled person would understand, partially unsaturated does not include fully unsaturated heterocyclic groups - i.e. where the group contains the maximum possible number of double bonds for the atomic framework in question.
[0076] Where reference is made to a cyclic group (e.g. a heterocyclic group) having a specified number of ring atoms, this includes the atoms making up the ring (including atoms involved in the bridge of a bridged ring, and all atoms of a fused or spiro ring) but does not include any hydrogen atoms or other substituent atoms attached to the ring atoms. Therefore, for example, a cyclic group which is l,4-piperazin-l,4-diyl has 6 ring atoms (4C and 2N).
[0077] In this specification an alkylene group (for example a C .salkvlene ) is a saturated group consisting only of carbon and hydrogen atoms with two points of attachment to adjacent atoms / groups. They may include straight chain(s), branched chain(s) and / or ring(s). Accordingly Cialkylene represents -CH2-, a C2alkylene can represent -CH2CH2- or -CH(Me)-, C i.salkvlene includes for example -CI hfcvclobut- 1,3 -diyl)-. A “straight chain Cui.^alkylene” corresponds to -(CH2)U- where u is an integer from ul to u2. In this specification a hydrocarbyl group means any group consisting only of C and H atoms. For example, Ci-yhydrocarbyl includes methyl, phenyl and p-tolvl.
[0078] The term “therapy” is intended to have its normal meaning of dealing with a disease in order to entirely or partially relieve one, some or all of its symptoms, or to correct or compensate for the underlying pathology. The term "therapy" also includes "prophylaxis" or “prophylactic” unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be interpreted in a corresponding manner.
[0079] The term “prophylactic” is intended to have its normal meaning and includes primary prophylaxis to prevent the development of the disease and secondary prophylaxis whereby the disease has already developed and the patient is temporarily or permanently protected against exacerbation or worsening of the disease or the development of new symptoms associated with the disease.
[0080] The term “treatment” is used synonymously with “therapy”. Similarly the term “treat” can be regarded as “applying therapy” where “therapy” is as defined herein.
[0081] Some values of variable groups are as follows. One, two or more of such values, may be used in any combination with any other definitions, claims, aspects or embodiments herein (unless the context doesn’t permit) to provide further embodiments / claims of the specification.
[0082] In one embodiment X1is C & 0 or 1 of X2, X3& X4is N and are otherwise C; or X3& X4are both C and are substituted by -X5=X6-X7=XS- with Xsattached to X3and Xsattached to Xs, where 1 of X1, X2, Xs, X6, X7& Xsis N, and are otherwise C.
[0083] In one embodiment X1is C & 0, 1 or 2 of X2, X3& X4is N and are otherwise C.
[0084] In one embodiment X1is C & 0 or 1 of X2, X3& X4is N and are otherwise C.
[0085] In one embodiment X1is C & 1 or 2 of X2, X3& X4is / are N and are otherwise C.
[0086] In one embodiment X1is C & 1 of X2, X3& X4is N and are otherwise C.
[0087] In one embodiment X1, X2, X3& X4are all C.
[0088] In one embodiment X1& X2are C and X3& X4are both C and are substituted by -X5=X6-X7=XS- with Xsattached to X3and Xsattached to Xs, where 1 of Xs, X6, X7& Xsis N, and are otherwise C.
[0089] In one embodiment X3& X4are both C and are substituted by -X5=X6-X7=XS- with Xsattached to X3and Xsattached to Xs; X6& X7are all C and Xsis N.
[0090] In one embodiment each R1is a substituent on X1, and when p is 2, on any other C atom at X2, X3& X4, (or each R1is a substituent at X1, X2, Xs, X6, X7or Xswhen X3& X4are substituted by -X5=X6-X7=X8-), and in each case is independently selected from F, Cl, Me, cyclopropyl, CHF2, CF3 and OMe.
[0091] In one embodiment each R1is a substituent on X1, and when p is 2, on any other C atom at X2, X3& X4when X3& X4are not substituted by -X5=X6-X7=X8-, and the values of R1is / are otherwise as defined herein.
[0092] In one embodiment each R1is selected from Cl, F, C i.vilkvl (optionally substituted by one or more F) and Ci-salkoxy.
[0093] In one embodiment p is 1 or 2 and X1is C attached to R1when X3& X4are not substituted by -X5=X6-X7=X8-, and otherwise p is 1 or 2.
[0094] In one embodiment p is 1 or 2 and X1is C attached to R1when X3& X4are not substituted by -X5=X6-X7=X8-, and otherwise p is 0 or 1. In one embodiment p is 1 or 2 and X1is C attached to R1when X3& X4are not substituted by -X5=X6-X7=X8-, and otherwise p is 0.
[0095] In one embodiment p is 1 and X1is C attached to R1when X3& X4are not substituted by -X5=X6-X7=X8-, and otherwise p is 0, 1 or 2.
[0096] In one embodiment p is 2 and X1is C attached to R1when X3& X4are not substituted by -X5=X6-X7=X8-, and otherwise p is 0, 1 or 2.
[0097] In one embodiment p is 2 and X1is C attached to R1when X3& X4are not substituted by -X5=X6-X7=X8-, and otherwise p is 0.
[0098] In one embodiment p is 0 and X3& X4are both C and are substituted by -X5=X6-X7=XS- with Xsattached to X3and Xsattached to Xs.
[0099] In one embodiment p is 1 or 2 and X3& X4are not substituted by -X5=X6-X7=X8-.
[0100] In one embodiment p is 1 or 2; X3& X4are not substituted by -X5=X6-X7=X8-, and X1is C attached to R1where-R1is CFs.
[0101] In one embodiment p is 1 ; X3& X4are not substituted by -X5=X6-X7=X8-, and X1is C attached to R1.
[0102] In one embodiment p is 1 ; X3& X4are not substituted by -X5=X6-X7=X8-, and X1is C attached to R1where R1is CF3.
[0103] In one embodiment p is 1 and R1is selected from Cl, C _;,alkvl (optionally substituted by one or more F) and Ci-aalkoxy.
[0104] In one embodiment p is 1 and R1is selected from Cl, Me, cyclopropyl, CHF2, CF3 and OMe.
[0105] In one embodiment p is 1, X1is C attached to R1, where R1is selected from Cl, Me, cyclopropyl, CHF2, CF3 and OMe.
[0106] In one embodiment p is 1 , X1is C attached to R1, X3& X4are not substituted by -X5=X6-X7=X8-, and R1is selected from Cl, Me, cyclopropyl, CHF2, CF3 and OMe.
[0107] In one embodiment p is 1 or 2; X3& X4are not substituted by -X5=X6-X7=X8-; X1is C attached to an R1where said R1is selected from Cl, Ci-salkyl (optionally substituted by one or more F) and C i-salkoxy, and if present (i.e. when p is 2) the other R1is F.
[0108] In one embodiment p is 1 or 2; X3& X4are not substituted by -X5=X6-X7=X8-; X1is C attached to an R1where said R1is selected from Cl, Me, cyclopropyl, CHF2, CF3 and OMe, and if present (i.e. when p is 2) the other R1is F.
[0109] In one embodiment p is 1 or 2; X3& X4are not substituted by -X5=X6-X7=X8-; X1is C attached to R1where R1is selected from Cl, Me, cyclopropyl, CHF2, CF3 and OMe, and if present (i.e. when p is 2) the additional R1substituent is F attached to X2where X2is C.
[0110] In one embodiment p is 1 and R1is C i-salkyl optionally substituted by one or more F.
[0111] In one embodiment p is 1 and R1is methyl, cyclopropyl, CF3 or CHF2.
[0112] In one embodiment p is 1 and R1is CF3 or CHF2.
[0113] In one embodiment p is 1 and R1is CHF2.
[0114] In one embodiment p is 1 and R1is CF3.
[0115] In one embodiment p is 1 and R1is methyl.
[0116] In one embodiment p is 1 and R1is cyclopropyl.
[0117] In one embodiment p is 1 and R1is methoxy. The above 8 embodiments may for example be in the context where X3& X4are not substituted by -X5=X6- X7=XS- X1is C and the above-mentioned R1is a substituent on said C at X1.
[0118] In one embodiment p is 2: X1& X2are both C; X3& X4are not substituted by -X5=X6-X7=X8- and the values of R1are such that X1is substituted by CFs and X2is substituted by F.
[0119] In one embodiment p is 1 ; X3& X4are not substituted by -X5=X6-X7=X8- X1, X2, X3& X4are all C and R1is a substituent on X1as defined herein.
[0120] In one embodiment p is 1 ; X3& X4are not substituted by -X5=X6-X7=X8- X1, X2, X3& X4are all C and R1is a substituent on X1and is CFs.
[0121] In one embodiment p is 2, and one R1is CFs and the other R1is F or ethyl.
[0122] In one embodiment p is 2, and one R1is CFs and the other R1is F.
[0123] In one embodiment p is 2, and one R1is CT; and the other R1is ethyl.
[0124] In one embodiment p is 2, X1is C attached to a first R1and X2is C attached to a second R1.
[0125] In one embodiment p is 2, X1is C attached to a CT; and X2is C attached to either F or ethyl.
[0126] In one embodiment p is 2, X1is C attached to a CT; and X2is C attached to F.
[0127] In one embodiment p is 2, X1is C attached to a CT; and X2is C attached to ethyl.
[0128] The above 7 embodiments may for example be in the context where X3& X4are not substituted by -X5=X6- X7=X8-.
[0129] In one embodiment n is 0.
[0130] In one embodiment n is 1.
[0131] In one embodiment n is 2.
[0132] In one embodiment m is 0.
[0133] In one embodiment m is 1.
[0134] In one embodiment n is 0 and m is 1.
[0135] In one embodiment n is 1 and m is 1.
[0136] In one embodiment n is 0 and m is 0.
[0137] In one embodiment n is 0, 1 or 2; and m is 1.
[0138] In one embodiment n is 1 , m is 1 and Q is CH.
[0139] In one embodiment n is 1 , m is 1 and Q is N.
[0140] In one embodiment n is 1 , m is 1 , Q is CH or N, R2ais H and R2bis H.
[0141] In one embodiment n is 1 , m is 1 , Q is CH, R2ais H and R2bis H.
[0142] In one embodiment n is 0, m is 1 , Q is CH, R2ais H and R2bis H
[0143] In one embodiment n is 1 , m is 0, R2ais H and R2bis C i.;alkyl attached to a C atom other than at Q, where said C atom has an ( T (-stereochemical configuration.
[0144] In one embodiment n is 1 , m is 0, R2ais H and R2bis C i.;alkyl attached to a C atom other than at Q, where said C atom has an (S)- stereochemical configuration.
[0145] In one embodiment n is 1 , m is 1 , R2ais H and R2bis C i.;alkyl attached to a C atom other than at Q, where said C atom has an ( T (-stereochemical configuration.
[0146] In one embodiment n is 1 , m is 1 , R2ais H and R2bis C i.;alkyl attached to a C atom other than at Q, where said C atom has an (S)- stereochemical configuration.
[0147] In one embodiment n is 1 , m is 1 , Q is N, R2ais H and R2bis H. In one embodiment Q is CH with an ( R)-stereochemical configuration at said C atom.
[0148] In one embodiment Q is CH with an (S)- stereochemical configuration at said C atom.
[0149] In one embodiment n is 2; m is 1 ; R2a& R2bare both H: and Q is CH.
[0150] In one embodiment n is 2: m is 1 : R2a& R2bare both H: and Q is CH with an (R)- stereochemical configuration at said C atom.
[0151] In one embodiment n is 2: m is 1 : R2a& R2bare both H: and Q is CH with an (.S')-stereochemical configuration at said C atom.
[0152] In one embodiment R2aand R2bare substituents on the same or different C atoms other than at Q, each independently selected from H and Chalky 1.
[0153] In one embodiment R2aand R2bare substituents on the same or different C atoms other than at Q, each independently selected from H and Me.
[0154] In one embodiment R2aand R2bare substituents on the same or different C atoms adjacent Q and are otherwise as defined herein.
[0155] In one embodiment R2aand R2bare substituents on the same or different C atoms adjacent Q, each independently selected from H and C .vilkvl (for example Me).
[0156] In one embodiment R2aand R2bare substituents on the same or different C atoms and are both H.
[0157] In one embodiment R2aand R2bare substituents on the same or different C atoms other than at Q, each independently selected from H, F and Ci-aalkyl.
[0158] In one embodiment R2aand R2bare substituents on the same or different C atoms other than at Q, each independently selected from H and Chalky 1, or R2a& R2btogether form a -(CH2)r- group where r is 1, 2 or 3.
[0159] In one embodiment r is 1.
[0160] In one embodiment r is 2.
[0161] In one embodiment r is 3.
[0162] In one embodiment R2aand R2bare substituents on the same or different C atoms other than at Q, where R2ais Me and R2bis H.
[0163] In one embodiment R2aand R2bare substituents on the same C atom other than at Q, where R2aand R2bare both Me.
[0164] In one embodiment R2aand R2bare substituents on the same C atom adjacent Q, where R2aand R2bare both Me.
[0165] In one embodiment Y1, Y2, Y3& Y4are respectively selected from (C, C, C, C), (N, C, C, C), (C, N, C, C) and (N, C, N, C).
[0166] In one embodiment 0 or 1 of Y1, Y2, Y3& Y4is N and are otherwise C.
[0167] In one embodiment 1 or 2 of Y1, Y2, Y3& Y4is / are N and are otherwise C.
[0168] In one embodiment Y1, Y2, Y3& Y4are respectively selected from (N, C, C, C), (C, N, C, C) and (N, C, N, C).
[0169] In one embodiment 1 of Y1, Y2, Y3& Y4is N and are otherwise C.
[0170] In one embodiment Y1is N: and Y2, Y3& Y4are all C.
[0171] In one embodiment Y2is N; and Y1, Y3& Y4are all C.
[0172] In one embodiment 2 of Y1, Y2, Y3& Y4are N and are otherwise C.
[0173] In one embodiment Y1& Y3are N: and Y2and Y4are C. In one embodiment Y1, Y2, Y3& Y4are all C.
[0174] In one embodiment q is 0 or 1.
[0175] In one embodiment q is 0.
[0176] In one embodiment q is 1.
[0177] In one embodiment q is 2.
[0178] In one embodiment q is 0, 1 or 2 and R3(when present) is a substituent on any C atom at Y1, Y2, Y3& Y4selected from F, CN and Chalky 1.
[0179] In one embodiment q is 0, 1 or 2 and R3(when present) is a substituent on any C atom at Y1, Y2, Y3& Y4selected from F and Ci-aalkyl.
[0180] In one embodiment q is 0 or 1 and R3(when present) is a substituent on any C atom at Y1, Y2, Y3& Y4selected from F or Ci-aalkyl.
[0181] In one embodiment q is 0 or 1 and R3(when present) is a substituent on any C atom at Y1, Y2, Y3& Y4selected from F or Me.
[0182] In one embodiment R3(when present) is Ci-aalkyl.
[0183] In one embodiment R3(when present) is Me.
[0184] In one embodiment R3(when present) is F.
[0185] In one embodiment R3(when present) is CN.
[0186] In one embodiment q is 1 and R3is attached to C at Y1.
[0187] In one embodiment q is 1 and R3is attached to C at Y1, and R3is selected from F, CN and Me.
[0188] In one embodiment q is 2 and both R3groups are F.
[0189] In one embodiment q is 2 and the R3groups are attached to C at Y1and Y3.
[0190] In one embodiment q is 2 and each R3group is F, which are attached to C at Y1and Y3.
[0191] In one embodiment Linker is a saturated or a partially or fully unsaturated framework comprising C and H atoms and at least one heteroatom, wherein said framework has end points of attachment ‘a’ and ‘b’ and a minimum length of from 6 to 26 atoms between ‘a’ and ‘b’; wherein said framework may include one or more straight and / or branched chains and / or rings and is optionally substituted on any available C atom(s) by one or more F.
[0192] In one embodiment the framework of the Linker is a saturated or partially unsaturated framework.
[0193] In one embodiment the framework of the Linker is a saturated framework.
[0194] In one embodiment the framework of the Linker comprises C and H atoms and at least two heteroatoms.
[0195] In one embodiment the framework of the Linker comprises C and H atoms and at least two heteroatoms selected from O and N.
[0196] In one embodiment the framework of the Linker comprises C and H atoms and at least one nitrogen heteroatom.
[0197] In one embodiment the framework of the Linker comprises C and H atoms and at least two heteroatoms including at least one nitrogen heteroatom.
[0198] In one embodiment the framework of the Linker comprises C and H atoms and at least one nitrogen heteroatom in the form of a secondary or tertiary amine.
[0199] In one embodiment the framework of the Linker comprises C and H atoms and at least one nitrogen heteroatom in the form of a tertiary amine. In one embodiment the framework of the Linker comprises C and H atoms and at least two heteroatoms including at least one nitrogen heteroatom in the form of a secondary or tertiary amine.
[0200] In one embodiment the framework of the Linker comprises C and H atoms and at least two heteroatoms including at least one nitrogen heteroatom in the form of a tertiary amine.
[0201] In one embodiment the Linker has a minimum length of from 6 to 20 atoms between ‘a’ and ‘b’.
[0202] In one embodiment the Linker has a minimum length of from 6 to 15 atoms between ‘a’ and ‘b’ .
[0203] In one embodiment the Linker has a minimum length of from 7 to 14 atoms between ‘a’ and ‘b’.
[0204] In one embodiment the total number of C and hetero atoms in the Linker framework is from 6 to 26.
[0205] In one embodiment the total number of C and hetero atoms in the Linker framework is from 7 to 24.
[0206] In one embodiment the total number of C and hetero atoms in the Linker framework is from 8 to 22.
[0207] In one embodiment the total number of C and hetero atoms in the Linker framework is from 9 to 20.
[0208] In one embodiment when W is -Z-RA, the Linker is attached at any available C atom at XBor Xcof Z.
[0209] In one embodiment the framework of the Linker may include one or more straight chains and / or rings and is optionally substituted on any available C atom(s) by one or more F.
[0210] In one embodiment the framework of the Linker consists of one or more straight chains and / or rings that are optionally substituted on any available C atom(s) by one or more F.
[0211] In one embodiment the framework of the Linker may include (or consist of) one or more straight and / or branched chains and / or rings (wherein the total number of branches is from 0 to 5) that are optionally substituted on any available C atom(s) by one or more F.
[0212] In one embodiment the framework of the Linker may include (or consist of) one or more straight and / or branched chains and / or rings (wherein the total number of branches is from 0 to 3) that are optionally substituted on any available C atom(s) by one or more F.
[0213] In one embodiment the framework of the Linker may include (or consist of) one or more straight and / or branched chains and / or rings (wherein the total number of branches is 0 or 1) that are optionally substituted on any available C atom(s) by one or more F.
[0214] In one embodiment the total number of branches is 0.
[0215] In one embodiment the total number of branches is 1.
[0216] In one embodiment the total number of branches is 2.
[0217] In one embodiment the total number of branches is 3.
[0218] In one embodiment any / each branch in the framework of a Linker has from 1 to 5 C and / or hetero atoms.
[0219] In one embodiment any / each branch in the framework of a Linker has 1 or 2 C and / or hetero atoms.
[0220] In one embodiment any / each branch in the framework of a Linker has 1 C and / or hetero atom.
[0221] In one embodiment any / each branch in the framework of a Linker has 1 C atom.
[0222] In one embodiment the total number of C and / or heteroatoms in the branch(es) (where present) of the framework of the Linker is from 1 to 5.
[0223] In one embodiment the total number of C and / or heteroatoms in the branch(es) (where present) of the framework of the Linker is from 1 to 3.
[0224] In one embodiment the total number of C and / or heteroatoms in the branch(es) (where present) of the framework of the Linker is 1.
[0225] In one embodiment any the framework of the Linker is either unbranched or has one branch that is Me. In one embodiment the framework of the Linker is optionally substituted on any available C atom(s) by 1 or 2 F (for example by 2 F, for example where said 2 F are substituted on the same carbon atom).
[0226] In one embodiment the framework of the Linker is not substituted by any F.
[0227] In one embodiment the Linker is a saturated or a partially unsaturated framework comprising C and H atoms and at least one heteroatom, wherein said framework has end points of attachment ‘a’ and ‘b’ and: a minimum length of from 7 to 14 atoms between ‘a’ and ‘b’; wherein the total number of C and hetero atoms in the Linker framework is from 9 to 20: where said framework comprises one or more straight and / or branched chains and / or rings that are optionally substituted on any available C atom(s) by 1 or 2 F (for example by 2 F); wherein the total number of branches is 0 or 1 and when present said branch is Me.
[0228] In one embodiment the framework of the Linker includes at least one nitrogen-containing saturated or partially unsaturated heterocyclic group (e.g. having from 4 to 12 ring atoms) or a A'-CI F-CI F-A2unit where A1and A2are each independently selected from N and O.
[0229] In one embodiment the framework of the Linker includes at least one nitrogen-containing saturated heterocyclic group (e.g. having from 4 to 12 ring atoms) or a A'-CI F-CI F-A2unit where A1and A2are each independently selected from N and O.
[0230] In one embodiment the framework of the Linker includes a A'-CI F-CI F-A2unit where A1and A2are each independently selected from N and O.
[0231] In one embodiment the framework of the Linker includes at least one nitrogen-containing saturated or partially unsaturated heterocyclic group (e.g. having from 4 to 12 ring atoms) or a A'-CI F-CI F-A2unit where one of A1& A2is N and the other of A1& A2is selected from N or O.
[0232] In one embodiment the framework of the Linker includes at least one nitrogen-containing saturated heterocyclic group (e.g. having from 4 to 12 ring atoms) or a A'-CI F-CI F-A2unit where one of A1& A2is N and the other of A1& A2is selected from N or O.
[0233] In one embodiment the framework of the Linker includes a A'-CI F-CI F-A2unit where one of A1& A2is N and the other of A1& A2is selected from N or O.
[0234] In one embodiment the framework of the Linker includes at least one nitrogen-containing saturated or partially unsaturated heterocyclic group (e.g. having from 4 to 12 ring atoms) or a A'-CI F-CI F-A2unit where one of A1& A2is N in the form of a secondary or tertiary amine, and the other of A1& A2is selected from N or O.
[0235] In one embodiment the framework of the Linker includes a A'-CI F-CI F-A2unit where one of A1& A2is N in the form of a secondary or tertiary amine, and the other of A1& A2is selected from N or O.
[0236] In one embodiment the framework of the Linker includes at least one saturated or partially unsaturated heterocyclic group.
[0237] In one embodiment the framework of the Linker includes at least one saturated heterocyclic group.
[0238] In one embodiment the framework of the Linker includes at least one nitrogen-containing saturated or partially unsaturated heterocyclic group.
[0239] In one embodiment the framework of the Linker includes at least one nitrogen-containing saturated heterocyclic group. In one embodiment the framework of the Linker includes at least one nitrogen-containing saturated or partially unsaturated heterocyclic group having from 4 to 12 ring atoms.
[0240] In one embodiment the framework of the Linker includes at least one nitrogen-containing saturated heterocyclic group having from 4 to 12 ring atoms.
[0241] In one embodiment the framework of the Linker includes:
[0242] (1) a A'-CI I2-CI 12- A2unit where A1and A2are each independently selected from N and C): and / or
[0243] (2) at least one nitrogen-containing saturated or partially unsaturated heterocyclic group selected from piperazine, azetidine, piperidine, 1 ,4-diazepane, 12-oxa-3,9-diazaspiro[5.6]dodecane, pyrrolidine, 3,9- diazaspiro-[5.5]undecane, 2,5-diazabicyclo[2.2.1]heptane, 1, 2, 3, 3a, 4, 5, 6,6a- octahydropyrrolo[3,4-c]pyrrole, 1,2,3,6-tetrahydropyridine and 9-azaspiro[5.5]undecane.
[0244] In one embodiment the framework of the Linker includes:
[0245] (1) a A'-CHi-CHi-A2unit where one of A1& A2is N in the form of a secondary or tertiary amine, and the other of A1& A2is selected from N or O: and / or
[0246] (2) at least one nitrogen-containing saturated or partially unsaturated heterocyclic group selected from piperazine, azetidine, piperidine, 1 ,4-diazepane, 12-oxa-3,9-diazaspiro[5.6]dodecane, pyrrolidine, 3,9- diazaspiro-[5.5]undecane, 2,5-diazabicyclo[2.2.1]heptane, l,2,3,3a,4,5,6,6a-octahydropyrrolo[3,4- c]pyrrole, 1,2,3,6-tetrahydropyridine and 9-azaspiro[5.5]undecane.
[0247] In one embodiment the framework of the Linker includes at least one nitrogen-containing saturated or partially unsaturated heterocyclic group selected from piperazine, azetidine, piperidine, 1 ,4-diazepane, 12-oxa-3,9-diazaspiro[5.6]dodecane, pyrrolidine, 3,9-diazaspiro[5.5]undecane, 2,5- diazabicyclo[2.2.1]heptane, l,2,3,3a,4,5,6,6a-octahydropyrrolo[3,4-c]pyrrole, 1,2,3,6- tetrahydropyridine and 9-azaspiro[5.5]undecane.
[0248] In one embodiment the framework of the Linker includes an O-CH2-CH2-N unit.
[0249] In one embodiment the framework of the Linker includes an O-CH2CH2-O-CH2CH2-N unit.
[0250] In one embodiment the framework of the Linker includes a piperazine group.
[0251] In one embodiment the framework of the Linker includes an azetidine group.
[0252] In one embodiment the framework of the Linker includes a piperidine group.
[0253] In one embodiment the framework of the Linker includes a 1 ,4-diazepane group.
[0254] In one embodiment the framework of the Linker includes a 12-oxa-3,9-diazaspiro[5.6]dodecane group.
[0255] In one embodiment the framework of the Linker includes a pyrrolidine group.
[0256] In one embodiment the framework of the Linker includes a 3,9-diazaspiro[5.5]undecane group.
[0257] In one embodiment the framework of the Linker includes a 2,5-diazabicyclo[2.2.1]heptane group.
[0258] In one embodiment the framework of the Linker includes a 1 ,2,3,3a,4,5,6,6a-octahydropyrrolo[3,4-c]pyrrole group.
[0259] In one embodiment the framework of the Linker includes a 1 ,2,3,6-tetrahydropyridine group.
[0260] In one embodiment the framework of the Linker includes a 9-azaspiro[5.5]undecane group.
[0261] In one embodiment the framework of the Linker includes at least two nitrogen-containing saturated or partially unsaturated heterocyclic groups.
[0262] In one embodiment the framework of the Linker includes at least two nitrogen-containing saturated heterocyclic groups. In one embodiment the framework of the Linker includes a C, N or O atom at the ‘a’ point of attachment.
[0263] In one embodiment the framework of the Linker includes an N or O atom at the ‘a’ point of attachment.
[0264] In one embodiment the framework of the Linker includes an N or O atom at the ‘b’ point of attachment.
[0265] In one embodiment the framework of the Linker includes a C atom at the ‘a’ point of attachment.
[0266] In one embodiment the framework of the Linker includes an N atom at the ‘a’ point of attachment.
[0267] In one embodiment the framework of the Linker includes a C or N atom at the ‘b’ point of attachment.
[0268] In one embodiment the framework of the Linker includes an N atom at the ‘b’ point of attachment.
[0269] In one embodiment the framework of the Linker includes a C atom at the ‘b’ point of attachment.
[0270] In one embodiment the framework of the Linker includes an O atom at the ‘a’ point of attachment.
[0271] In one embodiment the framework of the Linker includes an O atom at the ‘b’ point of attachment.
[0272] In one embodiment the framework of the Linker includes an N or O atom at both the ‘a’ and ‘b’ points of attachment.
[0273] In one embodiment the framework of the Linker includes a C, N or O atom at the ‘a’ point of attachment and a C or N atom at the ‘b’ point of attachment.
[0274] In one embodiment the framework of the Linker includes:
[0275] (1) a A1-CH2-CH2-A2unit where one of A1& A2is N in the form of a secondary or tertiary amine, and the other of A1& A2is selected from N or C): and / or
[0276] (2) at least one nitrogen-containing saturated or partially saturated heterocyclic group selected from piperazin- 1,4-diyl, azetidin- 1,3 -diyl, piperidin-l,4-diyl, l,4-diazepan-l,4-diyl, 12-oxa-3,9- diazaspiro[5.6]dodecan-3,9-diyl, pyrrolidin- 1,3 -diyl, 3,9-diazaspiro[5.5]undecan-3,9-diyl, 2,5- diazabicyclo[2.2.1]heptan-2,5-diyl, l,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2,5-diyl, 3,6-dihydro- 2 / / -pvridin- 1,4-diyl, and 9-azaspiro[5.5]undecan-3,9-diyl.
[0277] In one embodiment the framework of the Linker includes at least one nitrogen-containing saturated or partially saturated heterocyclic group selected from piperazin- 1,4-diyl, azetidin-l,3-diyl, piperidin- 1,4- diyl, 1 ,4-diazepan- 1,4-diyl, 12-oxa-3,9-diazaspiro[5.6]dodecan-3,9-diyl, pyrrolidin-l,3-diyl, 3,9- diazaspiro[5.5]undecan-3,9-diyl, 2,5-diazabicyclo[2.2.1]heptan-2,5-diyl, 1, 3 ,3a, 4 ,6,6a- hexahydropyrrolo[3,4-c]pyrrol-2,5-diyl, 3.6-dihvdro-2 / / -pvridin- 1 .4-divl. and 9-azaspiro[5.5]undecan- 3,9-diyl.
[0278] In one embodiment the framework of the Linker includes a piperazin- 1,4-diyl group.
[0279] In one embodiment the framework of the Linker includes an azetidin- 1 ,3-diyl group.
[0280] In one embodiment the framework of the Linker includes a piperidin- 1,4-diyl group.
[0281] In one embodiment the framework of the Linker includes a 1 ,4-diazepan-l ,4-diyl group.
[0282] In one embodiment the framework of the Linker includes a 12-oxa-3,9-diazaspiro[5.6]dodecan-3,9-diyl group.
[0283] In one embodiment the framework of the Linker includes a pyrrolidin-l,3-diyl group.
[0284] In one embodiment the framework of the Linker includes a 3,9-diazaspiro[5.5]undecan-3,9-diyl group.
[0285] In one embodiment the framework of the Linker includes a 2,5-diazabicyclo[2.2.1]heptan-2,5-diyl group.
[0286] In one embodiment the framework of the Linker includes a 1 ,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2,5- diyl group.
[0287] In one embodiment the framework of the Linker includes a 3.6-dihvdro-2 / / -pvridin- 1 .4-divl group. In one embodiment the framework of the Linker includes a 9-azaspiro[5.5]undecan-3,9-diyl group.
[0288] In one embodiment the Linker has the Formula: a -QA-QB-QC- b wherein:
[0289] ‘a’ and ‘b’ represent the end points of attachment;
[0290] QAis -G-QH- or -G-(Ci-5alkylene)-;
[0291] QBis a direct bond, -QB1-QB2-QB3- or C .vilkvlene optionally substituted by one or more F (for example 1 or 2 F, for example 2 F); where:
[0292] QB1& QB3each independently represent a direct bond or C ^alkylene;
[0293] QB2is QH, -O-CH2CH2-O-, -O- or -N(RJ)- where RJis H or Ci.3alkyl;
[0294] Qcis -QH-G- or -(Ci.5alkylene)-G-; each G is independently a direct bond, -CH2-, -O-, or -N(RG)- where each RGis independently H or Ci.3alkyl; each QHis independently a 4-12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group; where the values of QA, QBand Qcare selected so that the Linker does not contain any N-N or N-O bonds.
[0295] In one embodiment the Linker has the Formula: a -QA-QB-QC- b wherein:
[0296] ‘a’ and ‘b’ represent the end points of attachment;
[0297] QAis -G-QH- or -G-(Ci.5alkylene)-;
[0298] QBis a direct bond, -QB1-QB2-QB3- or C].3alkylene optionally substituted by one or more F (e.g. 1 or 2); where:
[0299] QB1& QB3each independently represent a direct bond or Chalky lene;
[0300] QB2is QH, -O-CH2CH2-O- or -N(RJ)- where RJis Ci.3alkyl;
[0301] Qcis -QH-G- or -(Ci.5alkylene)-G-; each G is independently a direct bond, -CH2-, -O-, or -N(RG)- where each RGis independently H or
[0302] Ci-3alkyl; each QHis independently a 4-12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group; where the values of QA, QBand Qcare selected so that the Linker does not contain any N-N or N-O bonds.
[0303] In one embodiment the Linker has the Formula: a -QA-QB-QC- b wherein:
[0304] ‘a’ and ‘b’ represent the end points of attachment;
[0305] QAis -GA-QHA- or -GA-(Ci-5alkylene)-; where GAis a direct bond, -CH2-, -O-, -NH- or -N(Me)-;
[0306] QHAis a 4 to 11 -membered nitrogen-containing saturated heterocyclic group; QBis a direct bond, -QB1-QB2-QB3- or C i-aalkylene optionally substituted by one or more F (e.g. 1 or 2); where:
[0307] QB1& QB3each independently represent a direct bond or Chalky lene;
[0308] QB2is piperazin- 1,4-diyl, -O-CH2CH2-O- or -N(RJ)- where RJis Ci-jalkyl;
[0309] Qcis -QHC-GC- or -(C i-2alkvlene)-Gc-: where Gcis a direct bond, -O- or -NH-;
[0310] QHCis a 6 to 12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group; where the values of QA, QBand Qcare selected so that the Linker does not contain any N-N or N-O bonds.
[0311] In one embodiment QAis -GA-QHA- or -GA-(C].5alkylene)- where:
[0312] GAis selected from a direct bond, -CH2-, -O- or -N(RG)-; each RGis independently H or Chalky 1; and
[0313] QHAis a 4 to 11 -membered nitrogen-containing saturated heterocyclic group.
[0314] In one embodiment QAis -GA-QHA- or -GA-(C].5alkylene)- where:
[0315] GAis selected from a direct bond, -CH2-, -O- or -N(RG)-; each RGis independently H or Chalky 1; and
[0316] QHAis selected from azetidin-l,3-diyl, pyrro lidin- 1,3 -diyl, piperidin- 1,4-diyl, piperazin- 1,4-diyl, 3,9- diazaspiro[5.5]undecan-3,9-diyl and 9-azaspiro[5.5]undecan-3,9-diyl.
[0317] In one embodiment QAis -GA-QHA- or -GA-(Ci-5alkylene)- where:
[0318] GAis selected from a direct bond, -CH2-, -O-or -NH- or -N(Me)-;
[0319] QHAis selected from azetidin-l,3-diyl, pyrro lidin- 1,3 -diyl, piperidin- 1,4-diyl, piperazin- 1,4-diyl, 3,9- diazaspiro[5.5]undecan-3,9-diyl and 9-azaspiro[5.5]undecan-3,9-diyl; and the C i.salkvlene within said -GA-(Ci-5alkylene)- is selected from -( C I F )i- where f is an integer from 1 to 5, cyclobut-l,3-diyl and -CH2(cyclobut-l,3-diyl)-.
[0320] In one embodiment QAis selected from azetidin- 1,3 -diyl, pyrrolidin-l,3-diyl, piperidin- 1,4-diyl, -O(piperidin- 1 ,4-diyl)-, -C I F( piperidin- 1 ,4-diyl)-, piperazin- 1 ,4-diyl, 3 ,9-diazaspiro[5.5]undecan-3 ,9- diyl, -O(9-azaspiro[5.5]undecan-3,9-diyl)-, -O(cyclobut-l,3-diyl)-, -OCH2(cyclobut-l,3-diyl)-, -(CH2)f-, -O-(CH2)f-, -NH-(CH2)f- and -N(Me)-(CH2)r-, where f is an integer from 1 to 5.
[0321] In one embodiment QAis azetidin-l,3-diyl.
[0322] In one embodiment QAis pyrro lidin- 1 ,3-diyl.
[0323] In one embodiment QAis piperidin- 1,4-diyl.
[0324] In one embodiment QAis -O(piperidin-l,4-diyl)-.
[0325] In one embodiment QAis -CI F( piperidin- 1,4-diyl)-.
[0326] In one embodiment QAis piperazin- 1,4-diyl.
[0327] In one embodiment QAis 3,9-diazaspiro[5.5]undecan-3,9-diyl.
[0328] In one embodiment QAis -O(9-azaspiro[5.5]undecan-3,9-diyl)-.
[0329] In one embodiment QAis -G-(Ci-5alkylene)-.
[0330] In one embodiment QAis selected from -O(cyclobut-l,3-diyl)-, -OCH2(cyclobut-l,3-diyl)-, -(CI F ir-. -O(CH2)f-, -NH-(CH2)f- and -N(Me)-(CH2)r-, where f is an integer from 1 to 5.
[0331] In one embodiment QAis -O(cyclobut-l,3-diyl)-. In one embodiment QAis -OCH2(cyclobut-l,3-diyl)-.
[0332] In one embodiment QAis -(CH2)f- where f is an integer from 1 to 4 (for example, f is 4)
[0333] In one embodiment QAis -O-(CH2)r- where f is an integer from 1 to 5 (for example, f is 1 or 2).
[0334] In one embodiment QAis -NH-(CH2)r- where f is an integer from 1 to 5.
[0335] In one embodiment QAis -N(Me)-(CH2)r-, where f is an integer from 1 to 4.
[0336] In one embodiment QBis a direct bond, -QB1-QB2-QB3- or a straight chain Ci-salkylene optionally substituted by one or more F (for example 1 or 2 F, for example by 2 F).
[0337] In one embodiment QBis a direct bond.
[0338] In one embodiment QBis -QB1-QB2-QB3-.
[0339] In one embodiment QBis C .;,alkvlerie optionally substituted by one or more F.
[0340] In one embodiment QBis C .;,alkvlerie optionally substituted by one or two F (for example by 2 F).
[0341] In one embodiment QBis a straight chain C .;,alkvlerie optionally substituted by 1 or 2 F (for example by 2 F).
[0342] In one embodiment QBis C i-salkylene.
[0343] In one embodiment QBis a straight chain C .;,alkvlerie.
[0344] In one embodiment QBis -CF2-CH2-CH2- or -(CFb)™- where w is 1 to 3.
[0345] In one embodiment QB1and QB3each independently represent a direct bond, -CH2- or -CH2CH2-.
[0346] In one embodiment QB1is a direct bond or -CH2-.
[0347] In one embodiment QB1is a direct bond.
[0348] In one embodiment QB1is -CH2-.
[0349] In one embodiment QB3is a direct bond, -CH2- or -CH2CH2-.
[0350] In one embodiment QB3is a direct bond.
[0351] In one embodiment QB3is -CH2-.
[0352] In one embodiment QB3is -CH2CH2-.
[0353] In one embodiment QB2is QH, -O-CH2CH2-O- or -N(RJ)- where RJis Ci-3alkyl.
[0354] In one embodiment QB2is QH, -O-CH2CH2-O- or -N(Me)-.
[0355] In one embodiment QB2is piperazin- 1,4-diyl, azetidin- 1,3 -diyl, -O-CH2CH2-O- or -N(Me)-.
[0356] In one embodiment QB2is piperazin- 1,4-diyl, -O-CH2CH2-O- or -N(Me)-.
[0357] In one embodiment QB2is QH.
[0358] In one embodiment QB2is piperazin- 1,4-diyl.
[0359] In one embodiment QB2is azetidin- 1 ,3-diyl.
[0360] In one embodiment QB2is -O-CH2CH2-O-.
[0361] In one embodiment QB2is -N(RJ)- where RJis Ci-salkyl.
[0362] In one embodiment QB2is -N(Me)-.
[0363] In one embodiment Qcis -QH-G- or -(Chalky lene)-G-.
[0364] In one embodiment Qcis -QH-G- or -(Ci-3alkylene)-G-.
[0365] In one embodiment Qcis -QH-G- or -(Chalky lene)-G-.
[0366] In one embodiment Qcis -QHC-GC- or -(Ci-5alkylene)-Gc- where:
[0367] Gcis selected from a direct bond, -O- or -NH-; and
[0368] QHCis a 6 to 12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group.
[0369] In one embodiment Qcis -QHC-GC- or -(Ci-2alkylene)-Gc- where: Gcis selected from a direct bond, -O- or -Ni l-: and
[0370] QHCis a 6 to 12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group.
[0371] In one embodiment Qcis -QHC-GC- or -(Ci-2alkylene)-Gc- where:
[0372] Gcis selected from a direct bond, -O- or -Ni l-: and
[0373] QHCis selected from piperazin- 1,4-diyl, piperidin-l,4-diyl, 2,5-diazabicyclo[2.2.1]heptan-2,5-diyl, 1,4- diazepan-l,4-diyl, 3,9-diazaspiro[5.5]undecan-3,9-diyl, 12-oxa-3,9-diazaspiro[5.6]-dodecan-3,9-diyl, l,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2,5-diyl and 3.6-dihvdro-2 / 7-pvridin- l ,4-divl.
[0374] In one embodiment Qcis selected from piperazin- 1,4-diyl, piperidin- 1,4-diyl, -(piperidin-l,4-diyl)O-, 2,5- diazabicyclo[2.2.1]heptan-2,5-diyl, 1,4-diazepan- 1,4-diyl, 3,9-diazaspiro[5.5]undecan-3,9-diyl, 12-oxa-
[0375] 3.9-diazaspiro[5.6]-dodecan-3,9-diyl, l ,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2,5-diyl, 3.6-dihvdro-2 / 7-pvridin- 1 ,4-divl. and -CH2CH2-NH- and -(CH2)g-O- where g is an integer from 1 to 4.
[0376] In one embodiment Qcis piperazin- 1,4-diyl.
[0377] In one embodiment Qcis piperidin- 1,4-diyl.
[0378] In one embodiment Qcis -(piperidin- 1,4-diy 1)0-.
[0379] In one embodiment Qcis 2,5-diazabicyclo[2.2.1]heptan-2,5-diyl.
[0380] In one embodiment Qcis 1,4-diazepan- 1,4-diyl.
[0381] In one embodiment Qcis 3,9-diazaspiro[5.5]undecan-3,9-diyl.
[0382] In one embodiment Qcis 12-oxa-3,9-diazaspiro[5.6]dodecan-3,9-diyl.
[0383] In one embodiment Qcis l,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2,5-diyl.
[0384] In one embodiment Qcis 3.6-dihvdro-2 / 7-pvridin- l ,4-divl.
[0385] In one embodiment Qcis -(Ci-5alkylene)-G- [for example, -(CH2)g-O- where g is an integer from 1 to 5],
[0386] In one embodiment Qcis -(Chalky lene)-G- [for example, -(CH2)g-O- where g is an integer from 1 to 4],
[0387] In one embodiment Qcis -(Ci-3alkylene)-G- [for example, -(CH2)g-O- where g is 1, 2 or 3],
[0388] In one embodiment Qcis -(Chalky lene)-G- [for example, -(CH2)g-O- where g is 1 or 2],
[0389] In one embodiment Qcis -(CH2)g-Gc- where g is an integer from 1 to 5 and Gcis -O- or -NH-.
[0390] In one embodiment Qcis -(CH2)g-Gc- where g is 1 or 2 and Gcis -O- or -NH-.
[0391] In one embodiment Qcis -CH2CH2NH-.
[0392] In one embodiment each QHis independently selected from piperazin- 1,4-diyl, azetidin- 1,3 -diyl, piperidin- 1,4-diyl, 1,4-diazepan- 1,4-diyl, 12-oxa-3,9-diazaspiro[5.6]dodecan-3,9-diyl, pyrrolidin-l,3-diyl, 3,9- diazaspiro[5.5]undecan-3,9-diyl, 2,5-diazabicyclo[2.2.1]heptan-2,5-diyl, 1, 3 ,3a, 4 ,6,6a- hexahydropyrrolo[3,4-c]pyrrol-2,5-diyl, 3.6-dihvdro-2 / 7-pvridin- 1 .4-divl and 9-azaspiro[5.5]undecan-
[0393] 3.9-diyl.
[0394] In one embodiment each QHis independently selected from piperazin- 1,4-diyl, azetidin- 1,3 -diyl, piperidin- 1,4-diyl, 1,4-diazepan- 1,4-diyl, 12-oxa-3,9-diazaspiro[5.6]dodecan-3,9-diyl, pyrrolidin-l,3-diyl, 3,9- diazaspiro[5.5]undecan-3,9-diyl, 2,5-diazabicyclo[2.2.1]heptan-2,5-diyl, 1, 3 ,3a, 4, 6,6a- hexahydropyrrolo[3,4-c]pyrrol-2,5-diyl and 9-azaspiro[5.5]undecan-3,9-diyl.
[0395] In one embodiment QHis piperazin- 1,4-diyl.
[0396] In one embodiment QHis azetidin- 1 ,3-diyl.
[0397] In one embodiment QHis piperidin- 1,4-diyl.
[0398] In one embodiment QHis 1,4-diazepan- 1,4-diyl. In one embodiment QHis 12-oxa-3,9-diazaspiro[5.6]dodecan-3,9-diyl.
[0399] In one embodiment QHis pyrrolidin-l,3-diyl.
[0400] In one embodiment QHis 3,9-diazaspiro[5.5]undecan-3,9-diyl.
[0401] In one embodiment QHis 2,5-diazabicyclo[2.2.1]heptan-2,5-diyl. In one embodiment QHis l,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2,5-diyl.
[0402] In one embodiment QHis 3,6-dihydro-2H-pyridin- 1 ,4-diyl.
[0403] In one embodiment QHis 9-azaspiro[5.5]undecan-3,9-diyl.
[0404] In one embodiment RJis Ci-aalkyl.
[0405] In one embodiment RJis Me. In one embodiment RGis Ci-aalkyl.
[0406] In one embodiment RGis H or Me.
[0407] In one embodiment RGis Me.
[0408] In one embodiment RGis H.
[0409] In one embodiment the Linker (for example ‘a’ -QA-QB-QC- ‘b’) is selected from any of Linkers 1 to 46 or 1 to 48 shown below:
[0410]
[0411] 16 17 18
[0412]
[0413]
[0414] In one embodiment W is an E3 ubiquitin ligase cereblon binder unit attached to the ‘b’ end of the Linker via an available C atom within said E3 ubiquitin ligase cereblon binder unit.
[0415] In one embodiment W is W1 which is: -Z-(RA)h where Z is: wherein: represents a single covalent bond or a double covalent bond;
[0416] 0, 1 or 2 of XA, XB, Xc, XD, XE& XFis / are N, where XE& XEare not both N, and are otherwise C;
[0417] 1 ofXG, XH& XJis C(O); 1 ofXG, XH& XJis N-(2,6-dioxopiperidin-3-yl) (Y); and 1 ofXG, XH& XJis selected from C(RT)2, -CH2CH2-, C(O), N(Ci.3alkyl), -O- and -N=, wherein each RTis selected from H, F, Me or together with the carbon of C(RT)2forms a cycloprop- 1,1 -diyl group; where XG, XH& XJare selected such that there are not two C(O) groups present at adjacent positions, and that the
[0418] N-(2,6-dioxopiperidin-3-yl) is not at an adjacent position to either N(Ci.3alkyl) or O; each RAis independently a substituent on any available C atom at XA, XB, Xcor XDselected from F, Cl, Ci-salkyl, C i-salkoxy wherein said Ci-salkyl and C i-salkoxy is independently optionally substituted by one or more F ; h is 0, 1 or 2; and wherein the Linker is attached to any C atom at XA, XB, Xcor XD.
[0419] In one embodiment 0 or 1 of XA, XB, Xc, XD, XE& XFis N and are otherwise C.
[0420] In one embodiment 1 or 2 of XA, XB, Xc, XD, XE& XEis / are N and are otherwise C.
[0421] In one embodiment XA, XB, Xc, XD, XE& XEare all C.
[0422] In one embodiment 1 of XA, XB, Xc, XD, XE& XEis N and are otherwise C.
[0423] In one embodiment 2 of XA, XB, Xc, XD, XE& XEare N where XE& XEare not both N, and are otherwise C.
[0424] In one embodiment XB, XD& XEare all C, and 0, 1 or 2 of XA, Xc& XEis / are N, and are otherwise C.
[0425] In one embodiment XB, XD& XEare all C, and 0, 1 or 2 of XA, Xc& XEis / are N, and are otherwise C; where the Linker is attached to XBor to XAwhen XAis C.
[0426] In one embodiment XB, XD& XEare all C, and 0, 1 or 2 of XA, Xc& XEis / are N, and are otherwise C; where the Linker is attached to XB.
[0427] In one embodiment XG-XH-XJis:
[0428] (i) XG-NY-C(O) where XGis -CH2-, -CH2CH2-, =N- or C(O);
[0429] (ii) XG-C(O)-NY where XGis -O- or N(Ci-3alkyl) [for example N(Me)]; or
[0430] (iii) C(O)-NY-CH2.
[0431] In one embodiment the Linker is attached to a C atom at XAor XBand XG-XH-XJis:
[0432] (i) XG-NY-C(O) where XGis -CH2-, -CH2CH2-, =N- or C(O);
[0433] (ii) XG-C(O)-NY where XGis -O- or N(Ci-3alkyl) [for example N(Me)]; or
[0434] (iii) C(O)-NY-CH2.
[0435] In one embodiment the Linker is attached to a C atom at XBand XG-XH-XJis:
[0436] (i) XG-NY-C(O) where XGis -CH2-, -CH2CH2-, =N- or C(O);
[0437] (ii) XG-C(O)-NY where XGis -O- or N(Ci-3alkyl) [for example N(Me)]; or
[0438] (iii) C(O)-NY-CH2.
[0439] In one embodiment XG-XH-XJis CH2-NY-C(O).
[0440] In one embodiment XG-XH-XJis CH2CH2-NY-C(O).
[0441] In one embodiment XG-XH-XJis =N-NY-C(O).
[0442] In one embodiment XG-XH-XJis C(O)-NY-C(O). In one embodiment XG-XH-XJis O-C(O)-NY.
[0443] In one embodiment XG-XH-XJis N(Ci-3alkyl)-C(O)-NY [for example N(Me)-C(O)-NY].
[0444] In one embodiment XG-XH-XJis C(O)-NY-CH2.
[0445] In one embodiment each RAis a substituent on any available C at XA, XB, Xcor XDselected from F, Cl and C i-salkoxy optionally substituted by one or more F.
[0446] In one embodiment each RAis a substituent on any available C at XA, XB, Xcor XDselected from F, Cl, OMe and -OCHF2.
[0447] In one embodiment h is 0.
[0448] In one embodiment h is 1.
[0449] In one embodiment h is 2.
[0450] In one embodiment the Linker is attached to Xc, where Xcis C: and XAis C attached to RAwhere RAis OMe where said methyl is optionally substituted by one or more F (e.g. -OCHF2).
[0451] In one embodiment the Linker is attached to Xc, where Xcis C: and XAis C attached to RAwhere RAis OMe or -OCHF2.
[0452] In one embodiment -Z-(RA)h together represent any one of groups 1, 4, 16, 17 and 19 (referring to the specific -Z-(RA)h groups 1 to 21 whose structures are drawn out below).
[0453] In one embodiment h is 1 and RAis Ci-salkoxy [for example OMe],
[0454] In one embodiment h is 1 or 2, one RAis OMe and the other RA(when present, i.e. when h is 2) is Cl.
[0455] In one embodiment h is 1 or 2, one RAis Cl and the other RA(when present, i.e. when h is 2) is OMe.
[0456] In one embodiment h is 1 and RAis F.
[0457] In one embodiment h is 1 and RAis Cl.
[0458] In one embodiment h is 1 and RAis -OCHF2.
[0459] In one embodiment the Linker is attached to a C at XAor XB, and h is 0.
[0460] In one embodiment the Linker is attached to a C at XAor XB, h is 1 and RAis a substituent on Xcwhere Xcis C and RAis F.
[0461] In one embodiment the Linker is attached to a C at XAor XB, h is 1 and RAis a substituent on XDwhere XDis C and RAis OMe or -OCHF2.
[0462] In one embodiment the Linker is attached to a C at XB, h is 0, 1 or 2; the first RA(when present, i.e. when h is 1 or 2) is a substituent on an available C at XDand the second RA(when present, i.e. when h is 2) is on an available C at XA.
[0463] In one embodiment the Linker is attached to a C at XB, h is 0, 1 or 2; the first RA(when present, i.e. when h is 1 or 2) is a substituent on an available C at XDselected from Cl, OMe and -OCHF2; and the second RA(when present, i.e. when h is 2) is on an available C at XAand is selected from Cl and OMe.
[0464] In one embodiment -Z-(RA)h together represent any of the groups 1 to 21 shown below:
[0465] In one embodiment W is W2 which is
[0466] ZAis: wherein: represents a single covalent bond or a double covalent bond;
[0467] 1 of X*2, XB2, XC2& XD2is C and covalently bound to Y ;
[0468] 0, 1 or 2 of XA2, XB2, XC2, XD2, XE2& XF2is / are N (where XE2& XE2are not both N) and are otherwise C;
[0469] 1 or 2 of XG2, XH2& XJ2is / are N; and are otherwise C; each RAAis a substituent on any available C or N atom of Z - in each case independently selected from RAAIoptionally substituted by one or more RAA2: where RAAis further selected from RAA2when RAAis a substituent on an available C atom of ZA; each RAAIis independently Ci.4alkyl, C2-3alkenyl, C2-3alkynyl,
[0470] Ci-salkoxyCi-salkyl, carboxyCi-salkyl, Cj-ycarbocyclyl or a 4-6 membered heterocyclyl; each RAA2is independently selected from F, Cl, Br, CN, NH2, Chalky 1,
[0471] O(C].3alkyl), NH(Ci-3alkyl) and N(Ci-3alkyl)2; wherein said Ci-salkyls are optionally substituted by one or more F; v is 0, 1 or 2;
[0472] Y is N-(2,6-dioxopiperidin-3-yl).
[0473] In one embodiment ZAis: wherein: represents a single covalent bond or a double covalent bond; 1 ol' XA2& XB2is C and covalently bound to Y and the other of XA2& XB2is C;
[0474] 0 or 1 of XC2& XD2is N and is / are otherwise C;
[0475] 1 ofXG2& XJ2is N and the other of XG2& XJ2is C; and
[0476] XH2xE2& XF2are all C.
[0477] In one embodiment -ZA-Y together represent any one or more of the groups Al to A6 shown below, where in each case said ZAgroup is optionally substituted on available C and / or N atom(s) by -[ RAA]v as further defined herein.
[0478] In one embodiment each RAAis a substituent on any available C or N atom of ZA- in each case independently selected from RAAIoptionally substituted by one or more RAA2: where RAAis further selected from RAA2w|lenRAA js a substituent on an available C atom of Z; wherein each RAAIis independently Ci. 4alkyl or a 4-6 membered heterocyclyl; and each RAA2is independently selected from F, Cl, CN and Ci. aalkyl.
[0479] In one embodiment each RAAis a substituent on any available C or N atom of ZA- in each case independently selected from RAAIoptionally substituted by one or more RAA2: where RAAis further selected from RAA2w|lenRAA js asubstituent on an available C atom of ZA; wherein each RAAIis independently methyl, isopropyl, cyclopropyl, pyridinyl or pvrazolvk and each RAA2is independently F, Cl, CN or methyl.
[0480] In one embodiment each RAAis a substituent on an available C atom of ZA, each independently selected from methyl, isopropyl, cyclopropyl, pyridin-2-yl, 1 -methylpyrazol-4-yl, -CH2CN, F, Cl, CN; and / or a methyl substituent on an available N atom of ZA.
[0481] In one embodiment v is 0.
[0482] In one embodiment v is 1.
[0483] In one embodiment v is 2.
[0484] In one embodiment v is 1 or 2.
[0485] In one embodiment v is 0 or 1.
[0486] In one embodiment v is 1 ; XA1is a C atom; and RAAis a substituent on XA1.
[0487] In one embodiment v is 1 ; XA1is a C atom; and RAAis a Ci.4alkyl substituent on XA1.
[0488] In one embodiment v is 1 ; XB1is a C atom; and RAAis a substituent on XB1. In one embodiment v is 1 ; XB1is a C atom; and RAAis a Cj_ ialkvl (e.g. methyl) substituent on XB1.
[0489] In one embodiment v is 1 ; XC1is a C atom; and RAAis a substituent on Xcl.
[0490] In one embodiment v is 1; XC1is a C atom; and RAAis a Ci- ialkvl (e.g. methyl) substituent on Xcl.
[0491] In one embodiment v is 1 ; XD1is a C atom; and RAAis a substituent on XD1.
[0492] In one embodiment v is 1 ; XD1is a C atom; and RAAis a Ci.4alkyl (e.g. methyl) or F substituent on XD1.
[0493] In one embodiment v is 1 ; XG1is a C atom; and RAAis a substituent on XG1.
[0494] In one embodiment v is 1 ; XG1is a C atom; and RAAis a substituent on XG1; where RAAis selected from RAAIoptionally substituted by one or more RAA2: or RAAis selected from RAA2: wherein RAAIis Ci.4alkyl or a 4-6 membered heterocyclyl; and RAA2is selected from F, Cl, CN and Ci-aalkyl.
[0495] In one embodiment v is 1 ; XG1is a C atom; and RAAis a substituent on XG1; where RAAis selected from methyl, isopropyl, cyclopropyl, pyridine- 2-yl, 1 -methylpyrazol-4-yl, -CH2CN, F, Cl and CN.
[0496] In one embodiment v is 1 or 2; XG1is a C atom; and one / the RAAis a substituent on XG1; where RAAis selected from RAAIoptionally substituted by one or more RAA2: or RAAis selected from RAA2: wherein RAAIis C].4alkyl or a 4-6 membered heterocyclyl; and RAA2is selected from F, Cl, CN and Ci-aalkyl; and when v is 2, the additional RAAis a fluoro substituted on an available C atom of ZA.
[0497] In one embodiment v is 1 ; XG1is a N atom; and RAAis a substituent on XG1.
[0498] In one embodiment v is 1 ; XG1is a N atom; and RAAis a Ci.4alkyl (e.g. methyl) substituent on XG1.
[0499] In one embodiment v is 1 ; XH1is a C atom; and RAAis a substituent on XH1.
[0500] In one embodiment v is 1 ; XH1is a C atom; and RAAis a substituent on XH1that is CN or Ci.4alkyl (e.g. methyl).
[0501] In one embodiment v is 1 or 2; XH1and XG1are both C atoms, one or both of which are substituted by RAAwhere each RAAis independently selected from CN or Ci.4alkyl (e.g. methyl).
[0502] In one embodiment the group: together represents one or more of the groups Al to A29, shown below:
[0503]
[0504] wherein:
[0505] XKand XLare either N-linker and CH or NMe and C-linker respectively;
[0506] 1 ofXMand X° is N-(2,6-dioxopiperidin-3-yl) (Y);
[0507] 0 or 1 of XMand XNis C-F;
[0508] XN may be N if XMis not C-F ; the remainder of XN, XMand X° are CH.
[0509] In one embodiment W represents any of the groups 22 to 26 shown below: In a further aspect of the specification Formula (la) is selected from any one or more of the following groups
[0510] (1) to (28) or (1) to (39):
[0511] ( 1 ) 4- [ 1 - [4-cy ano-3 -(trifluoromethyl)pheny 1] -4-piperidy l]phenyl,
[0512] (2) 4-[l-(4-cyano-3-cyclopropyl-phenyl)-4-piperidyl]phenyl,
[0513] (3) 4-[l-[4-cyano-2-fluoro-3-(trifluoromethyl)phenyl]-4-piperidyl]phenyl,
[0514] (4) 2-[l-[4-cyano-3-(trifluoromethyl)phenyl]-4-piperidyl]pyrimidin-5-yl,
[0515] (5) 6-[l-[4-cyano-3-(trifluoromethyl)phenyl]-4-piperidyl]pyridin-3-yl,
[0516] (6) 4-[l-[6-cyano-5-(trifluoromethyl)-3-pyridyl]-4-piperidyl]phenyl,
[0517] (7) 4-[l-(3-chloro-4-cyano-phenyl)-4-piperidyl]phenyl,
[0518] (8) 4-[l-(4-cyano-3-methoxy-phenyl)-4-piperidyl]phenyl,
[0519] (9) 4-[l-(5-cyano-6-methyl-2-pyridyl)-4-piperidyl]phenyl,
[0520] (10) 4-[l-(5-cyano-8-quinolyl)-4-piperidyl]phenyl,
[0521] (11) 4- [(4S)- 1 -[4-cyano-3-(trifluoromethyl)phenyl] -3 ,3-dimethyl-4-piperidyl]phenyl
[0522] (12) 4-[(4R)-l-[4-cyano-3-(trifluoromethyl)phenyl]-3,3-dimethyl-4-piperidyl]phenyl
[0523] (13) 4-[l - [4-cy ano-3 -(trifluoromethyl)pheny 1] -3 ,3 -dimethy 1-4-piperidy 1] phenyl,
[0524] (14) 4-[l-[4-cyano-3-(trifluoromethyl)phenyl]-4-piperidyl]-2-fluorophenyl,
[0525] (15) 4-[l-[4-cyano-3-(trifluoromethyl)phenyl]-4-piperidyl]-3-fluorophenyl,
[0526] (16) 4- [ 1 - [4-cy ano-3 -(trifluoromethyl)pheny 1] -4-piperidy 1]- 3-methy Iphenyl,
[0527] (17) 4-[(2>S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2-methyl-piperazin-l-yl]phenyl,
[0528] (18) 4- [(2R)-4- [4-cyano-3 -(trifluoromethyl)pheny 1] -2-methy 1-piperazin- 1 -yl] phenyl,
[0529] (19) 4-[4-[4-cyano-3-(trifluoromethyl)phenyl]-2-methyl-piperazin-l-yl]phenyl,
[0530] (20) 5- [ 1 - [4-cy ano-3 -(trifluoromethyl)pheny 1] -4-piperidy l]pyridin-2-y 1,
[0531] (21) 4- [4- [4-cy ano-3 -(trifluoromethyl)pheny l]piperazin- 1 -y l]pheny 1,
[0532] (22) 4-[(3R)-l-[4-cyano-3-(trifluoromethyl)phenyl]pyrrolidin-3-yl]phenyl,
[0533] (23) 4-[(3S)-l-[4-cyano-3-(trifluoromethyl)phenyl]pyrrolidin-3-yl]phenyl,
[0534] (24) 4-[l-[4-cyano-3-(trifluoromethyl)phenyl]pyrrolidin-3-yl]phenyl,
[0535] (25) 4-[l-[4-cyano-3-(difluoromethyl)phenyl]-4-piperidyl]phenyl,
[0536] (26) 4-[(4R)-l-[4-cyano-3-(trifluoromethyl)phenyl]azepan-4-yl]phenyl,
[0537] (27) 4- [(4R)- 1 - [4-cyano-3 -(trifluoromethyl)pheny 1] azepan-4-y l]pheny 1,
[0538] (28) 4-[l-[4-cyano-3-(trifluoromethyl)phenyl]azepan-4-yl]phenyl,
[0539] (29) 4-[l-[4-cyano-3-(trifluoromethyl)phenyl]-4-piperidyl]-3,5-difluoro-phenyl,
[0540] (30) 4-[(2S)-4-[4-cyano-2-fluoro-3-(trifluoromethyl)phenyl]-2-methyl-piperazin-l-yl]phenyl,
[0541] (31) 4-[(3R)-4-[4-cyano-3-(trifluoromethyl)phenyl]-3-methyl-piperazin-l-yl]phenyl,
[0542] (32) 4-[(3S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-3-methyl-piperazin-l-yl]phenyl,
[0543] (33) (3S,4R)-l-[4-cyano-2-fluoro-3-(trifluoromethyl)phenyl]-3-methyl-4-piperidyl,
[0544] (34) (3R,4S)-l-[4-cyano-2-fluoro-3-(trifluoromethyl)phenyl]-3-methyl-4-piperidyl,
[0545] (35) 4-[l-[4-cyano-2-ethyl-3-(trifluoromethyl)phenyl]-4-piperidyl]phenyl,
[0546] (36) 4-[l-[4-cyano-2-fluoro-3-(trifluoromethyl)phenyl]-4-piperidyl]-3,5-difluoro-phenyl,
[0547] (37) 4-[l-[4-cyano-2-fluoro-3-(trifluoromethyl)phenyl]-4-piperidyl]-3-fluoro-phenyl, (38) 4- [ 1 -(4-cyano-3-cyclopropyl-phenyl)-4-piperidyl] -3-fluoro-phenyl and
[0548] (39) 4-[l-[4-cyano-2-fluoro-3-(trifluoromethyl)phenyl]-4-piperidyl]-3-methyl-phenyl.
[0549] In a further aspect of the specification there is provided a PROTAC compound or a pharmaceutically acceptable salt thereof, containing an E3 ubiquitin ligase cereblon binder unit and an AR binding unit of Formula (la) or Formula (lb): where:
[0550] QAis -G-QH- or -G-(Ci.5alkylene)-;
[0551] G is a direct bond, -CH2-, -O-, or -N(RG)- where each RGis independently H or Ci-aalkyl;
[0552] QHis a 4-12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group; and where R1, p, X1, X2, X3, X4, n, m, R2a, R2b, Q, Y1, Y2, Y3, Y4, R3and q may take any of the values defined herein for each of these groups / variables respectively.
[0553] In one embodiment QHis a 4-12-membered nitrogen-containing saturated heterocyclic group.
[0554] For avoidance of doubt in Formula (lb) indicates a point of connection via a single covalent bond to the remainder of the PROTAC compound.
[0555] In a further aspect of the specification there is provided a PROTAC compound or a pharmaceutically acceptable salt thereof, containing an E3 ubiquitin ligase cereblon binder unit linked to an AR binding unit of Formula (la) of Formula (lb), as defined herein.
[0556] In further embodiments of this specification Formula (lb) may be: where Lxmay be any of the groups (1) to (28) or (1) to (39) listed hereinabove in connection with Formula (la); and where QAmay take any value(s) disclosed herein for QA.
[0557] In a further aspect of the specification there is provided a PROTAC compound or a pharmaceutically acceptable salt thereof, containing an E3 ubiquitin ligase cereblon binder unit and an AR binding unit of Formula (la) of Formula (Ic): where:
[0558] QAis -G-QH- or -G-(Ci.5alkylene)-;
[0559] G is a direct bond, -CH2-, -O-, or -N(RG)- where RGis H or Ci.jalkyl;
[0560] QBis a direct bond, -QB1-QB2-QB3- or Ci-aalkylene optionally substituted by one or more F (e.g. 1 or 2 ): where:
[0561] QB1& QB3each independently represent a direct bond or Chalky lene;
[0562] QB2is QH, -O-CH2CH2-O-, -O- or -N(RJ)- where RJis H or Ci.3alkyl; and each QHis indepdendently a 4-12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group; where the values of QAand QBare selected so that Formula (Ic) does not contain any N-N or N-O bonds; and where R1, p, X1, X2, X3, X4, n, m, R2a, R2b, Q, Y1, Y2, Y3, Y4, R3and q may otherwise take any of the values defined herein for each of these groups / variables respectively.
[0563] In one embodiment QHis a 4-12-membered nitrogen-containing saturated heterocyclic group. For avoidance of doubt in Formula (Ic) indicates a point of connection via a single covalent bond to the remainder of the PROF AC compound.
[0564] In a further aspect of the specification there is provided a PROF AC compound or a pharmaceutically acceptable salt thereof, containing an E3 ubiquitin ligase cereblon binder unit linked to an AR binding unit of Formula (la) of Formula (Ic), as defined herein.
[0565] In further embodiments of this specification Formula (lb) may be: where Lxmay be any of the groups (1) to (28) listed hereinabove in connection with Formula (la); and where QAand QBmay take any value(s) disclosed herein for QAand QB.
[0566] In further embodiments there is / are provided compound(s) or pharmaceutically acceptable salt thereof wherein said compound(s) is / are selected from one or more of the “Examples” listed hereinafter. Phus, these embodiments include one or more specific Examples (for instance one Example, or two or three specific Examples) selected from the group consisting of Examples 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43,
[0567] 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72,
[0568] 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101,
[0569] 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141 , 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 153, 164, 165, 166 and 167.
[0570] It is to be understood that the compound of an Example listed hereinafter relates to the title compound name, and is not limited in any way by the method of preparation nor whether a given compound was isolated in the form of a salt rather than as a neutral molecule.
[0571] In some embodiments there is provided a compound of Formula (VI): or a pharmaceutically acceptable salt thereof, wherein:
[0572] RZ1is H or F; is H or F;
[0573] RZ3 is H or F; is a linker selected from 1, 3, 45 and 47:
[0574] and Wzis selected from 1, 2, 3, 10, 16, 22, 23, 24 and 26: where Y is N-(2,6-dioxopiperidin-3-yl).
[0575] In some embodiments there is provided a compound of Formula (VI-1): or a pharmaceutically acceptable salt thereof, wherein:
[0576] RZ1is H or F;
[0577] Lzis a linker selected from 1 and 3: and Wzis selected from 1, 2 and 10: where Y is N-(2,6-dioxopiperidin-3-yl).
[0578] In some embodiments there is provided a compound of Formula (VI-2): or a pharmaceutically acceptable salt thereof, wherein:
[0579] RZ1isHorF;
[0580] RZ2isHorF;
[0581] RZ3is H or F; Lzis a linker selected from 3, 45 and 47 : and Wzis selected from 1, 3, 16, 22, 23, 24 and 26: where Y is N-(2,6-dioxopiperidin-3-yl).
[0582] A further embodiment provides any of the embodiments, claims or aspects defined herein with the proviso that one or more specific Examples (for instance one Example, or two or three specific Examples) selected from the group consisting of Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48,
[0583] 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77,
[0584] 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104,
[0585] 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135 and 136 is individually disclaimed. A further embodiment provides any of the embodiments, claims or aspects defined herein with the proviso that one or more specific Examples (for instance one Example, or two or three specific Examples) selected from the group consisting of Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,
[0586] 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48,
[0587] 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104,
[0588] 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126,
[0589] 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148,
[0590] 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 153, 164, 165, 166 and 167 is individually disclaimed. The compounds of Formula (I) and PROTAC compounds containing binding units of Formula (la) may have one or more chiral centres and it will be recognised that such compounds may be prepared, isolated and / or supplied with or without the presence of one or more of the other possible enantiomeric and / or diastereomeric isomers of said compounds or that such isomers may be provided in any relative proportions. The preparation of enantioenriched / enantiopure and / or diastereoenriched / diastereopure compounds may be carried out by standard techniques of organic chemistry that are well known in the art, for example by synthesis from enantioenriched or enantiopure starting materials, and / or by use of an appropriately enantioenriched or enantiopure catalyst during synthesis, and / or by resolution of a racemic or partially enriched mixture of stereoisomers, for example via chiral chromatography.
[0591] For use in a pharmaceutical context it may be preferable to provide such compounds (or a pharmaceutically acceptable salt thereof) without large amounts of the other stereoisomeric forms being present.
[0592] Accordingly, in one embodiment there is provided a composition comprising a compound of Formula (I) [or PROTAC compound containing a unit of Formula (la)] or a pharmaceutically acceptable salt thereof, optionally together with one or more of the other stereoisomeric forms of the compound of Formula (I) [or PROTAC compound containing a unit of Formula (la)] or pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) [or PROTAC compound containing a unit of Formula (la)] or pharmaceutically acceptable salt thereof is present within the composition with a diastereomeric excess (%de) of > 90%.
[0593] In a further embodiment the %de in the above-mentioned composition is > 95%.
[0594] In a further embodiment the %de in the above-mentioned composition is > 98%.
[0595] In a further embodiment the %de in the above-mentioned composition is > 99%.
[0596] In a further embodiment there is provided a composition comprising a compound of Formula (I) [or PROTAC compound containing a unit of Formula (la) as defined herein] or a pharmaceutically acceptable salt thereof, optionally together with one or more of the other stereoisomeric forms of the compound of Formula (I) [or PROTAC compound containing a unit of Formula (la) as defined herein] or pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) [or PROTAC compound containing a unit of Formula (la) as defined herein] or pharmaceutically acceptable salt thereof is present within the composition with an enantiomeric excess (%ee) of > 90%.
[0597] In a further embodiment the %ee in the above-mentioned composition is > 95%.
[0598] In a further embodiment the %ee in the above-mentioned composition is > 98%.
[0599] In a further embodiment the %ee in the above-mentioned composition is > 99%.
[0600] In a further embodiment there is provided a composition comprising a compound of Formula (I) [or PROTAC compound containing a unit of Formula (la) as defined herein] or a pharmaceutically acceptable salt thereof, optionally together with one or more of the other stereoisomeric forms of the compound of Formula (I) [or PROTAC compound containing a unit of Formula (la) as defined herein], or pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) [or PROTAC compound containing a unit of Formula (la) as defined herein], or pharmaceutically acceptable salt thereof is present within the composition with an enantiomeric excess (%ee) of > 90% and a diastereomeric excess (%de) of > 90%.
[0601] In further embodiments of the above-mentioned composition the %ee and %de may take any combination of values as listed below:
[0602] • The %ee is <5% and the %de is > 80%.
[0603] • The %ee is <5% and the %de is > 90%.
[0604] • The %ee is <5% and the %de is > 95%.
[0605] • The %ee is <5% and the %de is > 98%.
[0606] • The %ee is > 95% and the %de is > 95%.
[0607] • The %ee is > 98% and the %de is > 98%.
[0608] • The %ee is > 99% and the %de is > 99%.
[0609] In a further embodiment there is provided a pharmaceutical composition which comprises a compound of the Formula (I) [or PROTAC compound containing a unit of Formula (la) as defined herein], or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient.
[0610] In one embodiment there is provided a pharmaceutical composition which comprises a compound of the Formula (I) [or PROTAC compound containing a unit of Formula (la) as defined herein], or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient, optionally further comprising one or more of the other stereoisomeric forms of the compound of Formula (I) [or PROTAC compound containing a unit of Formula (la) as defined herein], or pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) [or PROTAC compound containing a unit of Formula (la) as defined herein] , or pharmaceutically acceptable salt thereof is present within the composition with an enantiomeric excess (%ee) of > 90%.
[0611] In a further embodiment the %ee in the above-mentioned composition is > 95%.
[0612] In a further embodiment the %ee in the above-mentioned composition is > 98%.
[0613] In a further embodiment the %ee in the above-mentioned composition is > 99%.
[0614] In one embodiment there is provided a pharmaceutical composition which comprises a compound of the Formula (I) [or PROTAC compound containing a unit of Formula (la) as defined herein], or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient, optionally further comprising one or more of the other stereoisomeric forms of the compound of Formula (I) [or PROTAC compound containing a unit of Formula (la) as defined herein], or pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) [or PROTAC compound containing a unit of Formula (la) as defined herein] , or pharmaceutically acceptable salt thereof is present within the composition with a diastereomeric excess (%de) of > 90%.
[0615] In a further embodiment the %de in the above-mentioned composition is > 95%.
[0616] In a further embodiment the %de in the above-mentioned composition is > 98%.
[0617] In a further embodiment the %de in the above-mentioned composition is > 99%.
[0618] In one embodiment there is provided a pharmaceutical composition which comprises a compound of the Formula (I) [or PROTAC compound containing a unit of Formula (la) as defined herein], or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient, optionally further comprising one or more of the other stereoisomeric forms of the compound of Formula (I) [or PROTAC compound containing a unit of Formula (la) as defined herein], or pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) [or PROTAC compound containing a unit of Formula (la) as defined herein] , or pharmaceutically acceptable salt thereof is present within the composition with an enantiomeric excess (%ee) of > 90% and a diastereomeric excess (%de) of > 90%.
[0619] In further embodiments of the above-mentioned pharmaceutical composition the %ee and %de may take any combination of values as listed below:
[0620] • The %ee is > 95% and the %de is > 95%.
[0621] • The %ee is > 98% and the %de is > 98%.
[0622] • The %ee is > 99% and the %de is > 99%.
[0623] The compounds of Formula (I) [or PROTAC compound containing a unit of Formula (la) as defined herein], and pharmaceutically acceptable salts thereof may be prepared, used or supplied in amorphous form, crystalline form, or semicrystalline form and any given compound of Formula (I) [or PROTAC compound containing a unit of Formula (la) as defined herein], or pharmaceutically acceptable salt thereof may be capable of being formed into more than one crystalline / polymorphic form, including hydrated (e.g. hemi-hydrate, a mono-hydrate, a di-hydrate, a tri-hydrate or other stoichiometry of hydrate) and / or solvated forms. It is to be understood that the present specification encompasses any and all such solid forms of the compound of Formula (I) [or PROTAC compound containing a unit of Formula (la) as defined herein], and pharmaceutically acceptable salts thereof.
[0624] In further embodiments there is provided a compound of Formula (I) [or PROTAC compound containing a unit of Formula (la) as defined herein] which is obtainable by the methods described in the ‘Examples’ section hereinafter.
[0625] Intermediate Compounds
[0626] As demonstrated in the experimental section hereinafter, the compounds of Formula (I) or PROTACs of Formula (la) may be prepared, for example, by the following methods.
[0627] A compound of Formula (I) [or salt thereof] or a PROTAC compound of Formula (la) [or a salt thereof] may be prepared from a compound of Formula (II): or a salt thereof, where:
[0628] QAis -G-QH- or -G-(Ci-5alkylene)-;
[0629] G is a direct bond, -CH2-, -O-, or -N(RG)- where RGis H or Ci-jalkyl;
[0630] QHis a 4 to 12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group;
[0631] QDis a direct bond or Ci.2alkylene optionally substituted by one or more F; RL1and RL2together form “=O”, RL3is H: where when QDis a direct bond and QAis -G-QH-;the value of QHis selected so that QDconnects to a C atom of Q": and
[0632] R1, p, X1, X2, X3, X4, n, m, Q, R2a, R2b, Y1, Y2, Y3, Y4, R3and q may take any of the values disclosed herein for each of those groups / variables respectively.
[0633] In one embodiment QHis a 4-12-membered nitrogen-containing saturated heterocyclic group.
[0634] Accordingly such compound of Formula (II) as described above is an aldehyde which may be reacted with a suitable molecule containing an amine group (for example a secondary amine group) to form the compound of Formula (I) or PROTAC compound of Formula (la) - either directly, or after one or more additional reaction steps. Such reaction of said aldehyde with said amine can be carried out under reductive amination conditions, using for example NaBI [(OAcy or another reductive amination protocol known to the skilled person.
[0635] Such aldehyde may in turn be prepared from the corresponding acetal, for example a compound of Formula (II), or salt thereof, as defined above, except that: RL1and RL2are each independently C ...alkoxv (for example Ci-aalkoxy) or RL1& RL2together form -O-(CH2)k-O- where k is 2 or 3. Such acetal may be converted to the corresponding aldehyde under acidic conditions, for example using formic acid under conditions well known to the skilled person.
[0636] Alternatively, as shown in the experimental section hereinafter, the above-mentioned aldehyde may be prepared by oxidation of the corresponding primary alcohol, i.e. a compound of Formula (II), or salt thereof, as defined above except that RL1is OH and RL2is H. Such oxidation may be carried out using mild oxidising conditions, for example Dess-Martin periodinane or some other mild oxidation protocol known to the skilled person.
[0637] As shown in the experimental section hereinafter, a compound of Formula (I) [or salt thereof] or a PROTAC compound of Formula (la) [or a salt thereof] may be prepared from a compound of Formula (II) or a salt thereof, as described above except that RL1is a leaving group and RL2is H. Accordingly, such compound of Formula (II) is an electrophile that may be reacted with a molecule containing an amine group (for example a secondary amine group) via an alkylation reaction to form the compound of Formula (I) or PROTAC compound of Formula (la) - either directly, or after one or more additional reaction steps. Suitable leaving groups for alkylation reactions are well known to the skilled person and include Cl, Br, I, trifluoromethanesulfonate, mesylate and tosylate. Alkylation reaction conditions are well known to the skilled person and generally involve a non-nucleophilic base (e.g. DIPEA) and a polar aprotic solvent (e.g. MeCN). As demonstrated in the experimental section hereinafter, in cases where the leaving group is not I, a metal iodide salt may be used in the reaction mixture to form the corresponding iodide in-situ (i.e. where RL1is I) to facilitate the overall alkylation process. As shown in the experimental section hereinafter, a compound of Formula (II) where RL1is a bromo leaving group may be prepared from the corresponding primary alcohol (i.e. as already described above where RL1is OH, and RL2& RL3are both H.
[0638] In turn, the above-mentioned primary alcohol compound of Formula (II) may be prepared by the reduction of the corresponding ester compound, i.e. a compound of Formula (II), or salt thereof, as defined above, except that: RL1and RL2together form “=O” and RL3is C ...alkoxv (for example C .vilkoxv ;. Such reduction may be carried out using strong reduction conditions, for example using DIBAL or other stronger reducing conditions which are well known to the skilled person.
[0639] Alternatively, as demonstrated in the experimental section hereinafter, it may be convenient to form the above-mentioned primary alcohol compound of Formula (II) via deprotection of a protected form of the alcohol. For example, deprotection of a compound where there alcohol is protected by a silicon-based protecting group, using a source of fluoride in order to achieve the deprotection, for example TBAF or other deprotection methods well-known to the skilled person.
[0640] Therefore, as described above, various compounds of Formula (II), and salts thereof, may be useful as intermediates in the synthesis of the compounds of Formula (I) or PROTAC compounds of Formula (la), and accordingly such intermediate compounds provide a further aspect of the specification.
[0641] Therefore, in a further aspect there is provided a compound of Formula (II), as shown above, or a salt thereof, wherein:
[0642] QAis -G-QH- or -G-(Ci-5alkylene)-;
[0643] G is a direct bond, -CH2-, -O-, or -N(RG)- where RGis H or Ci-jalkyl;
[0644] QHis a 4-12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group;
[0645] QDis a direct bond or C ^alkylene optionally substituted by one or more F (for example 1 or 2 F); and
[0646] (i) RL1& RL2together form “=O” and RL3is H or Ci-ealkoxy (for example OMe);
[0647] (ii) RL1& RL2are each independently Ci-salkoxy (for example OMe), and RL3is H;
[0648] (iii) RL1& RL2together form -O-(CH2)k-O- where k is 2 or 3, and RL3is H; or
[0649] (iv) RL1is OH, OPG1(where PG1is a protecting group), or LG1(where LG1is a leaving group), and
[0650] RL2& RL3are both H; where when QDis a direct bond and QAis -G-QH-, the value of QHis selected so that QDconnects to a C atom of QH; and R1, p, X1, X2, X3, X4, n, m, Q, R2a, R2b, Y1, Y2, Y3, Y4, R3and q may take any of the values disclosed herein for each of those groups / variables respectively.
[0651] In one embodiment QHis a 4-12-membered nitrogen-containing saturated heterocyclic group.
[0652] The skilled person is aware of suitable protecting groups for alcohol groups and therefore is aware of suitable values of PG1. For example PG1is an alcohol protecting group.
[0653] In one embodiment PG1is a silicon-based alcohol protecting group.
[0654] In one embodiment PG1is Si( RSlh where each RS|is independently a C i-ehydrocarbyl group.
[0655] In one embodiment PG1is tert-butyldimethylsilyl or tert-butyldiphenylsilyl.
[0656] In one embodiment the LG1is selected from Cl, Br, I, trifluoromethanesulfonate and C i.yhydrocarbylsulfonate (for example mesylate or p-toliienesiill'onate).
[0657] In one embodiment LG1is Br or I.
[0658] In one embodiment LG1is Br.
[0659] In one embodiment LG1is Cl.
[0660] In one embodiment LG1is I.
[0661] In one embodiment LG1is trifluoromethanesulfonate.
[0662] In one embodiment LG1is C .-Iwdrocarbv I sulfonate.
[0663] In one embodiment LG1is mesylate. In one embodiment LG1is / >-toluenesulfonate.
[0664] In one embodiment QDis a direct bond, -CH2-, -CH2CH2- or -CF2CH2-.
[0665] In one embodiment QDis a direct bond.
[0666] In one embodiment QDis CH2.
[0667] In one embodiment QDis Ci.2alkylene optionally substituted by 1 or 2 F.
[0668] In one embodiment QDis Ci.2alkylene.
[0669] In one embodiment QDis -CH2CH2-.
[0670] In one embodiment QDis -CF2CH2-.
[0671] In further embodiments of this specification Formula (II) may be Formula (Ila): where Lxmay be any of the groups (1) to (28) or (1) to (39) listed hereinabove in connection with Formula (la); and where QA, QD, RL1, RL2and RL3may take any of the values disclosed herein for each of said groups respectively.
[0672] As demonstrated in the experimental section hereinafter, certain compounds of Formula (I) and certain PROTACS of Formula (la) and certain intermediate compounds of Formula (II) may be prepared using a compound of Formula (III): or a salt thereof, where Gxis OH, where the oxygen atom of said OH is alkylated by a suitable molecule to form certain compounds of Formula (I) or PROTACs of Formula (la) - either directly, or after one or more further reaction steps (for example via Formula (II) as described hereinabove). Such alkylation reactions may be carried out under conditions well known to the skilled person, for example using a primary alkyl bromide (or using some other leaving group in place of Br) using a non-nucleophilic base such as a metal carbonate (e.g. K2CO3) in a polar aprotic solvent such as MeCN, optionally in the presence of a metal iodide salt such as KI.
[0673] Alternatively, as shown in the experimental section hereinafter, a compound of Formula (III) where Gxis -NH(RG) [where RGis H or C .vilkvl (for example Me)] may be used as an intermediate to prepare compounds of Formula (I) or PROTACs of Formula (la) via reductive amination chemistry with an appropriate aldehyde- containing compound. Alternatively, as shown in the experimental section hereinafter, a compound of Formula (III) where Gxis bromo may be coupled with a secondary amine compound to give certain compounds of Formula (I) or PROTACs of Formula (la) - either directly, or after one or more further reaction steps (for example via Formula (II) as described hereinabove). Similarly, compounds of Formula (111) where Gxis chloro or trifluoromethanesulfonate may also be used in a coupling reaction with the relevant secondary amine to give certain compounds of Formula (I) or PROTACs of Formula (la). Such coupling may be carried out under palladium-based coupling conditions (e.g. using ‘Ruphos Pd G3’ and ‘Ruphos’) in the presence of a base and an anhydrous solvent such as 1,4-dioxane under an inert atmosphere, or by heating with Cui in the presence of a base such as K3PO4 in a polar solvent such as DMSO. Alternatively, also as shown in the experimental section herein, a compound of Formula (III) where Gxis bromo may be coupled with a suitable alcohol to form certain compounds of Formula (I) or PROTACs of Formula (la) - either directly, or after one or more further reaction steps (for example via Formula (II) as described hereinabove). Such coupling may be carried out using a palladium-based reagent such as ‘Rockphos Pd G3’ in the presence of a base such as CS2CO3 in a solvent such as toluene.
[0674] Accordingly, compounds of Formula (III), and salts thereof, may be useful as intermediates in the synthesis of certain compounds of Formula (I) or PROP AC compounds of Formula (la) or compounds of Formula (II), and accordingly such intermediate compounds provide a further aspect of the specification.
[0675] Therefore, in a further aspect there is provided a compound of Formula (III), as shown above, or a salt thereof, wherein:
[0676] Gxis OH, Cl, Br, triflouoromethanesulfonate or -NH(RG) where RGis H or Ci-salkyl; and R1, p, X1, X2, X3, X4, n, m, Q, R2a, R2b, Y1, Y2, Y3, Y4, R3and q may take any of the values disclosed herein for each of those groups / variables respectively.
[0677] Gxis OH, Cl, Br, triflouoromethanesulfonate or -NH(RG) where RGis C i-salkyl (for example Me). In one embodiment Gxis OH, Br, trifluoromethanesulfonate or -NH(RG) where RGis C i-salkyl (for example Me).
[0678] In one embodiment Gxis OH, Br or -NH(RG) where RGis C i-salkyl (for example Me). In one embodiment Gxis OH or Br. In one embodiment Gxis OH. In one embodiment Gxis Br. In one embodiment Gxis Cl.
[0679] In one embodiment Gxis trifluoromethanesulfonate.
[0680] In one embodiment Gxis -NH(RG) where RGis H or Ci-salkyl. In one embodiment Gxis -NH(RG) where RGis Ci-salkyl. In one embodiment Gxis -NH(Me).
[0681] In further embodiments of this specification, Formula (III) may be Lx— Gxwherein Lxmay be any of the groups (1) to (28) or (1) to (39) listed hereinabove in connection with Formula (la); and where Gxmay take any value(s) disclosed herein for Gx.
[0682] As demonstrated in the experimental section hereinafter, certain compounds of Formula (I) and PROTACs of Formula (la) may be prepared using an intermediate compound of Formula (IV): or a salt thereof, as further defined below. For example, a compound of Formula (IV), or salt thereof, where J is H (i.e. a secondary amine compound) may be coupled to a further chemical fragment, using chemistry well known to the skilled person and exemplified in the experimental section hereinafter, to provide a compound of Formula (I) or PROTAC of Formula (la), either directly, or after one or more further reaction steps.
[0683] In turn, such a compound of Formula (IV) where J is H may conveniently be prepared via deprotection of an TV-protected form of the aforementioned amine compound. Accordingly compounds of Formula (IV) where J is H may be conveniently be prepared using a compound of Formula (IV) where J is PG2where PG2is a nitrogen protecting group (for example a Ci-ealkoxy carbonyl group such as tertbutoxycarbonyl). Therefore, compounds of Formula (IV) where J is PG2are useful intermediates in the preparation of the compound of Formula (I) and PROTAC of Formula (la) and provide a further aspect of the specification.
[0684] Therefore in a further aspect of the specification there is provided a compound of Formula (IV) as depicted above, or a salt thereof, wherein:
[0685] J is H or PG2where PG2is a nitrogen protecting group (for example a tert-butoxycarbonyl group);
[0686] QAis -G-QH- or -G-(Ci.5alkylene)-;
[0687] G is a direct bond, -CH2-, -O-, or -N(RG)- where RGis H or Ci-aalkyl;
[0688] QBis a direct bond, -QB1-QB2-QB3- or Ci.vilkvlene optionally substituted by one or more F (e.g. 1 or 2); where:
[0689] QB1& QB3each independently represent a direct bond or Chalky lene;
[0690] QB2is QH, -O-CH2CH2-O-, -O- or -N(RJ)- where RJis H or Ci.3alkyl; and each QH(including the “QHRing” attached to J) is independently a 4-12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group; where the values of QA, QBand QHRing are selected so that Formula (IV) does not contain any N-N or N-O bonds; and where R1, p, X1, X2, X3, X4, n, m, R2a, R2b, Q, Y1, Y2, Y3, Y4, R3and q may take any of the values defined herein for each of these groups / variables respectively.
[0691] In one embodiment each QH(including the “QHRing” attached to J) is independently a 4-12-membered nitrogen-containing saturated heterocyclic group.
[0692] In one embodiment the QHRing is piperidin-l,4-diyl or piperazin- 1 ,4-diyl.
[0693] In one embodiment J is H.
[0694] In one embodiment J is PG2.
[0695] In one embodiment PG2is C i-ealkoxycarbonyl.
[0696] In one embodiment PG2is tert-butoxycarbonyl. In one embodiment where PG2is C i-ealkoxycarbonyl (e.g. tert-butoxycarbonyl) the ‘and salts thereof element of the claim is excluded.
[0697] In further embodiments the compound of Formula (IV) may take any combination of alternative values mentioned in relation to QAQBand QHin any other context, embodiment, aspect or claim found herein.
[0698] In further embodiments of this specification Formula (IV) may be Formula (IVa): where Lxmay be any of the groups (1) to (28) or (1) to (39) listed hereinabove in connection with Formula (la); and where QA, QB, QHand J may take any of the values disclosed herein for each of said groups respectively.
[0699] As also demonstrated in the experimental section hereinafter, certain compounds of Formula (I) and PROTACs of Formula (la) may be prepared using an intermediate compound of Formula (V): or a salt thereof, wherein:
[0700] Xxis N substituted by J where J is H;
[0701] G is a direct bond, -CH2-, -O-, or -N(RG)- where RGis H or Ci-aalkyl;
[0702] QHRing is a 4-12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group; where the values of G and QHRing are selected so that Formula (V) does not contain any N-N or N-O bonds; and where R1, p, X1, X2, X3, X4, n, m, R2a, R2b, Q, Y1, Y2, Y3, Y4, R3and q may take any of the values defined herein for each of these groups / variables respectively.
[0703] Such a compound of Formula (V) may be converted to a compound of Formula (I) or PROTAC of Formula (la) via reductive amination or alkylation or other coupling chemistry known to the skilled person - to provide the compound of Formula (I) or PROTAC of Formula (la) either directly, or after one or more additional steps.
[0704] In turn, as shown in the experimental section hereinafter, such a compound of Formula (V), or a salt thereof, may be conveniently prepared by deprotection of the corresponding TV-protected compound. Such N- protected form may be a BOC-protected form (i.e. tert-butoxycarbonyl) or may use another A -protecting group known to the skilled person. Accordingly, such TV-protected compounds are also useful intermediates in the preparation of the compounds of Formula (I) and PROTACs of Formula (la) and provide a further aspect of the specification. Accordingly one aspect of the specification provides a compound of Formula (V), or a salt thereof, as described above except that Xxis N substituted by J where J is PG3and PG3is a protecting group. In one embodiment PG3is Ci-ealkoxy carbonyl. In one embodiment PG3is tert-butoxy carbonyl. In one embodiment where PG3is Ci-ealkoxycarbonyl (e.g. tert-butoxycarbonyl) the ‘and salts thereof element of the claim is excluded.
[0705] Other compounds of Formula (I) and PROTACs of Formula (la) - and salts thereof - may be prepared from an intermediate compound of Formula (V), or a salt thereof, as described above except that Xxis C=O. Such an intermediate may be converted to a compound of Formula (I) or PROTAC of Formula (la) by reductive amination chemistry using an appropriate amine- containing compound, using reductive amination conditions that well-known to the skilled person - either directly or via one or more additional synthetic steps.
[0706] In turn, as demonstrated in the experimental section hereinafter, such compounds of Formula (V) where Xxis C=O may be conveniently prepared from the corresponding compound where the ketone is protected / masked as a ketal. Accordingly such ketal compounds, and salts thereof are useful intermediates in the preparation of a compound of Formula (I) or a PROTAC of Formula (la) and provide a further aspect of the specification.
[0707] Accordingly such ketal compound may be represented as a compound of Formula (V), or a salt thereof, as described above except that Xxis C substituted by RU1and R1 2: where RU1and RU2are each Ci-ealkoxy; or RU1and RU2together represent -O-(CH2)u-O- where u is 2 or 3.
[0708] Therefore, in a further aspect of the specification there is provided compound of Formula (V), as depicted above, or a salt thereof, wherein: Xxis selected from:
[0709] (i) N substituted by J where J is H or PG3where PG3is a protecting group; and
[0710] (ii) C substituted by oxo, or by RU1and RU2; where RU1and RU2are each Ci-ealkoxy; or RU1and RU2together represent -O-(CH2)u-O- where u is 2 or 3 ;
[0711] G is a direct bond, -CH2-, -O-, or -N(RG)- where RGis H or Ci-aalkyl;
[0712] QHRing is a 4-12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group; and the values of G and QHRing are selected so that Formula (V) does not contain any N-N or N-O bonds; and where R1, p, X1, X2, X3, X4, n, m, R2a, R2b, Q, Y1, Y2, Y3, Y4, R3and q may take any of the values defined herein for each of these group s / variables respectively.
[0713] In one embodiment J is H.
[0714] In one embodiment J is PG3.
[0715] In one embodiment PG3is C i-ealkoxycarbonyl.
[0716] In one embodiment PG3is tert-butoxycarbonyl.
[0717] In one embodiment Xxis C=O.
[0718] In one embodiment Xxis C substituted by RU1and RU2; where RU1and RU2are each C ...alkoxv.
[0719] In one embodiment Xxis C substituted by RU1and RU2; where RU1and RU2together represent -O-(CH2)u-O- where u is 2 or 3 (for example u = 2).
[0720] In one embodiment G is a direct bond or -O-.
[0721] In one embodiment QHRing is a 4-12-membered nitrogen-containing saturated heterocyclic group. The values of QHRing may take any of the values mentioned herein for QH.
[0722] In one embodiment QHRing is a piperidine ring, a piperazine ring, a 9-azaspiro[5.5]undecane ring or a 3,9- diazaspiro[5.5]undecane ring.
[0723] In further embodiments of this specification Formula (V) may be Formula (Va): where Lxmay be any of the groups (1) to (28) or (1) to (39) listed hereinabove in connection with Formula (la); and where G, QHRing and Xxmay take any of the values disclosed herein for each of said groups respectively.
[0724] In addition to the methods described above, the compounds of Formulae (I), (II), (III), (IV) & (V) and PROTAC compounds including Formula (la) may be prepared according to the general procedures and chemical transformations demonstrated in the experimental section hereinafter and using standard procedures and knowledge known to the skilled chemist.
[0725] In further embodiments of this specification there is / are provided compound(s), or a salt thereof, wherein said compound(s) is / are selected from one or more of the “Intermediates” listed hereinafter in the experimental section.
[0726] It is to be understood that the compound of an Intermediate listed hereinafter relates to the title chemical name listed in the experimental section, and is not limited in any way by the method of preparation nor whether a given intermediate compound was isolated in the form of a salt rather than as a neutral molecule.
[0727] According to a further aspect of the specification there is provided a pharmaceutical composition, which comprises a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, in association with a pharmaceutically acceptable excipient.
[0728] According to a further aspect of the specification there is provided a pharmaceutical composition, which comprises a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, for use in the treatment of cancer.
[0729] According to a further aspect of the specification there is provided a pharmaceutical composition, which comprises a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, for use in the treatment of a solid tumour.
[0730] According to a further aspect of the specification there is provided a pharmaceutical composition, which comprises a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, for use in the treatment of an AR-sensitive tumour type. According to a further aspect of the specification there is provided a pharmaceutical composition, which comprises a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, for use in the treatment of tumour types that harbour one or more mutated forms of the androgen receptor.
[0731] According to a further aspect of the specification there is provided a pharmaceutical composition, which comprises a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, for use in the treatment of prostate cancer (for example CRPC, for example metastatic CRPC).
[0732] According to a further aspect of the specification there is provided a pharmaceutical composition, which comprises a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, for use in the treatment of AR-mutated cancer.
[0733] In any embodiment, aspect or claim herein that mentions “cancer” without further specificity, further embodiments, aspects or claims may be provided where said cancer is (or includes) AR+ breast cancer.
[0734] The compositions may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous or intramuscular dosing). The compositions may be obtained by conventional procedures using conventional pharmaceutical excipients that are well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and / or preservative agents.
[0735] For further information on formulations the reader is referred to Chapter 25.2 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.
[0736] The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host being treated and the particular route of administration.
[0737] The size of the dose for therapeutic or prophylactic purposes of compounds of the present specification will naturally vary according to the nature and severity of the disease state, the age and sex of the animal or patient and the route of administration, according to well-known principles of medicine.
[0738] As explained hereinabove, the compounds of the present specification may be of value as anti-tumour agents, in particular as selective inhibitors of the proliferation, survival, motility, dissemination and invasiveness of mammalian cancer cells leading to inhibition of tumour growth and survival and to inhibition of metastatic tumour growth. Particularly, the compounds of the present specification may be of value as antiproliferative and anti- invasive agents in the containment and / or treatment of solid tumour disease.
[0739] Accordingly, the compounds of the present specification may be useful in the prevention or treatment of those tumours which are sensitive to degradation of the androgen receptor and that are involved in the signal transduction steps which lead to the proliferation and survival of tumour cells and the migratory ability and invasiveness of metastasising tumour cells. Further, the compounds of the present specification may be useful in the prevention or treatment of those tumours which are treatable by degradation of androgen receptors, i.e. the compounds may be used to produce an androgen receptor degradation effect in a warmblooded animal in need of such treatment.
[0740] According to a further aspect of the specification, there is provided a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, for use as a medicament.
[0741] According to a further aspect of the specification, there is provided a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, for use in therapy.
[0742] According to a further aspect of the specification, there is provided a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, for use in a method of treatment of the human or animal body by therapy.
[0743] According to a further aspect of the specification, there is provided a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein for use in the production of an anti-proliferative effect (for example, in a warm-blooded animal such as man).
[0744] According to a further aspect of the specification, there is provided the use of a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, for the manufacture of a medicament for the production of an anti-proliferative effect (for example, in a warmblooded animal such as man).
[0745] According to a further aspect of the specification, there is provided a method for producing an antiproliferative effect in a warm-blooded animal, such as man, in need of such effect, which comprises administering to said animal an effective amount of a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein.
[0746] According to a further aspect of the specification, there is provided a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, for use as an anti- invasive agent in the containment and / or treatment of solid tumour disease (for example: in a warm-blooded animal such as man).
[0747] According to a further aspect of the specification, there is provided the use of a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, for the manufacture of a medicament for use as an anti-invasive agent in the containment and / or treatment of solid tumour disease (for example: in a warm-blooded animal such as man).
[0748] According to a further aspect of the specification, there is provided a method for producing an anti- invasive effect by the containment and / or treatment of solid tumour disease, in a warm-blooded animal, such as man, in need of such effect, which comprises administering to said animal an effective amount of a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein.
[0749] According to a further aspect of the specification, there is provided a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, for use in the prevention or treatment of cancer (for example: in a warm-blooded animal such as man).
[0750] According to a further aspect of the specification there is provided the use of a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, for the manufacture of a medicament for the prevention or treatment of cancer (for example: in a warm-blooded animal such as man).
[0751] According to a further aspect of the specification there is provided a method for the prevention or treatment of cancer in a warm-blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein.
[0752] According to a further aspect of the specification, there is provided a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, for use in the prevention or treatment of solid tumour(s) (for example, in a warm-blooded animal such as man).
[0753] According to a further aspect of the specification, there is provided the use of a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, for the manufacture of a medicament for the prevention or treatment of solid tumour(s) (for example, in a warmblooded animal such as man).
[0754] According to a further aspect of the specification, there is provided a method for the prevention or treatment of solid tumour(s) in a warm-blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein.
[0755] According to a further aspect of the specification, there is provided a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, for use in the prevention or treatment of tumour types that are sensitive to degradation of androgen receptors.
[0756] According to a further aspect of the specification, there is provided the use of a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, for the manufacture of a medicament for the prevention or treatment of those tumour types that are sensitive to degradation of androgen receptors. According to a further aspect of the specification, there is provided a method for the prevention or treatment of those tumour types that are sensitive to degradation of androgen receptors in a warm-blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein.
[0757] As explained hereinabove, tumour types that are sensitive to degradation of androgen receptors include prostate cancer (for example castrate-resistant prostate cancer (CRPC), for example metastatic CRPC).
[0758] According to a further aspect of the specification, there is provided a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, for use in providing a degrading effect on androgen receptors (for example in a warm-blooded animal such as man).
[0759] According to a further aspect of the specification, there is provided the use of a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, for the manufacture of a medicament for providing a degrading effect on androgen receptors (for example in a warm-blooded animal such as man).
[0760] According to a further aspect of the specification, there is provided a method for providing a degrading effect on androgen receptors in a warm-blooded animal, such as man, in need of such effect, which comprises administering to said animal an effective amount of a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein.
[0761] According to a further aspect of the specification, there is provided a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, for use in providing a selective degrading effect on androgen receptors (for example in a warm-blooded animal such as man).
[0762] According to a further aspect of the specification, there is provided the use of a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, for the manufacture of a medicament for providing a selective degrading effect on androgen receptors (for example in a warm-blooded animal such as man).
[0763] According to a further aspect of the specification, there is provided a method for providing a selective degrading effect on androgen receptors in a warm-blooded animal, such as man, in need of such effect, which comprises administering an effective amount of a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein.
[0764] According to a further aspect of the specification, there is provided a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, for use in the treatment of tumour types that harbour androgen receptor mutations. According to a further aspect of the specification, there is provided the use of a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, for the manufacture of a medicament for the prevention or treatment of those tumour types that harbour androgen receptor mutations.
[0765] According to a further aspect of the specification, there is provided a method for the prevention or treatment of those tumour types that harbour androgen receptor mutations in a warm-blooded animal, such as man, in need of such prevention or treatment, which comprises administering to said animal an effective amount of a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein.
[0766] As mentioned above, tumour types known to harbour androgen receptor mutations include prostate tumours and therefore prostate cancer, castrate-resistant prostate cancer (CRPC), and metastatic (CRPC).
[0767] According to a further aspect of the specification, there is provided a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, for use in the treatment of prostate cancer (for example castrate-resistant prostate cancer (CRPC), for example metastatic CRPC).
[0768] According to a further aspect of the specification, there is provided the use of a compound of the Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein, for the manufacture of a medicament for the treatment of prostate cancer (for example castrate-resistant prostate cancer (CRPC), for example metastatic CRPC).
[0769] According to a further aspect of the specification, there is provided a method for treating prostate cancer (for example castrate-resistant prostate cancer (CRPC), for example metastatic CRPC) in a warmblooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of Formula (I), [or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)] or a pharmaceutically acceptable salt thereof, as defined herein.
[0770] In one embodiment where cancer is mentioned herein, said cancer is prostate cancer.
[0771] In one embodiment where cancer is mentioned herein, said cancer is CRPC.
[0772] In one embodiment where cancer is mentioned herein, said cancer is metastatic CRPC.
[0773] General Experimental Conditions and Abbreviations
[0774] The following abbreviations are used: AcOH = acetic acid; AIBN = 2,2'-azobis(2-methylpropionitrile); aq. = aqueous; Boc = butoxy carbonyl; Brettphos = 2-(Dicyclohexylphosphino)3,6-dimethoxy-2',4',6'-triisopropyl- l,l '-biphenyl; Brettphos Pd G3 = [(2-Di-cyclohexylphosphino-3,6-dimethoxy-2',4',6'- triisopropyl- 1,1 '- biphenyl)-2-(2'-amino-l,l ' -biphenyl)]palladium(II) methanesulfonate; CDI = l,l'-Carbonyldiimidazole; Dave-phos-Pd G3 = Methane sulfonato 2-dicyclohexylphosphino-2-(A,A-dimethylamino)biphenyl(2'-amino- l,l '-bipheny 1-2-yl) palladium(II); DCM = dichloromethane; DIAD = Diisopropyl azodicarboxylate; DIPEA = A,A-diisopropylethylamine; Cbz = carboxybenzyl; Dess-Martin periodinane = 3-Oxo-115- benzo[< / |[l,2]iodaoxole-l,l,l(3 / / )-triyl triacetate; DMF = \\ \’-diineth\ llbnnainide: DMSO = dimethylsulfoxide; Et2O = diethyl ether; EtOAc = ethyl acetate; EtOEI = ethanol; FSC = flash silica chromatography; h = hour(s); EIPLC = high-performance liquid chromatography; IPA = isopropyl alcohol; MeCN = acetonitrile; MeOH = methanol; mins. = minutes; m / z = mass to charge ratio observed for major mass spectrometry peak(s); MTBE = methyl-tert-butyl-ether; NBS = A-bromosuccinimide; NMP = A-methyL 2-pyrrolidone; NMR = nuclear magnetic resonance; Pd;dba;, = tris(dibenzylideneacetone)dipalladium; Pd- PEPPSI-IEIeptcl= dichloro[l,3-bis(2,6-di-4-heptylphenyl)imidazol-2-yldiene(3-chloropyridyl)palladium(II); Pd-PEPPSI-IPent = dichloro[l,3-bis(2,6-Di-3-pentylphenyl)imidazol-2-ylidene](3- chloropyridyl)palladium(II), Pd(dppf)2C12-DCM = l,l'-bis(diphenylphosphino)ferrocene- palladium(II)dichloride dichloromethane complex; RockPhos Pd G3 = [(2-di-tert-butylphosphino-3-methoxy- 6-methyl-2 ',4 ',6 '-triisopropyl- 1 ,1 '-biphenyl)-2-(2-aminobiphenyl)]-palladium(II) methanesulfonate; RT = room temperature (~17-25°C); RuPhos = 2-dicyclohexylphosphino-2',6'-diisopropoxybiphenyl; RuPhos Pd G3 = methanesulfonato(2-dicyclohexylphosphino-2',6'-di-iso-propoxy- 1 ,l'-bipheny l)(2'-amino- 1 , l'-bipheny 1-2- yl)-palladium(II); TFA = trifluoroacetic acid; THF = tetrahydrofuran; sat. = saturated; SFC = supercritical fluid chromatography; S Phos = 2-dicyclohexylphosphino-2,6-di-methyloxy- 1,1 -biphenyl; XPhos = 2-dicyclo- hexylphosphino-2',4',6'-triisopropylbiphenyl.
[0775] NMR was carried out at 400 MHz in deuterated DMSO and at a temperature of 20-30°C unless otherwise stated. The following standard abbreviations are used for NMR data: s = singlet, d = doublet, m = multiplet, br = broad, dd = doublet of doublets, q = quartet, dt = doublet of triplets, etc.
[0776] Preparative reverse phase HPLC (RP HPLC) using decreasingly polar mixture of eluents (e.g. water and MeCN) may typically involve a gradient over 10-20 minutes, at 40-50mL per minute, from a 95:5 mixture of solvents a 5:95 mixture. The following Column and Eluent conditions are used herein:
[0777] Column A: Waters XSelect CSH Cl 8 ODB column, 5|im silica, 30 mm diameter, 100 mm length Column B: Waters XSelect CSH Cl 8 ODB column, 5 pm silica, 19 mm diameter, 150 mm length Eluent A: Decreasingly polar mixtures of water (containing 0.1% formic acid) and MeCN Eluent B: Decreasingly polar mixtures of water (containing 0.3% formic acid aq) and MeCN Eluent C: Decreasingly polar mixtures of water (containing 0.1% TFA) and MeCN Eluent D: Decreasingly polar mixtures of water (containing 0.1% NH3) and MeCN After HPLC (which often involves the presence of formic acid or trifluoroacetic acid in the eluent), the fractions containing desired product were in some cases treated with a suitable base as part of a further work-up step in order to ensure delivery of the title compound as a neutral molecule rather than a salt. Accordingly where “Basic Work-Up A” is mentioned: fractions containing the desired compound were concentrated to remove MeCN. The resulting, mainly-aqueous fractions were basified with Nal ICO;, solution (e.g. 50 mL) and extracted into DCM (e.g. 3 * 100 mL). The combined organic solutions were washed with brine (e.g. 100 mL), dried (e.g. with Na2SO4 or MgSO i ) and concentrated to give the title compound.
[0778] Concentration: where solutions or mixtures are described as being concentrated, this is generally performed on a rotary evaporator under reduced pressure using a warm or hot water bath.
[0779] Salts: Where certain compounds were obtained as an acid-addition salt, for example a monohydrochloride salt or a bis-hydrochloride salt, the stoichiometry of the salt is assumed, based on the number and nature of the basic groups in the compound, and may not have been determined experimentally e.g. by means of elemental analysis data.
[0780] Chemical naming: In general Examples and Intermediate compounds were named using ACD Name, “Structure to Name” part of ChemDraw Ultra (Cambridge Soft) or Biovia Draw 2016.
[0781] Intermediate la: Benzyl 4-(dimethoxymethyl)piperidine-l-carboxylate
[0782] 4-Formyl-A / -Cbz-piperidine (5.00 g, 20.22 mmol) was dissolved in MeOH (11 mL) at 0°C under N2. A solution of TiCl4(0.11 mL, 1.01 mmol) in DCM (1.1 mL) was then added, followed after 15 mins by NEta (0.338 mL, 2.43 mmol) and the resulting solution was stirred at RT for 0.5h. The mixture was then diluted with DCM (50 mL) and water (20 mL) and stirred at RT for 0.5h. The layers were then separated, the organic portion was dried over a hydrophobic frit and then concentrated. Purification by FSC (gradient: 0-50% EtOAc in heptane) gave the title compound (5.16 g, 87%) as a colourless oil; *H NMR: (CDCh) 1.14-1.33 (2H, m), 1.63-1.82 (3H, m), 2.63-2.84 (2H, m), 3.35 (6H, s), 4.02 (1H, d), 4.13-4.3 (2H, m), 5.12 (2H, s), 7.3-7.44 (5H, m).
[0783] Intermediate lb: 4-(DimethoxymethvDpiperidine
[0784] Pd(OH)2 (10wt%, 0.73 g, 0.52 mmol) was added to benzyl 4-(dimethoxymethyl)piperidine-l -carboxylate (7.60 g, 25.9 mmol) in MeOH (60 mL) at RT under N2 in a steel pressured reactor. The resulting suspension was purged with N2 followed by H2 and was then stirred at RT at a pressure of 4 atmospheres of H2 for 2 days. The mixture was then filtered through celite and washed through with MeOH (500 mL). The filtrate was concentrated to give the title compound (4.00 g, 97%) as a colourless oil; *H NMR: (CDCh) 1.19-1.41 (2H, m), 1.69-1.86 (3H, m), 2.61 (2H, td), 3.15 (2H, d), 3.35 (6H, s), 4.03 (1H, d), 4.47 (1H, s).
[0785] Intermediate 1c: Methyl 4-bromo-2-methoxy-6-methylbenzoate
[0786] A25% methanolic solution ofNaOMe (512 Lil,. 2.24 mmol) was added dropwise to a stirred solution of methyl 4-bromo-2-fluoro-6-methylbenzoate (527 mg, 2.13 mmol) in DMF (10 mL) at RT under N2. The resulting mixture was stirred at RT for 18h (reaction complete within Ih). The mixture was then cooled to 0°C and quenched with EtOAc (20 mL) and IN HC1 (10 mL). The phases were separated and the aqueous portion was extracted with EtOAc (2 x 30 mL). The combined organic solutions were dried (MgSOy) and concentrated. Purification by FSC (gradient 0-25% EtOAc in heptane) gave the title compound (0.410 g, 74%) as a colourless oil which solidified on standing; *H NMR: (CDCL) 2.25 (3H, s), 3.81 (3H, s), 3.90 (3H, s), 6.91 (IH, d), 6.98 (IH, dd).
[0787] Intermediate Id: 3-(5-Bromo-7-methoxy-l-oxo-l,3-dihvdro-2 / 7-isoindol-2-yl)piperidine-2,6-dione
[0788] NBS (1.574 g, 8.84 mmol) was added to a stirred solution of methyl 4-bromo-2-methoxy-6-methylbenzoate (1.432 g, 5.53 mmol) and AIBN (0.182 g, 1.11 mmol) in tert-butyl acetate (20 mL) and the mixture was stirred at 100°C for 3h. The mixture was then cooled to RT, diluted with EtOAc (50 mL) and washed with water (50 mL). The organic layer was passed through a phase separator cartridge and concentrated. Purification by FSC (gradient: 0-15% EtOAc in heptane) gave 4-bromo-2-(bromomethyl)-6-methoxybenzoate (1.495 g, 80 %) as a yellow gum, that was 70% pure. DIPEA (1.654 mL, 9.29 mmol) was added in one portion to a stirred solution of methyl 4-bromo-2-(bromomethyl)-6-methoxybenzoate (1.495 g, 3.10 mmol) and 3-aminopiperidine-2,6- dione hydrochloride (0.510 g, 3.10 mmol) in MeCN (20 mL) at RT under air. The resulting solution was stirred at 80°C for 16h. The mixture was then cooled to 0°C and a solid was collected by filtration. The solid was washed with MeCN (50 mL) and Et2O (50 mL) and dried under vacuum to give the title compound (0.761 g, 39% over 2 steps) as a mauve solid; >H NMR: 1.97 (1H, dtd), 2.34 (1H, qd), 2.54-2.63 (1H, m), 2.90 (1H, ddd), 3.90 (3H, s), 4.25 (1H, d), 4.38 (1H, d), 5.02 (1H, dd), 7.26 (1H, d), 7.39 (1H, d), 10.94 (1H, s); m / z\ ES+[M+H]+= 355.0.
[0789] Intermediate le: tert-Butyl 4-[2-(2,6-dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3-dihvdro-l / 7-isoindol-5- yllpiperazine-l-carboxylate
[0790] Pd-PEPPSI-IHeptcl(0.380 g, 0.39 mmol) was added to tert-butyl piperazine- 1 -carboxylate (2.183 g, 11.72 mmol), CS2CO3 (3.82 g, 11.72 mmol) and 3-(5-bromo-7-methoxy-l-oxo-l .3-dihvdro-2 / 7-isoindol-2-vl )- piperidine-2, 6-dione (1.38 g, 3.91 mmol) in degassed 1 ,4-dioxane (39 mL) at RT under N2. The resulting suspension was stirred at 100°C for 6h. The mixture was then diluted with DCM (100 mL) and washed sequentially with 5% AcOH in water (100 mL), water (100 mL), sat. Nal ICO;, (100 mL) and sat. brine (100 mL). The organic layer was dried (MgSO.4) and concentrated. Trituration with EtOAc (40 mL) and washing with Et2O (50 mL) gave a solid which was collected by filtration and dried under vacuum to give the title compound (1.154 g, 64%) as a dark grey powder; ‘H NMR: 1.43 (9H, s), 1.79-1.97 (1H, m), 2.28 (1H, dd), 2.53-2.62 (1H, m), 2.76-2.94 (1H, m), 3.32 (4H, s), 3.41-3.54 (4H, m), 3.85 (3H, s), 4.12 (1H, d), 4.24 (1H, d), 4.95 (1H, dd), 6.51 (1H, d), 6.62 (1H, s), 10.87 (1H, s); m / z\ ES+[M+H]+= 459.2.
[0791] Intermediate If: 3-[7-Methoxy-l-oxo-5-(piperazin-l-yl)-l,3-dihvdro-2 / T-isoindol-2-yllpiperidine-2,6- dione
[0792] 4M HCI in 1 ,4-dioxane (2 mL, 8.00 mmol) was added in one portion to tert-butyl 4-[2-(2,6-dioxopiperidin-3- yl)-7-methoxy-l-oxo-2,3-dihydro-l / f-isoindol-5-yl]piperazine-l-carboxylate (107 mg, 0.19 mmol) at RT under air. The resulting mixture was stirred at RT for 1 day, then diluted with Et2O (20 mL). The resulting mixture was filtered and the solid was washed with Et2O (20 mL) to give the title compound as a hydrochloride salt (0.080 g, 100%) as a white solid; >H NMR: 1.93 (1H, dd), 2.25-2.4 (1H, m), 2.57 (1H, d), 2.89 (1H, s), 3.19 (4H, s), 3.59 (4H, s), 3.86 (3H, s), 4.14 (1H, d), 4.26 (1H, d), 4.97 (1H, dd), 6.49-6.6 (1H, m), 6.68 (1H, s), 9.55 (2H, s), 10.89 (1H, s); m / z\ ES+[M+H]+= 359.2.
[0793] DIPEA (6.93 mL, 39.66 mmol), 4-fluoro-2-(trifluoromethyl)benzonitrile (5.00 g, 26.44 mmol) and 4- (piperidin-4-yl)phenol (4.69 g, 26.44 mmol) were stirred in DMSO (10 mL) at 50°C for 18h. The mixture was then cooled to RT, diluted with water (150 mL) and then stirred for 18h. A resulting solid was collected by filtration, washed with Et2O (50 mL) and dried under vacuum to give the title compound (5.65 g, 62%) as a yellow solid; ‘H NMR: (CDC13) 1.75 (2H, qd), 1.88-2 (2H, m), 2.73 (1H, tt), 3.06 (2H, td), 3.98-4.1 (2H, m), 4.78 (1H, s), 6.76-6.83 (2H, m), 6.99 (1H, dd), 7.06-7.12 (2H, m), 7.16 (1H, d), 7.62 (1H, d); m / z\ ES+[M+H]+= 347.0.
[0794] Intermediate Ih: 4-1 ,3-Dioxolan-2-’ i-l-vl)-2-i rom benzonitrile
[0795] 2-(3-Chloropropyl)-l,3-dioxolane (2.57 mL, 19.49 mmol) was added in one portion to 4-(4-(4-hydroxy- phenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (3.75 g, 10.83 mmol), K2CO3 (3.74 g, 27.07 mmol) and KI (4.49 g, 27.07 mmol) in MeCN (100 mL) at RT under air. The resulting suspension was stirred at 90°C for 2 days. The mixture was then cooled to RT, filtered and washed with DCM (100 mL). The filtrate was concentrated under reduced pressure. The crude residue was diluted with EtOAc (300 mL), washed with water (100 mL) then sat. brine (100 mL), dried (MgSCL) and concentrated. Purification by FSC (gradient 0-5% MeOH in DCM) gave the title compound (3.10 g, 62%) as a yellow solid; >H NMR: (CDCI3) 1.56-1.67 (2H, m), 1.71 (2H, ddd), 1.74-1.82 (2H, m), 1.85 (2H, d), 2.77 (IH, ddd), 3-3.1 (2H, m), 3.75-3.82 (2H, m), 3.85- 3.92 (2H, m), 3.95 (2H, q), 4.17 (2H, d), 4.85 (IH, t), 6.79-6.9 (2H, m), 7.15 (2H, d), 7.23-7.38 (2H, m), 7.81 (IH, d); m / z\ ES+[M+H]+= 461.3.
[0796] Example 1: 4-f4-[4-(4-f4-[2-(2.6-DioxoDiDeridin-3-yl)-7-methoxy-l-oxo-2.3-dihvdro- isoindol-5-yl1- piperazin-l-yllbutoxy)phenyl1piperidin-l-yll-2-(trifluoromethyl) benzonitrile
[0797] 4-(4-(4-(3-(l,3-Dioxolan-2-yl)propoxy)phenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (178 mg, 0.39 mmol) and tert-butyl 4-[2-(2,6-dioxopiperidin-3-yl )-7-methoxy- l-oxo-2,3-dihydro- 1 / / -isoindol-5- yl]piperazine-l -carboxylate (177 mg, 0.39 mmol) were stirred in formic acid (0.5 mL) and 1,4-dioxane (0.5 mL) at 40 °C for 18h. The mixture was then concentrated and the residue was re-dissolved in IPA (2 mL) and DCM (2 mL) at RT under air. NaBJ 1(0 Ac);, (164 mg, 0.77 mmol) was added in one portion after 10 mins. The resulting dark suspension was stirred at RT for Ih and then concentrated. Purification by preparative HPLC (Column A, Eluent A) gave the title compound in the form of a formate salt (70 mg, 23%) as a dry film; *H NMR: (CDClj) 1.54-1.68 (4H, m), 1.74 (2H, q), 1.84 (2H, d), 1.92 (IH, dd), 2.28 (IH, dd), 2.39 (2H, t), 2.54- 2.62 (2H, m), 2.76 (IH, td), 2.89 (IH, ddd), 3.04 (2H, t), 3.2-3.38 (6H, m), 3.47 (IH, s), 3.84 (3H, s), 3.97 (2H, t), 4.07-4.29 (4H, m), 4.96 (IH, dd), 6.48 (IH, d), 6.60 (IH, s), 6.81-6.94 (2H, m), 7.16 (2H, d), 7.27 (IH, dd), 7.32 (IH, d), 7.81 (IH, d), 8.16 (2H, s), 10.88 (IH, s); m / z\ ES+[M+H]+= 759.4.
[0798] Intermediate 2a: 3-(5-Bromo-l-oxo-l,3-dihvdro-2 / 7-isoindol-2-yl)piperidine-2,6-dione
[0799] DIPEA (25 mL, 143.52 mmol) was added to methyl 4-bromo-2-(bromomethyl)benzoate (14.65 g, 47.57 mmol) and 3-aminopiperidine-2, 6-dione hydrochloride salt (11.74 g, 71.35 mmol) in MeCN (200 mL) under N2. The resulting suspension was stirred at 80°C for 4h. The mixture was cooled to RT and filtered. The resulting solid was washed with MeCN (60 mL), MeCN:Et2O (50 mL [2:3]) and Et2O (2 x 50 mL) to give the title compound (13.10 g, 85%) as a dark blue solid; ‘HNMR: 1.95-2.08 (IH, m), 2.34-2.46 (IH, m), 2.57-2.65 (IH, m), 2.91 (IH, ddd), 4.35 (IH, d), 4.48 (IH, d), 5.11 (IH, dd), 7.67 (IH, d), 7.72 (IH, dd), 7.83-7.96 (IH, m), 10.98 (IH, s).Wz: ES+[M+H]+= 323.0. Intermediate 2b: tert- Butyl 4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihvdro- isoindol-5- yl1piperazine-l-carboxylate
[0800] CS2CO3 (57.40 g, 176 mmol) and Pd-PEPPSI-IPent (2.33 g, 2.94 mmol) were added in one portion to a degassed solution of tert-butyl piperazine- 1 -carboxylate (14.22 g, 76.36 mmol) and 3-(5-bromo-l-oxo-l,3- dihydro-2H-isoindol-2-yl)piperidine-2, 6-dione (19.0 g, 58.74 mmol) in 1,4-dioxane (590 mL) under N2. The resulting mixture was stirred at 90°C for 24h. The mixture was then cooled to RT, diluted with DCM (IL) and washed sequentially with 5% AcOH in water (500 mL) and brine (500 mL). The organic solution was then dried (MgSCL) and concentrated. Trituration with EtOAc (250 mL) gave a solid that was collected by filtration, washed with Et2O (100 mL) and dried under vacuum to give the title compound (22.10 g, 88%) as a grey solid; ‘H NMR: 1.43 (9H, s), 1.96 (1H, d), 2.31-2.41 (1H, m), 2.59 (1H, d), 2.87 (1H, s), 3.29 (4H, d), 3.47 (4H, d), 4.22 (1H, d), 4.34 (1H, d), 5.05 (1H, dd), 7.07 (2H, d), 7.54 (1H, d), 10.92 (1H, s); m / z\ ES+[M+H]+= 429.2.
[0801] Intermediate 2c: 3-[l-Oxo-5-(Piperazin-l-yl)-l,3-dihvdro-2 / T-isoindol-2-yl1piperidine-2,6-dione
[0802] A solution of 4M HC1 in dioxane (8.75 mL, 35.0 mmol) was added to tert-butyl 4-[2-(2,6-dioxopiperidin-3- vl )- 1 -oxo-2.3-dihvdro- 1 / 7-isoindol-5-vl Ipiperazine- 1 -carboxvlate (1.50 g, 3.50 mmol) in 1,4-dioxane (2 mL) at RT and the mixture was stirred for Ih. EtOAc (5 mL) was then added and the mixture was stirred for 10 mins. The resulting precipitate was collected by filtration, washed with EtOAc (2 x 5 mL) and dried under vacuum to give the title compound in the form of a hydrochloride salt (1.08 g, 85%) as a dark grey solid; *H NMR: 1.97 (IH, dd), 2.36-2.44 (IH, m), 2.60 (IH, d), 2.84-2.99 (IH, m), 3.23 (4H, s), 3.5-3.57 (4H, m), 4.27 (IH, s), 4.34 (IH, s), 5.06 (IH, dd), 7.11-7.18 (2H, m), 7.59 (IH, d), 9.17 (2H, s), 10.93 (IH, s); m / z\ ES+[M+H]+329.0.
[0803] Intermediate 2d: 4-(4-(4-(4-Oxobutoxy)phenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile
[0804] 4-(4-(4-(3-(l,3-Dioxolan-2-yl)propoxy)phenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (example Ih) (4.61 g, 10.01 mmol) was dissolved in 1,4-dioxane (100 mL) and formic acid (75 mL) and the mixture was warmed to 50°C for 18h. The solvent was then removed under reduced pressure to give the title compound as a yellow oil (used directly in next step, assumed 100% yield); m / z\ ES+[M+H]+= 417.0.
[0805] Example 2: 4-!4-[4-(4-!4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihvdro- isoindol-5-yl|piperazin-l- yllbutoxy)phenyl1piperidin-l-yll-2-(trifluoromethyl)benzonitrile
[0806] 4-(4-(4-(4-Oxobutoxy)phenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (4.17 g, 8.71 mmol), 3-[l-oxo-5- (piperazin-l-yl)-l,3-dihydro-2 / f-isoindol-2-yl]piperidine-2, 6-dione hydrochloride salt (3.18 g, 8.71 mmol) and NaOAc (2.144 g, 26.13 mmol) were dissolved in DCM (150 mL) at RT. The resulting suspension was stirred for Ih at RT then NaBH(OAc)3 (3.69 g, 17.42 mmol) was added and the mixture was stirred for 0.5h. The mixture was then diluted with DCM (200 mL) and washed sat. Nal ICO;, (2 x 200 mL) then sat. brine (200 mL). The organic solution was then dried (MgSO.4) and concentrated. Purification by preparative HPLC (Column A, Eluent B, Basic Work-Up A) gave the title compound (820 mg, 13%); *H NMR: 1.52-1.69 (4H, m), 1.74 (2H, p), 1.84 (2H, d), 1.91-2.03 (IH, m), 2.34-2.42 (3H, m), 2.52-2.54 (4H, m), 2.59 (IH, d), 2.76 (IH, td), 2.83-2.96 (IH, m), 2.96-3.1 (2H, m), 3.27-3.29 (4H, m), 3.97 (2H, t), 4.1-4.28 (3H, m), 4.33 (IH, d), 5.05 (IH, dd), 6.78-6.9 (2H, m), 7.05 (2H, d), 7.15 (2H, d), 7.23-7.36 (2H, m), 7.52 (IH, d), 7.81 (IH, d), 10.92 (IH, s); m / z\ ES+[M+H]+= 729.5.
[0807] Intermediate 3a: 2-Cvclopropyl-4-fluorobenzonitrile
[0808] Pd(OAc)2 (0.168 g, 0.75 mmol) was added to cyclopropylboronic acid (0.834 g, 9.71 mmol), 2-bromo-4- fluorobenzonitrile (1.50 g, 7.50 mmol), tricyclohexylphosphine (0.210 g, 0.75 mmol) and K3PO4 (5.57 g, 26.25 mmol) in toluene (20 mL) at RT under N2. The resulting mixture was stirred at 100°C for 3h. The mixture was then filtered through Celite and washed through with EtOAc (30 mL). The filtrate was concentrated and purification by FSC (gradient: 0-5% EtOAc in petroleum ether) gave the title compound (0.950 g, 79%) as a green solid; ‘HNMR: 0.85-0.94 (2H, m), 1.07-1.21 (2H, m), 2.13-2.25 (IH, m), 6.95-7.03 (IH, m), 7.15-7.25 (IH, m), 7.81-7.89 (IH, m).
[0809] 2-Cyclopropyl-4-fluorobenzonitrile (1.00 g, 6.20 mmol) was added to a mixture of 4-(4-bromophenyl)- piperidine (1.788 g, 7.45 mmol) and CS2CO3 (6.06 g, 18.61 mmol) in DMSO (1.5 mL) at 80°C. The resulting mixture was stirred at 80°C for 16h, then cooled to RT and diluted with water. The mixture was then filtered, diluted with EtOAc (1 L), and washed with water (500 mL) then sat. brine (500 mL). The organic layer was dried (Na2SO4) and concentrated. Purification by FSC (gradient: 0-20% EtOAc in petroleum ether) gave the title compound (1.70 g, 72%) as a yellow solid; ‘HNMR: 0.79-0.93 (2H, m), 0.97-1.08 (2H, m), 1.54-1.69 (2H, m), 1.78-1.87 (2H, m), 2.02-2.13 (1H, m), 2.70-2.83 (1H, m), 2.83-2.95 (2H, m), 4.00-4.08 (2H, m), 6.47 (1H, d), 6.82-6.90 (1H, m), 7.18-7.26 (2H, m), 7.45-7.52 (3H, m); m / z: ES+[M+H]+= 381.1.
[0810] Ruphos Pd G3 (88 mg, 0.10 mmol) and Ruphos (46 mg, 0.10 mmol) were added to a mixture of CS2CO3 (1.025 g, 3.15 mmol), 4-(dimethoxymethyl)piperidine (334 mg, 2.10 mmol) and 4-(4-(4-bromophenyl)- piperidin-l-yl)-2-cyclopropylbenzonitrile (400 mg, 1.05 mmol) in 1,4-dioxane (6 mL) at RT under N2. The resulting mixture was stirred at 100°C for 16h. After cooling, the solvent was removed under reduced pressure. Purification by FSC (gradient: 0-30% EtOAc in petroleum ether) gave the title compound (0.228 g, 47%) as a yellow solid; ‘H NMR: 0.79-0.90 (2H, m), 0.97-1.10 (2H, m), 1.20-1.41 (2H, m), 1.50-1.74 (5H, m), 1.80 (2H, d), 1.97-2.15 (lH, m), 2.52-2.71 (3H, m), 2.81-2.95 (2H, m), 3.27 (6H, s), 3.58-3.68 (2H, m), 3.99-4.11 (3H, m), 6.46 (1H, d), 6.81-6.90 (3H, m), 7.06 (2H, d), 7.47 (1H, d); m / z\ ES+[M+H]+= 460.3.
[0811] 2-Cyclopropyl-4-(4-(4-(4-(dimethoxymethyl)piperidin-l-yl)phenyl)piperidin-l-yl)benzonitrile (150 mg, 0.33 mmol) and 3-[7-methoxy-l-oxo-5-(piperazin-l-yl)-l,3-dihydro-2 / f-isoindol-2-yl]piperidine-2, 6-dione hydrochloride salt (130 mg, 0.33 mmol) were stirred in formic acid (0.5 mL) and 1,4-dioxane (0.5 mL) at 40°C for 7 days. The resulting mixture was then concentrated, and the residue dissolved in IPA (2 mL) and DCM (2 mL) at RT under air. NaBH(OAc)3 (138 mg, 0.65 mmol) was then added in one portion after 10 mins and the resulting dark suspension was stirred at RT for Ih. The mixture was then concentrated, dissolved in DMF (3 mL) and filtered. Purification by preparative HPLC (Column A, Eluent A) gave the title compound as a formate salt (59 mg, 24%) as a white solid; >H NMR: 0.8-0.88 (2H, m), 0.98-1.07 (2H, m), 1.23 (2H, q), 1.51-1.64 (2H, m), 1.67 (IH, d), 1.79-1.83 (4H, m), 1.88-1.96 (IH, m), 2.09 (IH, s), 2.23 (2H, d), 2.28-2.37 (IH, m), 2.52-2.53 (4H, m), 2.54-2.72 (4H, m), 2.82-2.95 (3H, m), 3.30-3.32 (4H, d), 3.62 (2H, d), 3.84 (3H, s), 4.02 (2H, d), 4.11 (IH, d), 4.24 (IH, d), 4.96 (IH, dd), 6.44-6.52 (2H, m), 6.61 (IH, s), 6.86 (3H, td), 7.07 (2H, d), 7.47 (IH, d), 8.15 (2H, s), 10.88 (IH, s); m / z\ ES+[M+H]+= 756.7.
[0812] Intermediate 4a: 4-(4-(4-Bromophenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile
[0813] CS2CO3 (73.6 g, 225.95 mmol) was added portion-wise to 4-fluoro-2-(trifluoromethyl)benzonitrile (20.51 g, 108.46 mmol) and 4-(4-bromophenyl)piperidine hydrochloride salt (25.0 g, 90.38 mmol) in DMSO (260 mL) at RT. The resulting cream suspension was stirred at RT for 18h and was then diluted slowly with water (600 mL). The resulting cream suspension was stirred at RT for 0.5h, then filtered, washed with water (2 x 25 mL) and Et2O (50 mL). The solid was dried under vacuum to give the title compound (35.0 g, 95%) as a cream solid; ‘HNMR: 1.65 (2H, qd), 1.87 (2H, d), 2.85 (1H, tt), 3.06 (2H, td), 4.19 (2H, d), 7.22-7.26 (2H, m), 7.28 (1H, dd), 7.33 (1H, d), 7.43-7.59 (2H, m), 7.74-7.88 (1H, m).
[0814] Intermediate 4b: 4-(4-(4-(4-(l,3-Dioxolan-2-yl)piperidin-l-yl)phenyl)piperidin-l-yl)-2-(trifluoromethyl)- benzonitrile
[0815] Anhydrous 1,4-dioxane (160 mL) was added to a mixture of 4-(4-(4-bromophenyl)piperidin-l-yl)-2-(trifluoro- methyl)benzonitrile (10.00 g, 24.43 mmol), 4-(l,3-dioxolan-2-yl)piperidine (4.17 g, 26.51 mmol), RuPhos Pd G3 (1.533 g, 1.83 mmol), RuPhos (0.855 g, 1 .83 mmol) and sodium 2-methylpropan-2-olate (7.04 g, 73.30 mmol). The mixture was degassed by bubbling N2 through the mixture for 5 mins and was then stirred at 100°C for 2h. The mixture was then cooled to RT and water (320 mL) was added. A precipitate formed which was collected by filtration to give an orange solid. The solid was slurried in MTBE (50 mL), heated at 45°C for 0.5h then allowed to cool to RT and filtered. The solid was washed with MTBE (2 x 5 mL) and dried to give the title compound (12.0 g, 100%) as a pale orange solid; 'H NMR: 1.39 (2H, qd), 1.54-1.68 (3H, m), 1.72 (2H, d), 1.84 (2H, d), 2.58 (2H, td), 2.65-2.79 (IH, m), 2.99-3.12 (2H, m), 3.66 (2H, d), 3.76-3.83 (2H, m), 3.83-3.91 (2H, m), 4.17 (2H, d), 4.61 (IH, d), 6.86 (2H, d), 7.08 (2H, d), 7.27 (IH, dd), 7.32 (IH, d), 7.81 (IH, d); m / z\ ES+[M+H]+= 486.3.
[0816] Intermediate 4c: 4-(4-(4-(4-Formylpiperidin-l-yl)phenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile
[0817] 4-(4-(4-(4-(l,3-Dioxolan-2-yl)piperidin-l-yl)phenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (10.00 g, 20.60 mmol) was dissolved in toluene (100 mL), formic acid (100 mL) and water (50 mL) and then warmed to 80°C for Ih. The mixture was then cooled to RT, diluted with EtOAc (50 mL) and water (50 mL). The layers were separated. The organic solution was washed with water (50 mL), sat. Nal ICO;, (50 mL) and brine (50 mL), then dried (MgSO.4) and concentrated. Purification by FSC (gradient: 0-100% EtOAc in heptane) gave the title compound (4.60 g, 51%) as a white solid; >H NMR: 1.53-1.68 (4H, m), 1.84 (2H, d), 1.92 (2H, dd), 2.45 (IH, dd), 2.73 (IH, d), 2.74-2.85 (2H, m), 2.97-3.11 (2H, m), 3.54 (2H, dt), 4.17 (2H, d), 6.88 (2H, d), 7.09 (2H, d), 7.22-7.4 (2H, m), 7.81 (IH, d), 9.59-9.72 (IH, m); m / z\ ES+[M+H]+442.3.
[0818] Example 4: 4-(4-!4-|4-(!4-|2-(2,6-Dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3-dihvdro- isoindol-5-yl|- piperazin-l-yllmethyl)piperidin-l-yl1phenyllpiperidin-l-yl)-2-(trifluoromethyl)benzonitrile
[0819] A mixture of 4-(4-(4-(4-formylpiperidin-l-yl)phenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (4.60 g, 10.42 mmol) and 3-[7-methoxy-l-oxo-5-(piperazin-l-yl)-l,3-dihydro-2 / f-isoindol-2-yl]piperidine-2, 6-dione hydrochloride salt (4.11 g, 10.42 mmol) and NaOAc (1.71 g, 20.84 mmol) was stirred in IPA(2 mL) and DCM (250 mL) at RT under air. NaBJ 1(0 Ac);, (4.42 g, 20.84 mmol) was added portion-wise after Ih. The resulting dark suspension was stirred at RT for Ih. The mixture was then diluted with DCM (2 x 250 mL), washed (sat. Nal ICO; (250 mL), water (250 mL) then sat. brine (250 mL)), dried (Na2SO4) and concentrated. Purification by FSC (gradient: 0- 100% EtOAc in heptane, then 0-5% IPA in EtOAc) gave a solid which was slurried in MeCN (100 mL) at RT and collected by filtration to give the title compound (2.05 g, 31%) as a white solid; *H NMR: 1.18-1.31 (2H, m), 1.55-1.74 (3H, m), 1.80-1.86 (4H, m), 1.88-1.97 (IH, m), 2.23 (2H, d), 2.27-2.34 (1H, m), 2.52-2.53 (4H, m), 2.54-2.67 (3H, m), 2.73 (1H, t), 2.82-2.97 (1H, m), 3.04 (2H, t), 3.32-3.35 (4H, s), 3.62 (2H, d), 3.84 (3H, s), 4.08-4.28 (4H, m), 4.96 (1H, dd), 6.49 (1H, s), 6.61 (1H, s), 6.87 (2H, d), 7.08 (2H, d), 7.27 (1H, dd), 7.32 (1H, d), 7.81 (1H, d), 10.88 (1H, s); m / z\ ES+[M+H]+= 784.6.
[0820] Intermediate 5a: Ethyl 2-(3-(4-(l-(4-cvano-3-(trifluoromethyl)phenyl)piperidin-4-yl)phenoxy)-
[0821] RockPhos Pd G3 (0.103 g, 0.12 mmol) was added in one portion to a degassed mixture of ethyl 2-(3-hydroxy- cyclobutyl)acetate (0.387 g, 2.44 mmol), 4-(4-(4-bromophenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (1.00 g, 2.44 mmol) and CS2CO3 (2.79 g, 8.55 mmol) in toluene (20 mL) at RT under N2. The resulting mixture was stirred at 90°C for 18h. The mixture was then cooled to RT and diluted with EtOAc (50 mL) and water (15 mL). The organic layer was separated and washed with sat. brine (20 mL), dried (MgSC>4) and concentrated. Purification by FSC (gradient: 0-60% EtOAc in heptane) gave the title compound (0.34 g, 29%) as a white solid; ‘H NMR: (CDCh) 1.25 (3H, td), 1.75 (2H, qd), 1.81-1.91 (1H, m), 1.97 (2H, d), 2.25 (1H, ddd), 2.29-2.45 (1H, m), 2.50 (2H, dd), 2.71 (3H, dddd), 3.05 (2H, td), 4.01 (2H, d), 4.07-4.18 (2H, m), 4.51 (1H, p), 6.7-6.81 (2H, m), 6.98 (1H, dd), 7.05-7.12 (2H, m), 7.15 (1H, d), 7.61 (1H, d); m / z\ ES+[M+H]+487.3.
[0822] Intermediate 5b and 5c: 4-(4-(4-((lr,3s)-3-(2-Hvdroxyethyl)cvclobutoxy)phenyl)piperidin-l-yl)-2-
[0823] (trifluoromethvDbenzonitrile and 4-(4-(4-((ls,3r)-3-(2-hvdroxyethyl)cvclobutoxy)phenyl)piperidin-l-yl)-
[0824] 2-(trifluoromethyl)benzonitrile
[0825] Diisobutylaluminum hydride (IM in toluene, 1.048 mL, 1.05 mmol) was added dropwise to a stirred solution of ethyl 2-(3-(4-(l-(4-cyano-3-(trifluoromethyl)phenyl)piperidin-4-yl)phenoxy)cyclobutyl)acetate (340 mg, 0.70 mmol) in THF (10 mL) at 0°C under N2. The resulting mixture was stirred at 0°C for 10 mins. The reaction was then quenched by addition of Rochelle’s salt (15 mL). EtOAc (25 mL) was added and the mixture was stirred at RT for 18h. The phases were then separated and the aqueous portion was extracted with EtOAc (3 x 50 mL). The combined organic solutions were washed with brine (50 mL), dried (MgSCM) and concentrated. Purification by FSC (gradient: 0- 100% EtOAc in heptane) gave a ~2 : 1 mixture of cis / trans isomers (0.280 g, 90%). A sample was purified on Sepiatec SFC system (Column: YMC Chiral Art Cellulose- SJ, 20 x 250 mm, 5|im, Eluent: 70% CO2, 30% MeOI 1+0. 1 %NH;,) to give the title compounds: Intermediate 5b {cis, 0.142 g, 53%) and Intermediate 5c {trans, 0.054 g, 20%); Intermediate 5b (cis): ‘H NMR: 1.52-1.69 (6H, m), 1.85 (2H, d), 1.98 (IH, ddd), 2.53-2.61 (2H, m), 2.7-2.83 (IH, m), 2.97-3.1 (2H, m), 3.36 (2H, td), 4.17 (2H, d), 4.31 (IH, t), 4.49 (IH, p), 6.65-6.83 (2H, m), 7.06-7.19 (2H, m), 7.27 (IH, dd), 7.32 (IH, d), 7.81 (lH, d); Intermediate 5c (trans): ‘H NMR: 1.55-1.72 (4H, m), 1.85 (2H, d), 2.14-2.16 (4H, m), 2.34-2.4 (IH, m), 2.7-2.82 (IH, m), 2.96-3.13 (2H, m), 3.34-3.44 (2H, m), 4.17 (2H, d), 4.33 (IH, t), 4.76 (IH, p), 6.64-6.78 (2H, m), 7.14 (2H, d), 7.27 (IH, dd), 7.32 (IH, d), 7.81 (IH, d).
[0826] Intermediate 5d: 4-(4-(4-((ls,3s)-3-(2-Bromoethyl)cvclobutoxy)phenyl)piperidin-l-yl)-2-(trifluoro-
[0827] A solution of PPh3(142 mg, 0.54 mmol) in THF (2 mL) was added dropwise to a stirred mixture of 4-(4-(4- ((lr,3s)-3-(2-hydroxyethyl)cyclobutoxy)phenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (120 mg, 0.27 mmol) and CBr i (179 mg, 0.54 mmol) in THF (2 mL) at 0°C. The resulting mixture was stirred at RT for Ih and then filtered. The solid was then washed with EtOAc (20 mL) and the filtrate concentrated under reduced pressure. Purification by FSC (gradient: 0-30% EtOAc in heptane) gave the title compound (0.140 g, 100%) as a colourless oil; ‘HNMR: (500 MHz, CDCh) 1.21-1.26 (IH, m), 1.63-1.78 (4H, m), 1.90 (2H, d), 1.95 (IH, d), 2.01-2.15 (IH, m), 2.49-2.73 (3H, m), 2.98 (2H, td), 3.28 (2H, t), 3.9-3.98 (2H, m), 4.44 (IH, p), 6.68-6.75 (2H, m), 6.92 (IH, dd), 6.98-7.07 (2H, m), 7.09 (IH, d), 7.55 (IH, s); m / z: ES+[M+H]+= 507.1.
[0828] Example 5: 4-14-14- !ltlr,3s)-3-t2- 14-12-12, 6-Dioxopiperidin-3-yl)-7-methoxy-l-oxo-2, 3-d ihvdro- isoindol-5-yl1piperazin-l-yllethyl)cvclobutyl1oxylphenyl)piperidin-l-yl1-2-(trifluoromethyl)benzonitrile
[0829] 4-(4-(4-((ls,3s)-3-(2-Bromoethyl)cyclobutoxy)phenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (65.0 mg, 0.13 mmol), 3-[7-methoxy-l-oxo-5-(piperazin-l-yl)-l,3-dihydro-2 / f-isoindol-2-yl]piperidine-2, 6-dione hydrochloride salt (50.6 mg, 0.13 mmol), KI (63.8 mg, 0.38 mmol) and DIPEA (112 Lil,. 0.64 mmol) were dissolved in MeCN (2.5 mL) and stirred at 70°C for 18h. The mixture was then diluted with DCM (20 mL), washed (5% AcOH in water (20 mL), water (20 mL) then sat. Nal ICO;, (20 mL)), dried (Na2SO4) and concentrated. Purification by preparative HPLC (Column A, Eluent A, Basic Work-Up A) gave the title compound (8 mg, 8%) as a white solid; ‘H NMR: 1.66-1.75 (3H, m), 1.75-1.84 (3H, m), 1.92-1.99 (3H, m), 2.15 (1H, dtd), 2.28 (1H, td), 2.32-2.4 (2H, m), 2.54-2.61 (4H, m), 2.61-2.69 (2H, m), 2.69-2.78 (1H, m), 2.78- 2.85 (1H, m), 2.85-2.91 (1H, m), 3.05 (2H, td), 3.27-3.36 (4H, m), 3.94 (3H, s), 4.02 (2H, d), 4.19 (1H, d), 4.35 (1H, d), 4.49 (1H, p), 5.12 (1H, dd), 6.36 (1H, d), 6.45 (1H, s), 6.7-6.82 (2H, m), 6.98 (1H, dd), 7.10 (2H, dd), 7.15 (1H, d), 7.61 (1H, d), 7.96 (1H, s); m / z\ ES+[M+H]+= 785.4.
[0830] Intermediate 6a: 3,4-Difluoro-2-(trifluoromethyl)benzonitrile l-Bromo-3,4-difluoro-2-(trifluoromethyl)benzene (5.00 g, 19.16 mmol) and cyanocopper (1.89 g, 21.07 mmol) were stirred in NMP (48 mL) at 150°C for 3h. The mixture was then cooled to RT, diluted with Et2O (100 mL), washed with sat. brine (3 * 100 mL) then dilute Ni l;, solution (50 mL), dried (MgSCL) and concentrated to give the title compound (4.27 g) which was used in the next step without further purification; ‘HNMR: (500 MHz, CDC13) 7.46 (1H, q), 7.59 (1H, dddd).
[0831] Intermediate 6b: 4-(4-(4-Bromophenyl)piperidin-l-yl)-3-fluoro-2-(trifluoromethyl)benzonitrile
[0832] 4-(4-Bromophenyl)piperidine (4.92 g, 20.49 mmol), 3,4-difluoro-2-(trifluoromethyl)benzonitrile (4.287 g,
[0833] 18.63 mmol) and DIPEA (3.90 mL, 22.36 mmol) were dissolved in NMP (43 mL). The mixture was then heated to 100°C for 0.5h, then cooled to RT and diluted with Et2O (100 mL). The mixture was washed with brine (2 x 100 mL), 2M aqueous HC1 (50 mL) then sat. Nal ICO; (50 mL) and brine (50 mL). The organic solution was dried (MgSO.4) and concentrated to give the title compound (6.16 g, 77%) as a pale brown solid which was used without further purification; ‘H NMR: (500 MHz, CDCh) 1.82 (2H, qd), 1.87-1.94 (2H, m),
[0834] 2.63 (1H, tt), 2.91 (2H, td), 3.63-3.73 (2H, m), 7.01-7.08 (3H, m), 7.36-7.4 (2H, m), 7.42 (1H, d); m / z\ ES+[M+H]+= 427.1.
[0835] Intermediate 6c: 3-Fluoro-4-(4-(4-(4-(hvdroxymethyl)piperidin-l-yl)phenyl)piperidin-l-yl)-2-(trifluoro- Cui (44.6 mg, 0.23 mmol) was added to a mixture of 4-(4-(4-bromophenyl)piperidin-l-yl)-3-fluoro-2- (trifluoro-methyl)benzonitrile (500 mg, 1.17 mmol), piperidin-4-ylmethanol (202 mg, 1.76 mmol), 2-((2,6- dimethyl-phenyl)amino)-2-oxoacetic acid (45.2 mg, 0.23 mmol) and K3PO4 (497 mg, 2.34 mmol) in DMSO (5 mL) under Na. The mixture was stirred at 110°C for 18h. The mixture was then cooled to RT and poured into water (50 mL) then extracted with EtOAc (3 x 50 mL). The combined organic solutions were washed with Nal ICO3 (50 mL) and brine (50 mL), dried (MgSCL) and concentrated. Purification by FSC (gradient: 0-100% EtOAc in heptane) gave the title compound (0.10 g, 19%) as a white solid; 'H NMR: (CDCI3) 1.28 (IH, d), 1.41 (2H, qd), 1.53 (IH, s), 1.57-1.71 (IH, m), 1.82-1.91 (3H, m), 1.91-1.99 (2H, m), 2.53-2.79 (3H, m), 2.98 (2H, td), 3.55 (2H, d), 3.63-3.81 (4H, m), 6.88-6.95 (2H, m), 7.05-7.16 (3H, m), 7.48 (IH, d); m / z\ ES+[M+H]+= 462.2.
[0836] Intermediate 6d: 3-Fluoro-4-(4-(4-(4-formylpiperidin-l-yl)phenyl)piperidin-l-yl)-2-(trifluoromethyl)-
[0837] Dess Martin periodinane (101 mg, 0.24 mmol) was added to 3-fluoro-4-(4-(4-(4-(hydroxymethyl)piperidin-l- yl)phenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (100 mg, 0.22 mmol) in DCM (3 mL) at 0°C. The resulting mixture was stirred at RT for Ih. The mixture was then diluted with DCM (15 mL) and poured into a mixture of sat. Nal ICOa (25 mL) and sodium thiosulfate solution (25 mL). The resulting suspension was stirred vigorously for 10 mins and the layers separated. The organic layer was dried (NaaSCL) and concentrated to give the title compound as a yellow dry film, which was used in the next step without further purification (assumed 100% yield); m / z\ ES+[M+H]+= 460.3.
[0838] Example 6: 4-(4-f4-[4-(f4-[2-(2.6-Dioxopiperidin-3-yl)-7-methoxy-l-oxo-2.3-dihvdro-l / 7-isoindol-5-yl1- piperazin-l-yllmethyl)piperidin-l-yl1phenyllpiperidin-l-yl)-2-(trifluoromethyl)benzonitrile
[0839] 3-Fluoro-4-(4-(4-(4-formylpiperidin- 1 -yl)phenyl)piperidin- 1 -yl)-2-(trifhioromethyl)benzonitrile (0.100 g, 0.22 mmol), 3-[7-methoxy-l-oxo-5-(piperazin-l-yl)-l,3-dihydro-2K-isoindol-2-yl]piperidine-2, 6-dione hydrochloride salt (0.086 g, 0.22 mmol) and NaOAc (0.054 g, 0.65 mmol) were dissolved in DCM (3 mL) at RT and stirred for 10 mins. NaBH(OAc)3 (0.092 g, 0.44 mmol) was added and the mixture stirred for Ih. The mixture was diluted with DCM (20 mL), washed (sat. Nal ICOa (20 mL), water (20 mL) then sat. brine (20 mL)), dried ( NaiSO i ) and concentrated. Purification by preparative HPLC (Column A, Eluent A) gave the title compound as a formate salt (42 mg, 24%) as a white solid; *H NMR: 1.23 (2H, q), 1.62-1.78 (3H, m), 1.82- 1.84 (4H, m), 1.89-1.97 (1H, m), 2.23 (2H, d), 2.26-2.38 (2H, m), 2.52-2.54 (4H, m), 2.56-2.67 (3H, m), 2.83- 2.96 (1H, m), 3.04 (2H, t), 3.31 (4H, s), 3.68 (4H, dd), 3.84 (3H, s), 4.12 (1H, d), 4.24 (1H, d), 4.96 (1H, dd), 6.49 (1H, s), 6.61 (1H, s), 6.88 (2H, d), 7.11 (2H, d), 7.46 (1H, t), 7.80 (1H, d), 10.88 (1H, s); m / z\ ES+[M+H]+= 802.7.
[0840] Intermediate 7a: 3-Fluoro-4-(4-(4-(4-hvdroxybutoxy)phenyl)piperidin-l-yl)-2-(trifluoromethyl)- benzonitrile
[0841] 4-(4-(4-Bromophenyl)piperidin-l-yl)-3-fluoro-2-(trifluoromethyl)benzonitrile (0.500 g, 1.17 mmol), CS2CO3 (1.335 g, 4.10 mmol) and butane- 1,4-diol (0.501 mL, 5.85 mmol) were dissolved in toluene (15 mL) and degassed with Ni. Rockphos Pd G3 (0.049 g, 0.06 mmol) was added and the mixture was heated at 90°C for 18h. The mixture was then diluted with EtOAc (100 mL), washed with water (100 mL) then sat. brine (100 mL), dried (TS^SCL) and concentrated. Purification by FSC (gradient: 0-50% EtOAc in heptane) gave the title compound (0.363 g, 71%) as a pale yellow solid; ‘H NMR: (CDCI3) 1.52 (1H, s), 1.69-1.8 (2H, m), 1.82-1.99 (6H, m), 2.67 (1H, tt), 2.98 (2H, td), 3.73-3.74 (4H, m), 4.00 (2H, t), 6.82-6.92 (2H, m), 7.06-7.18 (3H, m), 7.44-7.53 (1H, m); m / z\ ES+[M+H]+= 437.1.
[0842] Intermediate 7b: 3-Fluoro-4-(4-(4-(4-oxobutoxy)phenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile
[0843] 3-( )xo- l l5-ben / o| J|| 1 .2|iodaoxole- l .1 . l(3 / 7)-trivl triacetate (192 mg, 0.45 mmol) was added to 3-fluoro-4-(4- (4-(4-hydroxybutoxy)phenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (180 mg, 0.41 mmol) in DCM (2 mL) at 0°C and warmed to RT for Ih. The mixture was then diluted with DCM (15 mL) and poured into mixture of sat. Nal ICC);, (25 mL) and sodium thiosulfate solution (25 mL). The resulting suspension was stirred vigorously for 10 mins then the phases were separated. The organic solution was dried (Na2SO4) and concentrated to give the title compound (0.120 g, 67%) as a yellow film, which was used in the next step without further purification; m / z\ ES+[M+H]+= 435.1.
[0844] Example 7: 4-f4-[4-(4-f4-[2-(2,6-Dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3-dihvdro-l / 7-isoindol-5-yl1- piperazin-l-yllbutoxy)phenyl1piperidin-l-yll-3-fluoro-2-(trifluoromethyl) benzonitrile
[0845] 3-Fluoro-4-(4-(4-(4-oxobutoxy)phenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (0.120 g, 0.28 mmol), 3- [7-m ethoxy- 1 -oxo-5-(piperazin- 1 -yl)- 1 , 3-dihvdro-2 / 7-iso indo l-2-yl]piperidine-2, 6-dione hydrochloride salt (0.109 g, 0.28 mmol) and NaOAc (0.068 g, 0.83 mmol) were dissolved in DCM (3 mL) at RT and stirred for 10 mins. NaBH(OAc)a (0.117 g, 0.55 mmol) was then added and the mixture stirred for Ih. The mixture was then diluted with DCM (20 mL) and washed (sat. Nal ICO;, (20 mL), water (20 mL) then sat. brine (20 mL)), dried (Na2SO4) and concentrated. Purification by preparative HPLC (Column A, Eluent A) gave the title compound (0.084 g, 39%) as a white solid; ‘H NMR: 1.61 (2H, p), 1.75-1.76 (4H, m), 1.86 (2H, d), 1.89-1.98 (IH, m), 2.28 (IH, dd), 2.39 (2H, t), 2.52-2.53 (4H, m), 2.54-2.62 (IH, m), 2.67-2.78 (IH, m), 2.89 (IH, ddd), 2.99-3.08 (2H, m), 3.27-3.32 (4H, m), 3.72 (2H, d), 3.84 (3H, s), 3.98 (2H, t), 4.05-4.18 (IH, m), 4.24 (IH, d), 4.96 (IH, dd), 6.48 (IH, d), 6.60 (IH, s), 6.8-6.92 (2H, m), 7.18 (2H, d), 7.46 (IH, t), 7.80 (IH, d), 10.88 (IH, s); m / z\ ES+[M+H]+= 777.3.
[0846] Intermediate 8a: tert- Butyl 4-(5-hvdroxypyrimidin-2-yl)-3,6-dihvdropyridine-l carboxylate
[0847] Na;CO;, (1.211 g, 11.43 mmol) was added to a solution of 2-bromopyrimidin-5-ol (1.00 g, 5.71 mmol) and tert-butyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-l(2 / / )-carboxylate (2.65 g, 8.57 mmol) in toluene (8.0 mL), EtOH (2.0 mL) and water (4.0 mL). The mixture was degassed with N; for 15 mins. Pd(dppf)2C12-DCM complex (0.467 g, 0.571 mmol) was then added and the resulting mixture was heated to 100°C for 3h, then cooled to RT. The mixture was then diluted with water (150 mL) and extracted with EtOAc (2 x 200 mL). The combined organic solutions were washed with brine (80 mL), dried (TS^SCL) and concentrated. Purification by FSC (gradient: 0-40% EtOAc in heptane) gave the title compound (1.10 g, 65%) as a pale brown sticky liquid; ‘HNMR: 1.43 (9H, s), 2.56 (2H, d), 3.51 (2H, t), 4.04 (2H, s), 6.91 (IH, s), 8.34 (2H, s), 10.42 (IH, br s); m / z\ ES+[M-56]+= 222.2.
[0848] Intermediate 8b: tert-Butyl 4-(5-hvdroxypyrimidin-2-yl)piperidine-l-carboxylate tert-Butyl 4-(5-hydroxypyrimidin-2-yl)-3,6-dihydropyridine-l(2 / / )-carboxylate (1.10 g, 3.97 mmol) was dissolved in EtOH (30 mL) and the solution bubbled with N 2 for a period of 15 mins. Pd-on-C (0.55 g, 0.517 mmol) (10% w / w) was added under N2 and the mixture was then stirred under an atmosphere of H2 at RT for 5h. The mixture was then filtered through celite and the filter cake washed with MeOH (250 mL). The filtrate was concentrated to give the title compound (1.05 g, 70%) as a pale brown sticky liquid which was used in the next step without further purification; ‘H NMR: 1.41 (9H, s), 1.48-1.65 (2H, m), 1.86 (2H, d), 2.76-2.95 (3H, m), 3.99 (2H, d), 8.23 (2H, s); m / z\ ES- [M-H]’ = 278.3.
[0849] Intermediate 8c: 2-(Piperidin-4-yl)pyrimidin-5-ol
[0850] 4N HC1 in 1,4-dioxane (5 mL, 20.00 mmol) was added to a solution of tert-butyl 4-(5-hydroxypyrimidin-2- yl)-piperidine-l -carboxylate (500 mg, 1.79 mmol) in DCM (10 mL) at 0°C. The mixture was stirred at 0°C to RT for 2h and then concentrated. The resulting solid was triturated with hexanes (10 mL) gave the title compound as a hydrochloride salt (460 mg, 99%) as an off-white solid; *H NMR: 1.90-2.00 (2H, m), 2.03-2.15 (2H, m), 2.95-3.11 (3H, m), 3.29 (2H, d), 8.36 (2H, s), 8.89 (1H, br s), 9.14 (1H, br s), 10.60 (1H, br s); m / z\ ES+[M+H]+= 180.2.
[0851] DIPEA (0.831 mL, 4.76 mmol) was added to a solution of 4-fhioro-2-(trifhioromethyl)benzonitrile (300 mg, 1.586 mmol) and 2-(piperidin-4-yl)pyrimidin-5-ol hydrochloride salt (513 mg, 2.380 mmol) in DMSO (5 mL) at RT under air. The mixture was heated at 50°C for 6h, then cooled to RT, diluted with water (100 mL) and extracted with EtOAc (2 x 150 mL). The combined organic solutions were washed with cold water (2 x 80 mL), dried (Na2SC>4) and concentrated. Purification by FSC (gradient: 0-6% MeOH in DCM) gave the title compound (380 mg, 64%) as a pale yellow sticky liquid; >H NMR: (CDCI3) 1.92-2.05 (2H, m), 2.14 (2H, d), 3.11-3.21 (3H, m), 4.03 (2H, d), 7.00 (1H, dd), 7.17 (1H, d), 7.62 (1H, d), 8.37 (2H, s); m / z\ ES+[M+H]+= 349.2.
[0852] Intermediate 8e: 4-[4-[5-(4-Bromobutoxy)pyrimidin-2-yl1-l-piperidyl1-2-(trifluoromethyl)benzonitrile
[0853] CS2CO3 (711 mg, 2.182 mmol) and 1 ,4-dibromobutane (0.391 mL, 3.27 mmol) were added to a solution of 4- (4-(5-hydroxypyrimidin-2-yl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (380 mg, 1.091 mmol) in DMF (5 mL) at RT. The mixture was stirred at RT for 2h, then diluted with water (50 mL) and extracted with EtOAc (2 x 100 mL). The combined organic solutions were washed with brine (50 mL), dried (Na2SO4) and concentrated. Purification by FSC (gradient: 0-40% EtOAc in heptane) gave the title compound (390 mg, 71%) as an off-white solid; >H NMR: (CDCh) 1.96-2.21 (8H, m), 3.12-3.22 (3H, m), 3.51 (2H, t), 4.02 (2H, d), 4.11 (2H, t), 7.01 (1H, dd), 7.17 (1H, d), 7.62 (1H, d), 8.39 (2H, s); m / z\ ES+[M+H]+= 483.1.
[0854] Example 8: 4-[4-[5-[4-[4-[2-(2,6-Dioxo-3-piperidyl)-7-methoxy-l-oxo-isoindolin-5-yl1piperazin-l-yl1- butoxy1pyrimidin-2-yl1-l-piperidyl1-2-(trifluoromethyl)benzonitrile
[0855] Amixture of DIPEA (0.216 mL, 1.241 mmol), 3-[7-methoxy-l-oxo-5-(piperazin-l-yl)-l .3-dihvdro-2 / 7- isoindol-2-yl]piperidine-2, 6-dione hydrochloride salt (137 mg, 0.348 mmol), 4-(4-(5-(4- bromobutoxy)pyrimidin-2-yl)-piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (120 mg, 0.248 mmol) and KI (124 mg, 0.745 mmol) were stirred in DMSO (4 mL) at RT under N2. The mixture was then heated to 80°C for 16h, cooled to RT and diluted with DCM (30 mL). The phases were separated and the organic solution was washed (5% AcOH in water (20 mL), water (20 mL), sat. Nal ICO;, (20 mL)then sat. brine (20 mL)), dried (Na2SO4) and concentrated. The crude material was purified by preparative HPLC (Column B, Eluent C). Fractions containing the desired compound were combined, concentrated cold to a minimum amount of solvent and basified with sat. Nal ICO;, solution. The phases were separated and the aqueous phase was extracted with DCM (4 x 30 mL). The combined organic solutions were washed with water (20 mL), dried over a phase separator and lyophilized to give the title compound (55 mg, 29%) as an off white solid; *H NMR: 1.57-1.67 (2H, m), 1.69-1.83 (4H, m), 1.92-2.04 (3H, m), 2.34-2.42 (3H, m), 2.59 (1H, d), 2.85-2.97 (1H, m), 3.06-3.20 (3H, m), 3.26 (4H, s), 4.08-4.25 (5H, m), 4.30-4.38 (1H, m), 5.05 (1H, dd), 7.07 (2H, s), 7.27 (1H, dd), 7.32 (1H, s), 7.52 (1H, d), 7.82 (1H, d), 8.49 (2H, s), 10.95 (1H, s); m / z\ ES+[M+H]+= 761.2.
[0856] Intermediate 9a: tert-Butyl 5-hvdroxy-3’.6’-dihvdro-[2.4’-bipyridine1-l’ carboxylate
[0857] Na;CO; (1.218 g, 11.49 mmol) and tert-butyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,6-dihydro- pvndine- l(2 / 7)-carboxvlate (2.67 g, 8.62 mmol) were added to a solution of 6-bromopyridin-3-ol (1.0 g, 5.75 mmol) in EtOH (4.0 mL), toluene (8.0 mL) and water (2.0 mL) at RT. The mixture was degassed withN2 for 15 min, then Pd(dppf)C12-DCM (0.079 g, 0.575 mmol) was then added and the mixture was heated to 100°C for 3h. The mixture was then cooled to RT, diluted with water (120 mL) and the phases separated. The aqueous phase was extracted with EtOAc (2 x 150 mL) and the combined organic solutions were washed with brine (100 mL), dried (Na2SO4) and concentrated. Purification by FSC (gradient: 0-35% EtOAc in heptane) gave the title compound (1.52 g, 95%) as a pale yellow sticky liquid; *H NMR: (CDCh) 1.51 (9H, s), 2.61 (2H, d), 3.64 (2H, t), 4.11 (2H, d), 6.40 (1H, s), 7.18 (1H, dd), 7.30 (1H, d), 8.21 (1H, d); m / z\ ES+[M+H]+= 277.2.
[0858] Intermediate 9b: tert- Butyl 4-(5-hvdroxypyridin-2-yl)piperidine-l-carboxylate
[0859] 10% Pd-on-C (125 mg, 1.175 mmol) was added to a solution of tert-butyl 5-hydroxy-3',6'-dihydro-[2,4'-bi- pvridine|- 1'( 2' / 7)-carboxvlate (500 mg, 1 .809 mmol) in MeOH (10 mL) under N2. The resulting suspension was purged with H2 and stirred at RT for 2h under an atmosphere of 112. The mixture was then filtered through celite and washed through with MeOH (150 mL). Concentration of the filtrate gave the title compound (410 mg, 81%) as an off-white solid; >H NMR: 1.41 (9H, s), 1.46-1.59 (2H, m), 1.76 (2H, d), 2.67-2.83 (3H, m), 4.03 (2H, d), 7.08 (2H, d), 8.05 (1H, s), 9.63 (1H, br s); m / z\ ES+[M+H]+= 279.4.
[0860] Intermediate 9c: 6-(piperidin-4-yl)pyridine-3-ol. TFA salt
[0861] TFA (0.886 mL, 11.50 mmol) was added to a solution of tert-butyl 4-(5-hydroxypyridin-2-yl)piperidine-l- carboxylate (400 mg, 1.437 mmol) in DCM (8.0 mL) at 0°C. The mixture was then warmed to RT over 2h and then concentrated. Trituration with MTBE (50 mL) gave the title compound as a trifluoroacetate salt (430 mg, 99%) as an off white solid; ‘H NMR: 1.77-1.91 (2H, m), 1.94-2.03 (2H, m), 2.91-3.08 (3H, m), 3.37 (2H, d), 7.19-7.34 (2H, m), 8.13 (1H, d), 8.40 (1H, br s), 8.69 (1H, br s), 10.26 (1H, br s); m / z\ ES+[M+H]+= 179.1.
[0862] DIPEA (0.831 mL, 4.76 mmol) and 6-(piperidin-4-yl)pyridin-3-ol (424 mg, 2.380 mmol) were added to a stirred solution of 4-fluoro-2-(trifluoromethyl)benzonitrile (300 mg, 1.586 mmol) in DMSO (5.0 mL) at RT. The mixture was then heated to 50°C for 5h, then cooled to RT and diluted with water (80 mL). The phases were separated and the aqueous phase was extracted with EtOAc (2 * 120 mL). The combined organic solutions were dried (TS^SCL) and concentrated. Trituration with hexanes (100 mL) gave the title compound (530 mg, 96%) as an off-white solid; >H NMR: 1.69 (2H, qd), 1.88 (2H, d), 2.86-2.99 (1H, m), 3.09 (2H, t), 4.16 (2H, d), 7.08-7.12 (2H, m), 7.27 (1H, dd), 7.32 (1H, s), 7.81 (1H, d), 8.04 (1H, d), 9.66 (1H, s); m / z\ ES+[M+H]+= 348.1.
[0863] Intermediate 9e: 4-(4-(5-(4-Bromobutoxy)pyridin-2-yl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile
[0864] K2CO3 (80 mg, 0.576 mmol) and 1 ,4-dibromobutane (186 mg, 0.864 mmol) were added to a stirred solution of 4-(4-(5-hydroxypyridin-2-yl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (100 mg, 0.288 mmol) in acetone (3.0 mL) at RT. The mixture was then heated to 60°C for 4h, then cooled to RT and concentrated. The mixture was then partitioned between water (80 mL) and EtOAc (100 mL). The aqueous portion was extracted with EtOAc (2 x 100 mL) and the combined organic solutions were washed with sat. brine (50 mL), dried (Na2SO4) and concentrated to give crude compound (170 mg). The same method was repeated with CS2CO3 (188 mg, 0.576 mmol) instead of K2CO3 and the mixture was stirred at RT for 2h. After the same workup as previously described, the crude products from both reactions were combined. Purification by FSC (gradient: 0-20% EtOAc in heptane) gave the title compound (160 mg, 58%) as an off-white solid; 'H NMR: (CDCI3) 1.84-2.03 (4H, m), 2.05-2.14 (4H, m), 2.93-3.02 (1H, m), 3.13 (2H, td), 3.51 (2H, t), 4.02-4.10 (4H, m), 7.01 (1H, dd), 7.12 (1H, d), 7.17 (2H, dd), 7.63 (1H, d), 8.25 (1H, d); m / z\ ES+[M+H]+= 482.1.
[0865] Example 9: 4-(4-(5-(4-(4-(2-(2,6-Dioxopiperidin-3-yl)-7-methoxy-l-oxoisoindolin-5-yl)piperazin-l- yl)butoxy)pyridin-2-yl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile
[0866] DIPEA (0.221 mL, 1.266 mmol), 4-(4-(5-(4-bromobutoxy)pyridin-2-yl)piperidin-l-yl)-2-(trifluoromethyl)- benzonitrile (147 mg, 0.304 mmol) and KI (126 mg, 0.760 mmol) were added to a solution of 3-[7-methoxy-l- oxo-5-(piperazin-l-yl)-l,3-dihydro-2 / f-isoindol-2-yl]piperidine-2, 6-dione hydrochloride salt (100 mg, 0.253 mmol) in DMSO (3.0 mL) RT under N2. The mixture was then heated to 80°C for 12h, then cooled to RT and diluted with DCM (20 mL). The solution was washed (5% AcOH in water (20 mL), water (20 mL), sat.
[0867] Nal ICO, (20 mL) then sat. brine (20 mL)), dried (TS^SCL) and concentrated. The crude material was purified by preparative HPLC (Column C, Eluent C). Fractions containing the desired compound were combined, concentrated cold to a minimum amount of solvent and basified with sat. Nal ICO;, solution. The phases were separated and the aqueous portion was extracted with DCM (4 x 30 mL). The combined organic solutions were washed with water (20 mL), dried over a phase separator and lyophilized to give the title compound (28 mg, 14%) as an off white solid; ‘HNMR: 1.62-1.95 (10H, m), 2.34-2.40 (1H, m), 2.59 (2H, s), 2.75-3.03 (5H, m), 3.10 (4H, t), 3.84 (3H, s), 4.03-4.29 (7H, m), 4.97 (1H, dd), 6.52 (1H, s), 6.64 (1H, s), 7.21-7.38 (4H, m), 7.82 (1H, d), 8.21 (1H, s), 10.91 (1H, br s); m / z\ ES+[M+H]+= 760.3.
[0868] Intermediate 10a: tert-Butyl 3-(2-((tert-butyldiphenylsilyl)oxy)ethyl)azetidine-l-carboxylate
[0869] Imidazole (0.474 g, 6.96 mmol) and tert-butylchlorodiphenylsilane (1.48 g, 5.37 mmol) were added to a solution of tert-butyl 3 -(2-hydroxyethyl)azetidine-l -carboxylate (1.00 g, 4.97 mmol) in DCM (8 mL) at 0°C. The mixture was stirred at RT for 2h and then partitioned between water (2 mL) and DCM (10 mL). The organic phase was dried (IS^SCL) and concentrated to give the title compound (1.10 g, 90%) which was used in the next step without further purification; *H NMR: 0.99 (9H, s), 1.21 (9H, s), 1.74-1.86 (2H, m), 2.61-2.79 (1H, m), 3.42-3.54 (2H, m), 3.58-3.68 (2H, m), 3.81-3.94 (2H, m), 7.42-7.52 (6H, m), 7.58-7.65 (4H, m).
[0870] Intermediate 10b: 3-(2-((tert-Butyldiphenylsilyl)oxy)ethyl)azetidine
[0871] TFA (1.92 mL, 25.0 mmol) was carefully added to a solution of tert-butyl 3-(2-((tert-butyldiphenylsilyl)oxy)- ethyl)azetidine-l -carboxylate (1.10 g, 2.502 mmol) in DCM (8 mL) at 0°C. The mixture was then stirred at 0°C for 2h then further diluted with DCM (5 mL) and washed with sat Nal ICO;, (20 mL). The organic solution was dried (Na2SO4) and concentrated to give the title compound (810 mg, 91%) as thick liquid that was used in the next step without further purification; m / z\ ES+[M+H]+= 340.4.
[0872] Intermediate 10c: 4-(4-(4-(3-(2-((tert-ButyldiphenylsilvDoxy)ethvDazetidin-l-vDphenvDpiperidin-l-vD-2-
[0873] (trifluoromethvDbenzonitrile 3-(2-((tert-Butyldiphenylsilyl)oxy)ethyl)azetidine (809 mg, 2.382 mmol) and CS2CO3 (1.04 g, 3.18 mmol) were added to a solution of 4-(4-(4-bromophenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (650 mg, 1.588 mmol) in 1,4-dioxane (12 mL). The mixture was purged with N 2 for 15 min at which point Pd;dba; (145 mg, 0.159 mmol) and SPhos (85 mg, 0.318 mmol) were added. The mixture was then stirred at 120°C for 3h, cooled to RT and diluted with DCM (25 mL). The mixture was then filtered through celite. The filtrate was concentrated under reduced pressure and diluted with DCM (50 mL). The organic layer was separated, dried (Na2SC>4) and concentrated to give the title compound (1.20 g, 43%) as a grey solid that was used in the next step without further purification; m / z\ ES+[M+H]+= 668.2.
[0874] Intermediate IQd: 4-(4-(4-(3-(2-Hvdroxyethyl)azetidin-l-yl)phenyl)piperidin-l-yl)-2-(trifluoromethyl)- benzonitrile
[0875] Tetra w-butylammonium fluoride (IN solution in THF, 0.843 mL, 0.843 mmol) was added to a solution of 4- (4-(4-(3-(2-((tert-butyl-diphenylsilyl)oxy)ethy l)azetidin- 1 -yl)phenyl)piperidin- 1 -yl)-2-(trifluorom ethylbenzonitrile (512 mg, 0.767 mmol) in THF (4 mL) at 0°C and the resulting mixture was stirred for 3h. The mixture was then concentrated and dissolved into DCM (25 mL). The resulting solution was washed with sat. Nal ICO;, solution (25 mL), dried (Na2SO4) and concentrated to give the title compound (360 mg, 67%) as a thick liquid; m / z\ ES+[M+H]+= 430.2.
[0876] Intermediate IQe: 4-(4-(4-(3-(2-Bromoethyl)azetidin-l-yl)phenyl)piperidin-l-yl)-2-(trifluoromethyl)- benzonitrile
[0877] PPhs (286 mg, 1.090 mmol) was added to a solution of 4-(4-(4-(3-(2-hydroxyethyl)azetidin-l-yl)phenyl)- piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (360 mg, 0.838 mmol) in DCM (5 mL) and the mixture was stirred for 5 min at RT. CBrj (361 mg, 1.090 mmol) was then added and the mixture was stirred at RT for 2h. The solvent was reduced to half quantity (2 mL) after concentration then the product was triturated with pentane to give the title compound that was used in the next step without further purification; m / z\ ES+[M+H]+= 492.0.
[0878] Example 10: 4-(4-(4-(3-(2-(4-(2-(2.6-Dioxopiperidin-3-vD-7-methoxy-l-oxoisoindolin-5-vDpiperazin-l- yl)ethvDazetidin-l-vDphenvDpiperidin-l-vD-2-(trifluoromethvDbenzonitrile
[0879] Amixture ofDIPEA (0.25 mL, 1.422 mmol), 4-(4-(4-(3-(2-bromoethyl)azetidin-l-yl)phenyl)piperidin-l-yl)-2- (trifluoro-methyl)benzonitrile (140 mg, 0.284 mmol), 3-[7-methoxy-l-oxo-5-(piperazin-l-yl)-l .3-dihvdro-2 / 7- isoindol-2-yl]piperidine-2, 6-dione hydrochloride salt (112 mg, 0.284 mmol) and KI (142 mg, 0.853 mmol) was stirred in DMSO (5 mL) at RT. The mixture was then heated to 80°C for 12h, then concentrated and slowly poured into ice- water. The resulting solids were collected by filtration, washed with water (10 mL) and dried under vacuum. Purification by preparative HPLC (Column B, Eluent C, Basic Work-Up A) gave the title compound (34 mg, 15%) as an off white solid; ‘H NMR: 1.50-1.66 (2H, m), 1.66-1.77 (1H, m), 1.77-1.87 (2H, m), 1.87-1.99 (1H, m), 2.09-2.18 (1H, m), 2.24-2.43 (4H, m), 2.54-2.61 (4H, m), 2.65-2.75 (2H, m), 2.79-2.93 (1H, m), 2.93-3.10 (4H, m), 3.17-3.26 (2H, m), 3.84 (3H, s), 4.04-4.30 (4H, m), 4.94 (1H, dd), 6.39-6.51 (3H, m), 6.57-6.68 (1H, m), 6.96-7.11 (2H, m), 7.23-7.37 (2H, m), 7.81 (1H, d), 11.0 (1H, br s); m / z\ ES+[M+H]+= 770.2.
[0880] Intermediate Ila: 5-(4-(4-Hvdroxyphenyl)piperidin-l-yl)-3-(trifluoromethyl)picolinonitrile
[0881] K2CO3 (826 mg, 5.98 mmol) was added to a solution of 5-bromo-3-(trifluoromethyl)picolinonitrile (500 mg, 1.992 mmol), 4-(piperidin-4-yl)phenol hydrobromide (771 mg, 2.99 mmol) and A0,A5-dimethylethane-l,2- diamine (35.1 mg, 0.398 mmol) in 1,4-dioxane (8 mL). The mixture was degassed with N2 for 15 mins and then Cui (37.9 mg, 0.199 mmol) was added. The mixture was heated to 120°C for 16h, then cooled to RT, diluted with water (100 mL) and extracted with EtOAc (2 * 150 mL). The combined organic solutions were washed with brine (80 mL), dried (TS^SCL) and concentrated. Purification by FSC (gradient: 0-30% EtOAc in heptane) gave the title compound (310 mg, 43%) as a pale yellow solid; 'H NMR: 1.56-1.69 (2H, m), 1.84 (2H, d), 2.66-2.79 (1H, m), 3.06-3.15 (2H, m), 4.29 (2H, d), 6.69 (2H, d), 7.05 (2H, d), 7.63 (1H, d), 8.65 (1H, d), 9.18 (1H, s); m / z\ ES+[M+H]+= 348.0.
[0882] Intermediate 11b: 5-(4-(4-(4-Bromobutoxy)phenyl)piperidin-l-yl)-3-(trifluoromethyl)picolinonitrile K2CO3 (119 mg, 0.864 mmol) was added to a solution of 5-(4-(4-hydroxyphenyl)piperidin-l-yl)-3-(trifluoro- methyl)picolinonitrile (150 mg, 0.432 mmol) and 1 ,4-dibromobutane (140 mg, 0.648 mmol) in DMF (3.0 mL) at RT. The mixture was heated to 70°C for 6h, then cooled to RT, diluted with water (50 mL) and extracted with EtOAc (2 x 80 mL). The combined organic solutions were washed with sat. brine (30 mL), dried (NaaSCL) and concentrated. Purification by FSC (gradient: 0-30% EtOAc in heptane) gave the title compound (145 mg, 65%) as an off-white semi-solid; ‘H NMR: 1.23-1.32 (4H, m), 1.60-1.73 (2H, m), 1.91-2.04 (2H, m), 2.75-2.90 (1H, m), 3.11 (2H, t), 3.54-3.67 (2H, m), 3.97 (2H, t), 4.30 (2H, d), 6.86 (2H, d), 7.17 (2H, d), 7.64 (1H, d), 8.66 (1H, d); m / z\ ES+[M+H]+= 482.1.
[0883] Example 11: 5-(4-(4-(4-(4-(2-(2,6-Dioxopiperidin-3-yl)-7-methoxy-l-oxoisoindolin-5-yl)piperazin-l- yl)butoxy)phenvDpiperidin-l-vD-3-(trifluoromethvDpicolinonitrile
[0884] DIPEA (0.332 mL, 1.899 mmol) was added to a solution of 3-[7-methoxy-l-oxo-5-(piperazin-l-yl)-l,3- dihvdro-2 / / -isoindol-2-vl |piperidine-2.6-dione hydrochloride salt (150 mg, 0.380 mmol), 5-(4-(4-(4- bromobutoxy)-phenyl)piperidin-l-yl)-3-(trifluoromethyl)picolinonitrile (220 mg, 0.456 mmol) and KI (189 mg, 1.140 mmol) in DMSO (4 mL) at RT under N2. The mixture was stirred at 80°C for 16h, then cooled to RT and diluted with DCM (20 mL). This solution was washed (5% AcOH in water (20 mL), water (20 mL), sat. Nal ICO3 (20 mL) then sat. brine (20 mL)), dried ( Na^SO i ) and concentrated. Purification by preparative HPLC (Column B, Eluent C, Basic Work-Up A) and trituration with pentane (10 mL) gave the title compound (52 mg, 18 %) as an off white solid; ‘HNMR: 1.58-1.78 (6H, m), 1.81-2.01 (3H, m), 2.27-2.38 (3H, m), 2.60- 2.78 (2H, m), 2.80-2.98 (2H, m), 3.11 (3H, t), 3.83 (3H, s), 3.97 (2H, s), 4.06-4.34 (4H, m), 4.97 (1H, d), 6.48 (1H, s), 6.61 (1H, s), 6.86 (2H, d), 7.17 (2H, d), 7.65 (1H, s), 8.65 (1H, s), 10.91 (1H, s); m / z\ ES+[M+H]+= 760.4.
[0885] Intermediate 12a: 4-(4-(4-((3,3-Difluoro-5-hvdroxypentvDoxy)phenvDpiperidin-l-vD-2-(trifluoro-
[0886] RockPhos Pd G3 (0.290 g, 0.34 mmol) was added to 4-(4-(4-bromophenyl)piperidin-l-yl)-2-(trifluoro- methyl)benzonitrile (1.39 g, 3.40 mmol), 3,3-difluoropentane-l,5-diol (1.19 g, 8.49 mmol) and CS2CO3 (239 mg, 0.73 mmol) in 1,4-dioxane (50 mL) at RT. The resulting mixture was then stirred at 100°C for Ih. The mixture was then cooled to RT and concentrated. The resulting residue was dissolved into EtOAc (50 mL) and brine (50 mL). The phases were separated and the aqueous phase was extracted with EtOAc (2 x 50 mL). The combined organic solutions were dried (MgSCL) and concentrated. Purification by FSC (gradient: 0-50% EtOAc in heptane) gave the title compound (0.60 g, 38%) as a yellow gum; *H NMR: (CDCh) 1.62 (IH, t), 1.7-1.89 (2H, m), 1.94-2.04 (2H, m), 2.25 (2H, tt), 2.43 (2H, tt), 2.66-2.82 (IH, m), 2.96-3.16 (2H, m), 3.91 (2H, q), 4.02 (2H, d), 4.17 (2H, t), 6.76-6.92 (2H, m), 6.99 (IH, dd), 7.09-7.21 (3H, m), 7.61 (IH, d).
[0887] Intermediate 12b: 5-(4-(l-(4-Cvano-3-(trifluoromethyl)phenyl)piperidin-4-yl)phenoxy)-3,3- difluoropentyl methanesulfonate
[0888] Methane sulfonic anhydride (167 mg, 0.96 mmol) was added in one portion to 4-(4-(4-((3,3-difluoro-5- hydroxy-pentyl)oxy)phenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (180 mg, 0.38 mmol) and NEta (160 pL, 1.15 mmol) in DCM (2 mL) at RT and the mixture was stirred for 18h. The mixture was then diluted with DCM (25 mL) and washed sequentially with sat NH4CI (10 mL), sat Nal ICO;, (10 mL), water (20 mL) and sat. brine (10 mL). The solution was then dried with a phase separating cartridge, filtered and concentrated to give the title compound which was used in the next step without further purification; m / z\ ES+[M+H]+547.2. Dioxopiperidin-3-yl)-7-methoxy-l-oxoisoindolin-5-yl)piperazin-l-yl)- idin-l-yl)-2-(trifluorom
[0889] KI (200 mg, 1.21 mmol), 5-(4-(l-(4-cyano-3-(trifluoromethyl)phenyl)piperidin-4-yl)phenoxy)-3,3-difluoro- pentyl methane sulfonate (220 mg, 0.40 mmol), 3-[7-methoxy-l-oxo-5-(piperazin-l-yl)-l,3-dihydro-2 / 7- isoindol-2-yl]piperidine-2, 6-dione hydrochloride salt (166 mg, 0.42 mmol) and DIPEA (0.247 mL, 1.41 mmol) were dissolved in MeCN (3 mL) and stirred at 80°C for 18h. The mixture was then cooled to RT, concentrated. The resulting residue was dissolved with DCM (20 mL), washed with water (20 mL), separated through a phase separator and concentrated. Purification by preparative HPLC (Column A, Eluent A, Basic Work-Up A) gave the title compound (10.2 mg, 3%) as a yellow dry film; *H NMR: ( CDCh ) 1.75 (2H, qd), 1.97 (2H, d), 2.13-2.34 (4H, m), 2.34-2.48 (2H, m), 2.64-2.93 (9H, m), 3.06 (2H, td), 3.29-3.39 (4H, m), 3.94 (3H, s), 4.02 (2H, d), 4.13-4.26 (3H, m), 4.36 (1H, d), 5.13 (1H, dd), 6.36 (1H, d), 6.46 (1H, s), 6.79-6.9 (2H, m), 6.99 (1H, dd), 7.09-7.19 (3H, m), 7.61 (1H, d), 7.89 (1H, s); m / z\ ES' [M-H]’ 807.5.
[0890] Intermediate 13a: 4-(4-(4-(3-Hvdroxypropoxy)phenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile
[0891] Prepared from 4-(4-(4-bromophenyl)piperidin-l-yl)-2-(trifluoro-methyl)benzonitrile according to the procedure described in Example 12 but using propane- 1,3-diol.
[0892] Intermediate 13b: 4-(4-(4-(3- in-l-vl)-2-i
[0893] A solution of PPh3(419 mg, 1.60 mmol) in TEIF (10 mL) was added dropwise to a stirred mixture of 4-(4-(4- (3-hydroxypropoxy)phenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (323 mg, 0.80 mmol) and CBr i (530 mg, 1.60 mmol) in THF (10 mL) at 0°C. The resulting mixture was stirred at RT for Ih, then filtered and washed with EtOAc (20 mL). The combined filtrate was concentrated. Purification by FSC (gradient: 0-50% EtOAc in heptane) gave the title compound (346 mg, 93%) as a pale yellow solid; *H NMR: (CDCla) 1.76 (2H, qd), 1.98 (2H, dd), 2.31 (2H, p), 2.74 (IH, tt), 3.06 (2H, td), 3.60 (2H, t), 4.02 (2H, dd), 4.09 (2H, t), 6.83-6.91 (2H, m), 6.99 (IH, dd), 7.09-7.19 (3H, m), 7.58-7.64 (IH, m).
[0894] ,6-Dioxopiperidin-3-yl)-7-methoxy-l-oxoisoindolin-5-yl)piperazin-l- l-vl)-2-i A mixture of 3-[7-methoxy-l-oxo-5-(piperazin-l-yl)-l,3-dihydro-2 / f-isoindol-2-yl]piperidine-2, 6-dione hydrochloride salt (100 mg, 0.253 mmol), DIPEA (164 mg, 1.266 mmol), 4-(4-(4-(3-bromopropoxy)phenyl)- piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (142 mg, 0.304 mmol) and KI (126 mg, 0.760 mmol) was stirred in DMSO (4 mL) at RT under N2. The mixture was then heated at 80°C for 12h, then cooled to RT and diluted DCM (20 mL). The solution was washed (5% AcOH in water (20 mL), water (20 mL), sat. Nal ICO;, (20 mL) then sat. brine (20 mL)), dried (Na2SO4) and concentrated. Purification by preparative HPLC (Column B, Eluent C, Basic Work-Up A) with lyophilizing and washing with hexanes gave the title compound (26 mg, 13%) as brown solid; ‘H NMR: 1.55-1.72 (2H, m), 1.80-1.97 (5H, m), 2.22-2.31 (1H, m), 2.58 (2H, br s), 2.75-2.82 (1H, m), 2.85-2.96 (1H, m), 3.05 (2H, br t), 3.44-3.59 (4H, m), 3.83 (3H, s), 4.00 (2H, br t), 4.07- 4.29 (5H, m), 4.96 (1H, br dd), 6.49 (1H, s), 6.61 (1H, s), 6.87 (2H, br d), 7.16 (2H, br d), 7.27 (1H, br d), 7.33 (1H, br s), 7.81 (1H, br d), 10.90 (1H, br s); m / z\ ES+[M+H]+745.4.
[0895] Intermediate 14a: 2-Cvclopropyl-4-(4-(4-(4-hvdroxybutoxy)phenyl)piperidin-l-yl)benzonitrile
[0896] RockPhos Pd G3 (88 mg, 0.10 mmol) was added to a mixture of butane- 1,4-diol (142 mg, 1.57 mmol), CS2CO3 (1.03 g, 3.15 mmol) and 4-(4-(4-bromophenyl)piperidin-l-yl)-2-cyclopropylbenzonitrile (400 mg, 1.05 mmol) in 1 ,4-dioxane (5 mL) at RT under N2. The resulting mixture was stirred at 100°C for 16h and then concentrated. Purification by FSC (gradient: 0-50% EtOAc in petroleum ether) gave the title compound (0.10 g, 25%) as a white solid; >H NMR: (300 MHz) 0.77-0.88 (2H, m), 0.93-1.08 (2H, m), 1.43-1.91 (8H, m), 1.98- 2.13 (1H, m), 2.60-2.74 (1H, m), 2.79-2.93 (2H, m), 3.36-3.48 (2H, m), 3.86-3.96 (2H, m), 3.99 (1H, s), 4.03 (1H, s), 4.36-4.46 (1H, m), 6.44 (1H, d), 6.77-6.88 (3H, m), 7.07-7.17 (2H, m), 7.45 (1H, d); m / z ES+[M+H]+= 391.3.
[0897] Intermediate 14b 4-(4-(4-(4-Bromobutoxy)phenyl)piperidin-l-yl)-2-cvclopropylbenzonitrile
[0898] CBt' i (153 mg, 0.46 mmol) was added to a mixture of PPh;, (121 mg, 0.46 mmol) and 2-cyclopropyl-4-(4-(4- (4-hy droxy butoxy )phenyl)piperidin-l-yl)benzonitrile (90 mg, 0.23 mmol) in DCM (1 mL) at RT and the mixture was stirred for 2h then concentrated. Purification by FSC (gradient: 0-23% EtOAc in petroleum ether) gave the title compound (81 mg, 78%) as a white solid; *H NMR: 0.79-0.90 (2H, m), 1 .00-1.10 (2H, m), 1.60 (2H, m), 1.78-1.86 (4H, m), 1 .91-2.03 (2H, m), 2.08 (1H, m), 2.65-2.75 (1H, m), 2.85-2.95 (2H, m), 3.61 (2H, t), 3.94-4.07 (4H, m), 6.47 (1H, d), 6.83-6.89 (3H, m), 7.12-7.19 (2H, m), 7.48 (1H, d); m / z ES+[M+H]+= 453.2.
[0899] Example 14: 2-CvcloDroDyl-4-(4-(4-(4-(4-(2-(2.6-dioxoDiDeridin-3-yl)-7-methoxy-l-oxoisoindolin-5- yllpiperazin-l-vDbutoxylphenvDpiperidin-l-yr) benzonitrile
[0900] DIPEA (57.8 Lil,. 0.33 mmol) was added to a mixture of KI (4 mg, 0.02 mmol), 4-(4-(4-(4-bromobutoxy)- phenyl)piperidin-l-yl)-2-cyclopropylbenzonitrile (50 mg, 0.11 mmol) and 3-[7-methoxy-l-oxo-5-(piperazin-l- vl 1 .3-dihvdro-2 / 7-isoindol-2-vl |piperidine-2.6-dione hydrochloride salt (43.5 mg, 0.12 mmol) in MeCN (2 mL) at RT. The resulting mixture was stirred at 80°C for 16h and then concentrated. Purification by preparative TLC (DCM / MeOH = 20 / 1) gave the title compound (13 mg, 16%) as a white solid; *H NMR: 0.78-0.89 (3H, m), 0.97-1.08 (2H, m), 1.15 (1H, s), 1.24 (4H, s), 1.35 (1H, s), 1.45-1.67 (4H, m), 1.69-1.84 (4H, m), 1.91 (1H, d), 2.03-2.14 (2H, m), 2.14-2.21 (1H, m), 2.22-2.34 (2H, m), 2.37 (2H, s), 2.82-2.96 (3H, m), 3.83 (3H, s), 3.94-4.05 (4H, m), 4.10 (1H, d), 4.23 (1H, d), 4.91-5.01 (1H, m), 6.43-6.50 (2H, m), 6.60 (1H, s), 6.81-6.89 (3H, m), 7.11-7.18 (2H, m), 7.47 (1H, d), 10.89 (1H, s); m / z ES+[M+H]+= 731.3.
[0901] I
[0902] To a solution of 2-(piperidin-4-yl)ethan-l-ol (5.00 g, 38.7 mmol) in DCM (100 mL) was added NaiCO, (18.46 g, 174.1 mmol) in water (100 mL) at 0°C, and then benzyl carbonochloridate (6.08 mL, 42.6 mmol) was added drop wise. The mixture was stirred for 6h at RT, then diluted with water (100 mL) and extracted with DCM (2 x 100 mL). The combined organic solutions were washed with sat. brine (100 mL), dried (NaaSO^ and concentrated. Purification by FSC (gradient: 0-70% EtOAc in heptane) gave the title compound (8.34 g, 82%) as a pale yellow oil; ‘H NMR: (CDCh) 1.15 (2H, qd), 1.43 (lH, t), 1.52 (2H, q), 1.62 (1H, dddd), 1.69 (2H, t), 2.78 (2H, t), 3.69 (2H, q), 4.14 (2H, dd), 5.12 (2H, s), 7.28-7.45 (5H, m); m / z\ ES+[M+H]+264.3.
[0903] To a solution of benzyl 4-(2-hydroxyethyl)piperidine-l -carboxylate (8.34 g, 31.7 mmol) in DCM (150 mL) at 0°C was added Dess-Martin periodinane (14.78 g, 34.84 mmol). The reaction was stirred at RT for 3h, then quenched by the addition of sat. NaHCOa solution (50 mL) and filtered to remove solid residue. The solid residue was washed with DCM (50 mL). The phases were separated and the organic solution was washed with sat. brine (20 mL x 2), dried (TS^SCL) and concentrated. Purification by FSC (gradient: 0-50% EtOAc in heptane) gave the title compound (5.20 g, 63%) as a colourless oil; 'H NMR: (CDCI3) 1.20 (2H, q), 1.71 (2H, d), 2.07 (IH, tq), 2.38 (2H, dd), 2.82 (2H, t), 4.16 (2H, s), 5.12 (2H, s), 7.31-7.43 (5H, m), 9.77 (IH, t); m / z\ ES+[M+H]+262.2.
[0904] Intermediate 15c: Benzyl 4-(2,2-dimethoxyethyl)piperidine-l-carboxylate
[0905] To a solution of benzyl 4-(2-oxoethyl)piperidine-l -carboxylate (5.20 g, 19.9 mmol) in MeOH (60 mL) was added trimethoxymethane (10.9 mL, 99.5 mmol) and 4-methylbenzenesulfonic acid (0.17 g, 0.99 mmol) at 15°C. The mixture was stirred at this temperature for Ih. The reaction was then quenched by addition of water (50 mL) and diluted with DCM (100 mL). The phases were separated and the organic solution was washed with sat. brine (3 x 20 mL), dried (Na2SO4) and concentrated under reduced pressure to give the title compound (5.90 g, 96%) as a colourless oil; >H NMR: (CDCh) 1.04-1.25 (2H, m), 1.5-1.57 (2H, m), 1.57-1.63 (IH, m), 1.68 (2H, t), 2.78 (2H, t), 3.31 (6H, s), 4.15 (2H, d), 4.46 (IH, t), 5.12 (2H, s), 7.27-7.37 (5H, m).
[0906] Intermediate 15d: 4-(2,2-Dimethoxyethyl)piperidine
[0907] 10% Ph(OH)2 on carbon (0.54 g, 0.38 mmol) was added to benzyl 4-(2,2-dimethoxyethyl)piperidine-l- carboxylate (5.90 g, 19.2 mmol) in MeOH (60 mL) at RT under N2 in a steel pressure reactor. The resulting suspension was purged with N2 and then H2 and then stirred at RT at a pressure of 4 atmospheres for 3 days. The mixture was then filtered through celite and washed through with MeOH (250 mL). The filtrate was concentrated to give the title compound (3.14 g, 94%) as a colourless oil; *H NMR: (CDCI3) 1.15-1.28 (2H, m), 1.53-1.56 (2H, m), 1.72 (2H, d), 2.63 (2H, td), 3.04-3.14 (2H, m), 3.31 (8H, s), 4.47 (IH, t).
[0908] Intermediate 15e: 4-(4-(4-(4-(2.2-DimethoxyethvDpiperidin-l-vDphenvDpiperidin-l-vD-2-(trifluoro- methvDbenzonitrile
[0909] RuPhos Pd G3 (0.205 g, 0.24 mmol) was added to a mixture of 4-(4-(4-bromophenyl)piperidin-l-yl)-2- (trifluoromethyl)benzonitrile (1.00 g, 2.44 mmol), 4-(2,2-dimethoxyethyl)piperidine (0.64 g, 3.67 mmol), CS2CO3 (2.388 g, 7.33 mmol) and RuPhos (0.114 g, 0.24 mmol) in 1,4-dioxane (20 mL) at RT under N2. The resulting solution was stirred at 100°C for 1 Oh and then concentrated. Purification by flash C 18-flash chromatography (gradient: 0-100% MeCN in water) gave the title compound (1.20 g, 98%) as a yellow solid; ‘HNMR: 1.21-1.31 (2H, m), 1 .39-1.51 (3H, m), 1 .52-1.67 (2H, m), 1.70-1.77 (2H, m), 1.79-1.87 (2H, m), 2.51-2.61 (2H, m), 2.71 (1H, t), 2.98-3.08 (2H, m), 3.22 (6H, s), 3.58 (2H, d), 4.16 (2H, d), 4.43-4.50 (1H, m), 6.84 (2H, d), 7.07 (2H, d), 7.26 (1H, d), 7.32 (1H, s), 7.80 (1H, d); m / z ES+[M+H]+= 502.2.
[0910] Intermediate 15f: 4-(4-(4-(4-(2-* idin-1 -yl)phenyl)piperidin- 1 -yl)-2 - 1 benzonitrile
[0911] A solution of 4-(4-(4-(4-(2,2-dimethoxyethyl)piperidin- 1 -yl)phenyl)piperidin- 1 -yl)-2-(trifluorom ethylbenzonitrile (200 mg, 0.40 mmol) in formic acid (2 mL) was stirred at RT for 5h. The mixture was then concentrated to give the title compound (0.17 g, 94%) which was used in the next step without further purification; ‘HNMR: 1.23-1.33 (2H, m), 1.54-1.67 (2H, m), 1.67-1.76 (2H, m), 1.79-1.87 (2H, m), 1.95 (1H, s), 2.36-2.43 (2H, m), 2.57-2.69 (2H, m), 2.69-2.76 (1H, m), 3.03 (2H, t), 3.58 (2H, d), 4.16 (2H, d), 6.85 (2H, d), 7.07 (2H, d), 7.22-7.29 (1H, m), 7.31 (1H, s), 7.80 (1H, d), 9.70 (1H, d); m / z ES+[M+H]+= 456.1. Dioxopiperidin-3-vl)-7-methoxv-l-oxoisoindolin-5-vl)piperazin-l- in-l-yD-2-i tert-Butyl-4-(2-(2,6-dioxopiperidin-3-yl)-7-methoxy-l-oxoisoindolin-5-yl)piperazine-l -carboxylate (50 mg, 0.11 mmol) was added to a solution of 4-(4-(4-(4-(2-oxoethyl)piperidin-l-yl)phenyl)piperidin-l-yl)-2- (trifluoromethyl)benzonitrile (50 mg, 0.11 mmol) in formic acid (2 mL) at RT. The resulting solution was stirred at 40°C for Ih, then cooled to RT and concentrated. The resulting residue was dissolved in DCM (2 mL) and then NaBH(OAc)3 (47 mg, 0.22 mmol) was added. This mixture was stirred at RT for Ih. The mixture was then diluted with DCM, washed (AcOH (5%, aq), water (20 mL) then sat. brine (20 mL)), dried (Na2SC>4) and concentrated. Purification by preparative SFC (Column: Torus 2-PIC; Mobile Phase A: CO2, Mobile Phase B: MeOH (0.5% 2M NI L-MeOH ): Flow rate: 50 mL / min; isocratic gradient: 30% B) gave the title compound (6.1 mg, 7%) as a pale yellow solid; ‘H NMR: (300 MHz) 1.15- 1.30 (2H, m), 1.30-1.50 (3H, m), 1.52-1.70 (2H, m), 1.71-1.97 (5H, m), 2.29-2.43 (3H, m), 2.60 (3H, d), 2.75-3.10 (4H, m), 3.10-3.50 (8H, m), 3.61 (2H, d), 3.84 (3H, s), 4.04-4.29 (4H, m), 4.97 (IH, dd), 6.49 (IH, s), 6.61 (IH, s), 6.86 (2H, d), 7.08 (2H, d), 7.19-7.39 (2H, m), 7.82 (IH, d), 10.91 (IH, s); m / z ES+[M+H]+ = 798.4. idin-3-yl)-l-oxoisoindolin-5-yl)piperazin-l-
[0912] 4-(Piperidin-4-yl)phenol hydrobromide salt (5.14 g, 19.91 mmol) and di-tert-butyl dicarbonate (4.56 g, 20.91 mmol) was slurried in DCM (60 mL) at RT. NEta (5.53 mL, 39.82 mmol) was then added in one portion and the mixture was stirred for 45 mins. The mixture was then diluted with DCM (200 mL), washed with water (3 x 100 mL), dried over a phase separator and concentrated to give the title compound (5.70 g, 100%) as a white solid; ‘HNMR: 1.34-1.46 (11H, m), 1.70 (2H, d), 2.54-2.6 (1H, m), 2.77 (2H, br s), 4.05 (2H, d), 6.59-6.73 (2H, m), 6.94-7.06 (2H, m), 9.12 (1H, s). m / z\ ES- [M-H]' = 276.3.
[0913] Intermediate 16b: tert-Butyl 4-(4-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)piperazin-l- yllbutoxylphenvDpiperidine-l-carboxylate tert-Butyl 4-(4-hydroxyphenyl)piperidine-l -carboxylate (2.20 g, 7.93 mmol), K2CO3 (1.32 g, 9.52 mmol) and 1,4-dibromobutane (2.37 mL, 19.83 mmol) were dissolved in anhydrous MeCN (80 mL) under N 2. The mixture was stirred at 80°C for 3h then cooled to RT. The mixture was then filtered and washed through with DCM (200 mL). The filtrate was then concentrated. Purification by FSC (gradient: 0-30% EtOAc in heptane) gave the title compound (1.08 g, 33%) as a white oil which solidified on standing; *H NMR: (CDCI3) 1.48 (9H, s), 1.51-1.69 (2H, m), 1.75-1.86 (2H, m), 1.89-1.98 (2H, m), 2-2.13 (2H, m), 2.58 (1H, tt), 2.78 (2H, t), 3.48 (2H, t), 3.97 (2H, t), 4.16-4.32 (2H, m), 6.75-6.89 (2H, m), 7.10 (2H, dt). (1H, m); m / z\ ES+| M- / Bu| 356.0.
[0914] Intermediate 16c: tert- Butyl 4-(4-(4-(4-(2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)piperazin-l- yl)butoxy)phenyl)piperidine-l -carboxylate
[0915] DIPEA (2.3 mL, 13.10 mmol) was added to 3-[l-oxo-5-(piperazin-l-yl)-l,3-dihydro-277-isoindol-2-yl]- piperidine-2, 6-dione hydrochloride salt (1.05 g, 2.88 mmol) in DMSO (20 mL) at RT. The mixture was sonicated until a hazy solution was obtained and was then stirred at RT for 0.5h. KI (1.30 g, 7.86 mmol) then a solution of tert-butyl 4-(4-(4-bromobutoxy)phenyl)piperidine-l -carboxylate (1.08 g, 2.62 mmol) in DMSO (7 mL) were then added and the mixture was stirred at 70°C for 18h. After cooling the mixture was diluted with EtOAc (200 mL), washed with water (3 * 100 mL) then brine (2 x 100 mL), dried (MgSOy) and concentrated. Purification by FSC (gradient: 0-10% MeOH in DCM) gave the title compound (1.08 g, 63%) as a pale yellow gum; ‘H NMR: 1.48 (9H, s), 1.53-1.89 (9H, m), 2.14-2.25 (1H, m), 2.32 (lH, qd), 2.41-2.52 (2H, m), 2.53- 2.65 (5H, m), 2.71-2.95 (4H, m), 3.26-3.39 (3H, m), 3.98 (2H, t), 4.15-4.31 (3H, m), 4.41 (1H, d), 5.18 (1H, dd), 6.79-6.89 (3H, m), 6.99 (1H, dd), 7.08-7.16 (2H, m), 7.73 (1H, d), 8.01-8.25 (1H, m); m / z\ ES+[M+H]+
[0916] 660.3.
[0917] Intermediate 16d: 3-(l-Oxo-5-(4-(4-(4-(piperidin-4-yl)phenoxy)butyl)piperazin-l-yl)isoindolin-2-
[0918] 4M HC1 in dioxane (2 mL, 8.00 mmol) was added in one portion to tert-butyl 4-(4-(4-(4-(2-(2,6- dioxopiperidin-3 -y 1)- 1 -oxoisoindolin- 5-y l)piperazin- 1 -y l)butoxy)phenyl)piperidine- 1 -carboxylate ( 1.07 g, 1.62 mmol) in DCM (5 mL) at RT under air and the mixture was stirred for 2h. The mixture was then concentrated, slurried in Et2O (30 mL) and filtered to give the title compound as a hydrochloride salt as a beige solid that was used in the next step without further purification; m / z\ ES+[M+H]+560.3.
[0919] Example 16: 2-Chloro-4-f4-[4-(4-f4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihvdro-l / 7-isoindol-5-yl1- piperazin-l-yl!butoxy)phenyl|piperidin-l-yl!benzonitrile
[0920] A mixture of 3-( 1 -oxo-5-(4-(4-(4-(piperidin-4-yl)phenoxy)butyl)piperazin- 1 -yl)isoindolin-2-yl)piperidine-2,6- dione hydrochloride salt (100 mg, 0.17 mmol), 2-chloro-4- fluorobenzonitrile (27.4 mg, 0.18 mmol) and K2CO3 (58.0 mg, 0.42 mmol) was suspended in DMSO (1 mL) and stirred at 90°C for 1 ,5h. Purification by preparative HPLC (Column A, Eluent A) gave the title compound (65 mg, 56%) as a white solid; *H NMR: 1.55-1.65 (4H, m), 1.68-1.77 (2H, m), 1.81 (2H, d), 1.89-2.02 (1H, m), 2.34-2.43 (3H, m), 2.52-2.64 (1H, m), 2.7-2.94 (2H, m), 2.99 (2H, t), 3.21-3.4 (8H, m), 3.97 (2H, t), 4.09 (2H, d), 4.21 (1H, d), 4.33 (1H, d), 5.04 (1H, dd), 6.85 (2H, d), 7.00 (1H, dd), 7.05 (2H, d), 7.11-7.18 (3H, m), 7.51 (1H, d), 7.62 (1H, d), 10.91 (1H, s); Wz: ES+[M+H]+695.5.
[0921] Example 17: 4-!4-[4-(4-!4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihvdro- isoindol-5-yl|piperazin-l- yllbutoxy)phenyl1piperidin-l-yll-2-methoxybenzonitrile
[0922] A mixture of 3-( 1 -oxo-5-(4-(4-(4-(piperidin-4-yl)phenoxy)butyl)piperazin- 1 -yl)isoindolin-2-yl)piperidine-2,6- dione hydrochloride salt (100 mg, 0.17 mmol), 4-fluoro-2-methoxybenzonitrile (26.6 mg, 0.18 mmol) and K2CO3 (58.0 mg, 0.42 mmol) was suspended in DMSO (1 mL) and stirred at 90°C for 2.5h. After cooling to RT, purification by preparative HPLC (Column A, Eluent A) gave the title compound (40 mg, 35%) as a white solid; ‘HNMR: 1.54-1.68 (4H, m), 1.74 (2H, q), 1.83 (2H, d), 1.92-2.02 (1H, m), 2.29-2.44 (4H, m), 2.56-2.8 (3H, m), 2.82-3.02 (3H, m), 3.11-3.49 (6H, m), 3.88 (3H, s), 3.98 (2H, t), 4.08 (2H, d), 4.21 (1H, d), 4.33 (1H, d), 5.05 (1H, dd), 6.53-6.67 (2H, m), 6.87 (2H, d), 7.06 (2H, d), 7.16 (2H, d), 7.41 (1H, d), 7.52 (1H, d), 10.92 (1H, s); m / z\ ES+[M+H]+691.5. dihydro-lZT-isoindol-5-yllpiperazin-l-
[0923] A mixture of 3-( 1 -oxo-5-(4-(4-(4-(piperidin-4-yl)phenoxy)butyl)piperazin- 1 -yl)isoindolin-2-yl)piperidine-2,6- dione hydrochloride salt (68 mg, 0.11 mmol), 6-fhioro-2-methylnicotinonitrile (16.3 mg, 0.12 mmol) and K2CO3 (39.4 mg, 0.29 mmol) was suspended in DMSO (1.5 mL) and then stirred at 120°C for Ih in a microwave. Purification by preparative HPLC (Column A, Eluent A) gave the title compound (0.018 g, 23%) as a beige solid; ‘H NMR: (CDCI3) 1.62-1.77 (4H, m), 1.79-1.88 (2H, m), 1.93 (2H, d), 2.20 (IH, ddq), 2.32 (IH, qd), 2.42-2.51 (2H, m), 2.56 (3H, s), 2.59-2.64 (4H, m), 2.71-2.9 (3H, m), 2.91-3.02 (2H, m), 3.24-3.41 (4H, m), 3.98 (2H, t), 4.25 (IH, d), 4.41 (IH, d), 4.60 (2H, d), 5.19 (IH, dd), 6.47 (IH, d), 6.81-6.9 (3H, m), 6.99 (IH, dd), 7.07-7.16 (2H, m), 7.54 (IH, d), 7.73 (IH, d), 7.91 (IH, s); m / z\ ES+[M+H]+= 676.6.
[0924] Intermediate 19a: 8-Fluoroquinoline-5-carbonitrile
[0925] KO Ac (0.104 g, 1.062 mmol) and potassium hexacyanoferrate(II) trihydrate (1.869 g, 4.42 mmol) were added to 5-bromo-8-fluoroquinoline (2.00 g, 8.85 mmol) in 1,4-dioxane (30 mL) and water (30 mL). The mixture was degassed under N2 for 5 min at RT followed by the addition of XPhos (0.422 g, 0.885 mmol) and Xphos Pd G3 (0.374 g, 0.442 mmol). The mixture was then stirred at 100°C for 3h and then cooled to RT. The mixture was extracted with EtOAc (2 x 100 mL). The combined organic solutions were washed with sat. brine (100 mL), dried (T^SCh) and concentrated. Purification by FSC (gradient: 0-30% EtOAc in hexanes) gave the title compound (0.4 g, 26%) as off white solid; ‘H NMR: 7.82 (IH, dd), 7.91 (IH, dd), 8.35 (IH, dd), 8.56 (IH, dt), 9.15 (IH, dd); m / z\ ES+[M+H]+= 173.0.
[0926] Intermediate 19b: 8-(4-(4-Hydroxyphenyl)piperidin-l-yl)quinoline-5-carbo nitrile
[0927] 4-(Piperidin-4-yl)phenol hydrobromide (0.900 g, 3.49 mmol) and DIPEA (1.217 mL, 6.97 mmol) were added to 8-fluoroquinoline-5-carbonitrile (0.400 g, 2.323 mmol) in DMSO (10 mL) at RT. The mixture was stirred at 50°C for 6h, then cooled to RT and concentrated. The mixture was slowly poured into ice- water. A solid was collected by filtration, washed with water (20 mL) and dried under vacuum to give the title compound (0.700 g, 89%) as yellow solid; ‘HNMR: 1.81-1.98 (4H, m), 2.63-2.79 (1H, m), 2.95-3.16 (2H, m), 4.37 (2H, d), 6.63-6.78 (2H, m), 7.11 (2H, d), 7.21 (1H, d), 7.74 (1H, dd), 8.04 (1H, d), 8.40 (1H, dd), 8.97 (1H, dd), 9.14 (1H, s); m / z\ ES- [M-H]’ = 328.0.
[0928] Intermediate 19c: 8-(4-(4-(4-Bromobutoxy)phenyl)piperidin-l-yl)quinoline-5-carbonitrile
[0929] 1 ,4-Dibromobutane (0.262 g, 1.214 mmol) and K2CO3 (0.252 g, 1.821 mmol) were added to 8-(4-(4-hydroxy- phenyl)piperidin-l-yl)quinoline-5-carbonitrile (0.200 g, 0.607 mmol) in MeCN (5 mL) atRT. The mixture was then stirred at 60°C for 6h. Water (40 mL) was then added and the mixture was extracted with EtOAc (2 x 70 mL). The combined organic solutions were washed with sat. brine (50 mL), dried (Na2SO4) and concentrated. Purification by FSC (gradient: 0-30% EtOAc in hexanes) gave the title compound (0.200 g, 68%) as yellow solid; ‘HNMR: 1.76-2.02 (8H, m), 2.70-2.82 (1H, m), 3.00-3.12 (2H, m), 3.62 (2H, t), 3.99 (2H, t), 4.37 (2H, d), 6.89 (2H, d), 7.23 (3H, dd), 7.74 (1H, dd), 8.05 (1H, d), 8.40 (1H, dd), 8.98 (1H, dd).
[0930] Example 19: 8-f4-[4-(4-f4-[2-(2.6-Dioxopiperidin-3-yl)-l-oxo-2.3-dihvdro-l / T-isoindol-5-yl1piperazin-l- yllbutoxy)phenyl1piperidin-l-yllquinoline-5-carbonitrile
[0931] KI (0.205 g, 1.233 mmol) and DIPEA (0.359 mL, 2.056 mmol) were added to a mixture of 3-[l-oxo-5- (piperazin-l-yl)-l,3-dihydro-2 / f-isoindol-2-yl]piperidine-2, 6-dione hydrochloride salt (0.150 g, 0.411 mmol) and 8-(4-(4-(4-bromobutoxy)phenyl)piperidin-l-yl)quinoline-5-carbonitrile (0.115 g, 0.247 mmol) in DMSO (5 mL) at RT. The mixture was then stirred at 80°C for 16h, then cooled to RT and concentrated. The residue was slowly poured into ice-water. Solids were collected by filtration, washed with water (10 mL) and dried under vacuum. Preparative HPLC (Column C, Eluent C, Basic Work-Up A) gave the title compound (0.090 g, 30%) as off white solid; ‘H NMR: 1.57-1.67 (2H, m), 1.70-1.80 (2H, m), 1.84-2.00 (5H, m), 2.27-2.43 (3H, m), 2.51-2.64 (5H, m)2.69-2.82 (1H, m), 2.84-2.97 (1H, m), 3.00-3.11 (2H, m), 3.24-3.31 (4H, m), 3.99 (2H, t), 4.17-4.25 (1H, m), 4.27-4.42 (3H, m), 5.05 (1H, dd), 6.89 (2H, d), 7.01-7.10 (2H, m), 7.22 (3H, dd), 7.52 (1H, d), 7.71-7.77 (1H, m), 8.05 (1H, d), 8.40 (1H, dd), 8.97 (1H, dd), 10.94 (1H, s); m / z\ ES+[M+H]+= 712.4. Intermediate 20a: 2-(2,6-Dii idin-3-yl)-5,6-difluoroisoindoline-l, 3-dione
[0932] Potassium acetate (5.04 g, 51.37 mmol) was added in one portion to 3-aminopiperidine-2, 6-dione hydrochloride salt (3 g, 18.23 mmol) and 4,5-difhiorophthalic acid (3.35 g, 16.57 mmol) inAcOH (30 mL) at RT. The resulting solution was stirred at 90°C for 18h. The mixture was then cooled to RT and a solid formed. Water (30 mL) was added. The solid was collected by filtration, washed with water (2 x5 mL) and dried at 45°C under vacuum overnight to give the title compound (3.43 g, 70%) as a dark grey / purple solid; *H NMR: 2.01-2.12 (1H, m), 2.53-2.7 (2H, m), 2.83-2.95 (1H, m), 5.17 (1H, dd), 8.15 (2H, t), 11.13 (1H, s); m / z\ ES- [M-H]- 293.
[0933] Intermediate 20b: tert-butyl 4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-l,3-dioxoisoindolin-5-yl)piperazine-
[0934] DMSO (0.5 mL) and then DIPEA (118 Lil,. 0.68 mmol) were added to a mixture of 2-(2,6-dioxopiperidin-3- yl)-5,6-difluoroisoindoline- 1,3-dione (100 mg, 0.34 mmol) and tert-butyl piperazine- 1 -carboxylate (69.6 mg, 0.37 mmol). This mixture was then heated at 100°C for 2h. Sat. NH4CI solution (0.5mL) and water (1.5 mL) were then added. A brown precipitate was collected by filtration, washed with water and dried in a vacuum oven to give the title compounds (86 mg, 55%) as dark brown / black solid; *H NMR: 1.44 (9H, s), 2.04 (1H, dq), 2.55-2.62 (1H, m), 2.89 (1H, ddd), 3.09 (1H, d), 3.16-3.26 (4H, m), 3.45-3.55 (4H, m), 5.11 (1H, dd), 7.49 (1H, d), 7.75 (1H, d), 11.09 (1H, s); m / z\ ES- [M-H]’ 459.
[0935] Intermediates 20c and 20d: 3-(5-Fluoro-l-oxo-6-(piperazin-l-yl)isoindolin-2-yl)piperidine-2,6-dione and
[0936] 3-(6-Fluoro-l-oxo-5-(piperazin-l-yl)isoindolin-2-yl)piperidine-2.6-dione
[0937] Zinc powder (72.4 mg, 1.11 mmol) was added in one portion to tert-butyl-4-(2-(2,6-dioxopiperidin-3-yl)-6- fluoro-l,3-dioxoisoindolin-5-yl)piperazine-l-carboxylate (170 mg, 0.37 mmol) inAcOH (3.4 mL) at RT. The resulting suspension was stirred at 60°C for 48h. Further Zn powder (72.4 mg, 1.11 mmol) was added and the mixture was stirred at 60°C for 24h. The mixture was then diluted with MeOH (25 mL), filtered and the filtrate was concentrated. The resulting gum was dissolved in TFA (5 mL) at RT and triethylsilane (587 Lil ,. 3.68 mmol) was added in one portion. The resulting orange solution was stirred at RT for Ih. The mixture was then concentrated. Trituration with Et2O and collection of a solid by filtration gave the title compounds (in the form of trifluoroacetate salts) as a mixture of isomers (170 mg, 57%) as beige solids that were used in the next step without further purification; m / z\ ES+[M+H]+= 347.
[0938] Example 20: 4-f4-[4-(4-f4-[2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-3-oxo-2,3-dihvdro-l / f-isoindol-5-yl1- piperazin-l-yllbutoxy)phenyl1piperidin-l-yll-2-(trifluoromethyl) benzonitrile
[0939] Intermediate 2d was reacted with Intermediates 20c and 20d using the general synthetic method illustrated by Example 1 to give the title compound after purification by HPLC (Column A, Eluent A). *H NMR: (500 MHz, CDClj) 1.85 (2H, q), 1.88-1.94 (1H, m), 1.94-2.01 (3H, m), 2.22 (1H, dtd), 2.35 (1H, qd), 2.77 (OH, s), 2.82- 2.88 (1H, m), 2.88-2.98 (3H, m), 3.06 (2H, td), 3.13 (4H, s), 3.32-3.44 (4H, m), 3.98 (2H, t), 4.02 (2H, dq), 4.22-4.47 (2H, m), 5.18 (1H, dd), 6.81-6.88 (2H, m), 6.96-7.03 (2H, m), 7.1-7.15 (2H, m), 7.16 (1H, d), 7.52 (1H, d), 7.62 (1H, dd), 8-8.04 (1H, m), 8.21 (2H, s); m / z ES+[M+H]+ = 747.4.
[0940] Example 21: 4-f4-[4-(4-f4-[2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-l-oxo-2,3-dihvdro-l / f-isoindol-5-yl1- in-l-vll-2-i
[0941] Intermediate 2d was reached with Intermediate 20c and 20d using the general synthetic method illustrated by Example 2 to give the title compound after purification by HPLC (Column A, Eluent A); *H NMR: (500 MHz, CDClj) 0.87-0.94 (1H, m), 1.76 (2H, qd), 1 .8-1.94 (1H, m), 1.94-2.01 (2H, m), 2.22 (1H, dtd), 2.34 (1H, qd), 2.74 (1H, tt), 2.84-2.89 (2H, m), 2.93 (1H, ddd), 3.01-3.1 (5H, m), 3.32 (3H, q), 3.48-3.55 (1H, m), 3.98 (2H, t), 4.02 (2H, dt), 4.28 (1H, d), 4.42 (1H, d), 5.19 (1H, dd), 6.65 (OH, s), 6.82-6.88 (2H, m), 6.99 (1H, dd), 7.09-7.18 (4H, m), 7.48 (1H, d), 7.55 (OH, dd), 7.61 (1H, d), 7.98 (1H, s), 8.16 (2H, s); m / z ES+[M+H]+ = 747.4.
[0942] Example 22: 4-f4-[5-(4-f4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihvdro-l / f-isoindol-5-yl1piperazin-l- yllbutoxy)pyrimidin-2-yl1piperidin-l-yll-2-(trifluoromethyl)benzonitrile
[0943] Intermediate 8e was reacted with Intermediate 2c using the general synthetic method illustrated by Example 8 to give the title compound after purification by HPLC (Column: Zorbax Eclipse Plus C18 50 x 2.1mm, 1.8 pm, Eluent C, Basic Work-Up A); ‘H NMR: 1.52-1.68 (2H, m), 1.66-1.84 (4H, m), 1.9-2.08 (3H, m), 2.26- 2.49 (6H, m), 2.59 (2H, d), 2.8-2.98 (IH, m), 3.05-3.2 (3H, m), 3.23-3.3 (4H, m), 4.05-4.26 (5H, m), 4.33 (IH, d), 5.05 (IH, dd), 6.99-7.12 (2H, m), 7.27 (IH, d), 7.32 (IH, s), 7.52 (IH, d), 7.82 (IH, d), 8.49 (2H, s), 10.95 (IH, s); m / z ES+[M+H]+ = 731.2.
[0944] Example 23: 4-f4-[4-(4-f4-[2-(2,6-Dioxopiperidin-3-vD-6-fhioro-l,3-dioxo-2,3-dihvdro-l / Z-isoindol-5-yl1- piperazin-l-yllbutoxy)phenyl1piperidin-l-yll-2-(trifluoromethyl) benzonitrile
[0945] Intermediate Ih was reacted with Intermediate 20b using the general synthetic method illustrated by Example 1 to give the title compound after purification by HPLC (Column A, Eluent A, Basic Work-Up A); *H NMR: (CDClj) 1.65-1.87 (6H, m), 1.92-2 (2H, m), 2.07-2.2 (1H, m), 2.41-2.53 (2H, m), 2.56-2.67 (4H, m), 2.67-2.96 (4H, m), 3.06 (2H, td), 3.22-3.35 (4H, m), 3.92-4.1 (4H, m), 4.93 (1H, dd), 6.78-6.92 (2H, m), 6.99 (1H, dd), 7.07-7.21 (3H, m), 7.37 (1H, d), 7.47 (1H, d), 7.61 (1H, d), 7.97 (1H, s); m / z ES+[M+H]+ = 761.5.
[0946] Intermediate 24a: tert-Butyl 3,3-dimethyl-4-(((trifluoromethyl)sulfonyl)oxy)-3,6-dihvdropyridine-l(2 / / )- carboxylate
[0947] Lithium bid(trimethylsilyl)amide (60.7 mL, 60.71 mmol) was added slowly to tert-butyl 3,3-dimethyl-4- oxopiperidine-1 -carboxylate (9.2 g, 40.47 mmol) in THF (80 mL) at -78°C over 20 min under N2. The resulting mixture was stirred at -78°C for 0.5h. A-(5-Chloropyridin-2-yl)-l ,1 , l-trifluoro-A-((trifluoromethyl)- sulfonyl)methanesulfonamide (23.84 g, 60.71 mmol) was then added and the resulting mixture was stirred at RT for 16h. The reaction was then quenched with sat. NH4CI solution. The mixture was diluted with EtOAc, washed with water then sat. brine, dried (Na2SC>4) and concentrated Purification by FSC (gradient: 0-5% EtOAc in petroleum ether) gave the title compound (11.00 g, 76 %) as a yellow liquid; *H NMR (300 MHz) 5.82 (s, IH), 4.01 (d, 2H), 3.35 (s, 2H), 1.40 (s, 9H), 1.05 (s, 6H).
[0948] Intermediate 24b: tert-Butyl 4-(4-(benzyloxy)phenyl)-3.3-dimethyl-3.6-dihvdropyridine- carboxylate
[0949] Pd(dppf)2C12-DCM (0.818 g, 1.00 mmol) was added to tert-butyl 3,3-dimethyl-4-(((trifhioromethyl)sulfonyl)- oxy)-3,6-dihydropyridine-l(2H)-carboxylate (3.600 g, 10.02 mmol), 2-(4-(benzyloxy)phenyl)-4,4,5,5-tetra- methyl-l,3,2-dioxaborolane (4.66 g, 15.03 mmol) and K2CO3 (4.15 g, 30.05 mmol) in 1,4-dioxane (40 mL) and water (10 mL) at RT under N2. The resulting mixture was stirred at 100°C for 3h. The mixture was then diluted with EtOAc, washed with water then sat. brine, dried QS^SCL) and concentrated. Purification by CIS- flash chromatography (gradient: 5- 90% MeCN in water (0.1 % NH4HCO3)) gave the title compound (1.980 g, 50%) as a pale yellow solid; >H NMR: 7.47-7.43 (m, 2H), 7.42-7.37 (m, 2H), 7.36-7.30 (m, IH), 7.12-7.05 (m, 2H), 6.99-6.93 (m, 2H), 5.40 (s, IH), 5.08 (s, 2H), 3.94 (d, 2H), 3.26 (s, 2H), 1.43 (s, 9H), 0.97 (s, 6H); m / z ES+[M-tBu+MeCN]+= 379.
[0950] Intermediate 24c: tert-butyl 4-(4-hvdroxyphenyl)-3.3-dimethyl-piperidine-l-carboxylate
[0951] A mixture of tert-butyl 4-(4-(benzyloxy)phenyl)-3,3-dimethyl-3,6-dihydropyridine-l(2 / / )-carboxylate (1.00 g, 2.54 mmol) and Pd-on-C (0.27 g, 0.25 mmol) in MeOH (10 mL) was stirred under an atmosphere of H2 at 20 atm and 80°C for Ih. Concentration of the mixture then gave the title compound (0.844 g, 109 %) which was used in the next step without further purification; *H NMR (300 MHz) 0.68 (s, 6H), 1.41 (s, 9H), 1.80-2.10 (m, IH), 2.33-2.43 (m, IH), 2.73 - 2.75 (m, IH), 3.32 (s, 2H), 3.66-3.69 (m, IH), 4.10-4.12 (m, IH), 6.67 (d, 2H), 6.93 (d, 2H), 9.21 (s, IH); m / z ES+[M-tBu]+= 250.
[0952] Intermediates 24d: 4-(3,3-Dimethylpiperidin-4-yl)phenol
[0953] 4M HC1 in dioxane (7.00 mL, 28.00 mmol) was added to tert-butyl 4-(4-hydroxyphenyl)-3,3-dimethyl- piperidine-1 -carboxylate (820 mg, 2.68 mmol) in DCM (7 mL) at RT and the mixture was stirred for 16h. Concentration of the mixture then gave the title compound as a hydrochloride salt (0.750 g, 116 %) which was used in the next step without further purification; *H NMR (300 MHz) 6.93 (d, 2H), 6.71 (d, 2H), 3.29 (d, 1H), 3.04 (d, 1H), 2.92 (d, 1H), 2.78 (d, 1H), 2.60 (m, 1H), 2.25-2.06 (m, 1H), 1.61 (d, 1H), 0.87 (s, 3H), 0.76 (s, 3H); m / z ES+[M+H]+= 206.
[0954] Intermediates 24e and 24f: (.S,)-4-(4-(4-Hvdroxyphenyl)-3,3-dimethylpiperidin-l-yl)-2-
[0955] (trifluoromethvDbenzonitrile (isomer 1) and )-4-(4-(4-Hvdroxyphenyl)-3,3-dimethylpiperidin-l- yl)-2-(trifluoromethyl)benzonitrile (isomer 2)
[0956] 4-Fluoro-2-(trifluoromethyl)benzonitrile (2017 mg, 10.67 mmol) was added to 4-(3,3-dimethylpiperidin-4- yl)phenol (730 mg, 3.56 mmol) and DIPEA (1863 Lil,. 10.67 mmol) in DMSO (10 mL) at RT. The resulting mixture was stirred at 60°C for 16h. The mixture was then diluted with EtOAc, washed with water then sat. brine, dried (TS^SCL) and concentrated. Purification by FSC (gradient: 0-30% EtOAc in petroleum ether) gave material that was further purified by preparative chiral-HPLC (Column: CHIRALPAK AD-3, 3.0mm*100mm, 3Lim: Mobile Phase A, Mobile Phase B:MeOH(0.1% diethylamine); Flow rate:2 mL / min; Gradient:10% B; 220 nm) to give the title compounds as pale yellow solids: Intermediate 24e (0.320 g, 24 %); Intermediate 24f (0.289 g, 22%). Intermediate 24e (eluting first): ‘HNMR: 0.69 (3H, s), 0.78 (3H, s), 1.53 (1H, d), 2.12 (1H, qd), 2.55 (1H, d), 2.82 (1H, d), 2.91-3.03 (1H, m), 3.90 (1H, dd), 4.19 (1H, d), 6.65-6.70 (2H, m), 6.92-6.98 (2H, m), 7.24-7.31 (2H, m), 7.77 (1H, d), 9.21 (1H, s); m / z ES+[M+H]+= 375. Intermediate 24f: >H NMR: 0.69 (3H, s), 0.78 (3H, s), 1.53 (1H, d), 2.12 (1H, m), 2.55 (1H, d), 2.82 (1H, d), 2.91-3.03 (1H, m), 3.85-3.93 (1H, m), 4.14-4.25 (1H, m), 6.56-6.78 (2H, m), 6.81-7.06 (2H, m), 7.16-7.35 (2H, m), 7.77 (1H, d), 9.21 (1H, s); m / z ES+[M+H]+= 375. 3-dimethylpiperidin-l-yl)-2- rel-(S)-4-(4-(4-Hy droxyphenyl)- 3 ,3 -dimethylpiperidin- 1 -yl)-2-(trifluoromethy l)benzonitrile (Intermediate 24e, Isomer 1, 100 mg, 0.27 mmol), K2CO3 (44.3 mg, 0.32 mmol) and 1 ,4-dibromobutane (80 Lil,. 0.67 mmol) were dissolved in anhydrous MeCN (2.59 mL) under N2. The mixture was stirred at 60°C for 5h then at 40°C for 2 days. The mixture was then cooled to RT, filtered and washed through with DCM (20 mL). The filtrate was then concentrated to give the title compound as a colourless oil which was used in the next step without further purification.
[0957] Example 24: / •<? / -(.S,)-4-!4-[4-(4-!4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihvdro-l / / -isoindo 1-5- yl1piperazin-l-yllbutoxy)phenyl1-3,3-dimethylpiperidin-l-yll-2-(trifluoromethyl)benzonitrile (absolute stereochemistry not yet confirmed)
[0958] Intermediate 2c was reacted with Intermediate 24g using the general synthetic method illustrated by Example 5 to give the title compound (as a formate salt) after purification by HPLC (Column A, Eluent A). *H NMR: (CDCI3) 0.84 (3H, s), 0.86 (3H, s), 1.65-1.79 (1H, m), 1.77-1.95 (4H, m), 2.14-2.42 (3H, m), 2.54 (1H, dd),
[0959] 2.7-3.05 (10H, m), 3.46 (4H, q), 3.63 (1H, dd), 3.93-4.14 (3H, m), 4.26 (1H, d), 4.42 (1H, d), 5.19 (1H, dd),
[0960] 6.8-6.86 (2H, m), 6.89 (1H, d), 6.98 (2H, ddd), 7.02-7.08 (2H, m), 7.12 (1H, d), 7.58 (1H, d), 7.75 (1H, d), 8.07 (1H, s), 8.23 (1H, s); m / z ES+[M+H]+ = 757.4.
[0961] Intermediate 25a: reZ-(R)-4-(4-(4-(4-Bromobutoxy)phenyl)-3,3-dimethylpiperidin-l-yl)-2-(trifluoro- rel-( R)-4-(4-( 4-1 lydroxyphenyl )-3,3-dimethylpiperidin- 1 -yl )-2-( trilliioromethvl )benzonitrile (intermediate 24f, isomer 2, 250 mg, 0.67 mmol), K2CO3 (346 mg, 0.80 mmol) and 1 ,4-dibromobutane (0.199 mL, 1.67 mmol) were dissolved in anhydrous MeCN (4 mL) under N2. The mixture was stirred at 70°C for 2h then cooled to RT. The mixture was filtered and washed through with DCM (20 mL). The filtrate was concentrated to give the title compound as a colourless oil that was use in the next step without further purification.
[0962] Example 25: reZ-tf?)-4-f4-[4-(4-f4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihvdro-l / T-isoindol-5- yl1piperazin-l-yllbutoxy)phenyl1-3,3-dimethylpiperidin-l-yll-2-(trifluoromethyl)benzonitrile (absolute stereochemistry not yet confirmed)
[0963] Intermediate 2c was reacted with Intermediate 25a using the general synthetic method illustrated by Example 5 to give the title compound (as a formate salt) after purification by HPLC (Column A, Eluent A); *H NMR: (CDCI3) 0.84 (3H, s), 0.86 (3H, s), 1.66-1.78 (1H, m), 1.81-2 (4H, m), 2.13-2.26 (2H, m), 2.33 (1H, qd), 2.54 (1H, dd), 2.76-2.91 (5H, m), 2.92-3.05 (5H, m), 3.49-3.59 (4H, m), 3.63 (1H, dd), 3.95-4.1 (3H, m), 4.27 (1H, d), 4.42 (1H, d), 5.19 (1H, dd), 6.8-6.86 (2H, m), 6.90 (1H, d), 6.98 (2H, td), 7.02-7.09 (2H, m), 7.12 (1H, d), 7.59 (1H, d), 7.75 (1H, d), 7.97 (1H, s); m / z ES+[M+H]+ = 757.4.
[0964] Intermediate 26a: tert-Butyl 4-(2-oxo-2,3-dihvdrobenzo[< / loxazol-6-yl)piperazine-l-carboxylate
[0965] 6-Bromobenzo| J|oxazol-2( 3 / 7)-one (0.321 g, 1.5 mmol) and Dave-phos-Pd G3 (0.114 g, 0.15 mmol) were added to an oven-dried microwave vial with stir bar. The vial was sealed by a rubber septum and then degassed by N2. THF (3 mL), lithium bis(trimethylsilyl)amide (3.30 mL, 3.30 mmol) and tert-butyl piperazine- 1-carboxylate (0.335 g, 1.80 mmol) were then added. The reaction was degassed by N2 again. The resulting solution was stirred at 70°C for 16h. AcOH was then added and the mixture was concentrated. Purification by FSC (gradient: 0-80% EtOAc in hexanes) gave the title compound (0.250 g, 52 %) as a grey solid; ‘HNMR (500 MHz) 1.41 (11H, s), 2.35 (1H, br s), 2.51-2.53 (1H, m), 2.94-3.04 (5H, m), 3.26-3.32 (3H, m), 3.44 (5H, br s), 6.73 (1H, dd), 6.93 (1H, d), 6.98 (1H, d), 11.30 (1H, br s); m / z (ES-) [M-H]' = 318.2.
[0966] Intermediate 26b: tert-Butyl-4-(3-(2,6-dioxopiperidin-3-yl)-2-oxo-2,3-dihvdrobenzo[< / loxazol-6- vf)piperazine-l-carboxylate tert-Butyl 4-( 2-oxo-2.3-dihvdrobenzo| J|oxazol-6-vl )piperazine- 1 -carboxylate (0.048 g, 0.15 mmol), 3- bromopiperidine-2, 6-dione (1.1 eq) and CS2CO3 (0.147 g, 0.45 mmol) were added to an oven-dried microwave vial with stir bar. The vial was then purged with N2. DMF (1 mL) was then added. The resulting slurry was stirred at 90°C for 16h and then concentrated. Purification by FSC (gradient: 0-100% EtOAc in hexanes) gave the title compound (0.027 g, 41.8 %) as a white solid; >H NMR (500 MHz, CDCI3) 1.49-1.54 (9H, m), 2.28- 2.41 (1H, m), 2.64-2.78 (1H, m), 2.79-2.90 (1H, m), 2.95-3.02 (1H, m), 3.05-3.23 (4H, m), 3.55-3.81 (4H, m), 4.95-5.15 (1H, m), 6.66-6.78 (1H, m), 6.79-6.92 (1H, m), 6.94-7.07 (1H, m), 7.95-8.13 (1H, m); Wz ES+[M+H]+= 431.
[0967] Intermediate 26c: 3-(2-Oxo-6-(piperazin-l-yl)benzo[d1oxazol-3(2 / D-yl)piperidine-2,6-dione
[0968] 4M HC1 in dioxane (2.3 mL, 9.3 mmol) was added to a solution of tert-butyl 4-(3-(2,6-dioxopiperidin-3-yl)-2- oxo-2, 3-dihydrobenzo[<7]oxazol-6-yl)piperazine-l-carboxylate (0.20 g, 0.46 mmol) in 1,4-dioxane (2.3 mL) at RT and the mixture was stirred at 40°C for 3h. Concentration of this mixture then gave the title compound as a hydrochloride salt (0.170 g, 100 %) as an off-white solid which was used without further purification; *H NMR (500MHz) 2.09-2.20 (1H, m), 2.60-2.74 (2H, m), 2.84-2.97 (1H, m), 3.22 (4H, br s), 3.33 (4H, br d), 5.33 (1H, br dd), 6.85 (1H, br d), 7.10-7.28 (2H, m), 9.13 (2H, br s), 11.18 (1H, s); Wz ES+[M+H]+= 331.
[0969] Example 26: 4- (4-[4-(4-f4-[3-(2,6-Dioxopiperidin-3-yl )-2-oxo-2,3-dihvdro-l,3-benzoxazol-6-yl 1 piperazinl-yllbutoxy)phenyl1piperidin-l-yll-2-(trifluoromethyl)benzonitrile
[0970] Intermediate 2d was reacted with Intermediate 26c using the general synthetic method illustrated by Example 2 to give the title compound (as a formate salt) after purification by HPLC (Column A, Eluent A). *H NMR: 1.56-1.69 (4H, m), 1.74 (2H, p), 1.85 (2H, d), 2.13 (1H, dt), 2.38 (2H, t), 2.53 (4H, d), 2.59-2.71 (2H, m), 2.71-2.83 (1H, m), 2.83-2.94 (1H, m), 2.99-3.06 (2H, m), 3.09 (4H, d), 3.31 (1H, s), 3.97 (2H, t), 4.17 (2H, d), 5.29 (1H, dd), 6.77 (1H, dd), 6.82-6.89 (2H, m), 7.03-7.12 (2H, m), 7.16 (2H, d), 7.27 (1H, dd), 7.32 (1H, d), 7.81 (1H, d), 8.18 (1H, s), 11.15 (1H, s); m / z ES+[M+H]+ = 731.6. intermediate 27a: tert-butyl 4-((l-((benzyloxy)carbonyl)piperidin-4-yl)methyl)piperazine-l-carboxylate
[0971] NaBH(C)Ac h (6.80 g, 32.08 mmol) was added in one portion to 1-Boc-piperazine (4.00 g, 21.48 mmol), 4- formyl-A-Cbz-piperidine (6.40 g, 25.88 mmol) and AcOH (1.50 mL, 26.23 mmol) in DCM (50 mL) at RT under air and the mixture was stirred at RT for 2h. The mixture was then diluted with sat. NaHCOa solution (60 mL) and the phases were separated. The aqueous layer was extracted with DCM (3 x 40 mL). The combined organic solutions were dried (MgSCL) and concentrated. Purification by FSC (gradient: 50-70% EtOAc in heptane) gave the title compound (8.83 g, 98 %) as a colourless oil; *H NMR: 0.91-1.05 (2H, m), 1.40 (9H, s), 1.6-1.77 (3H, m), 2.12 (2H, d), 2.22-2.32 (4H, m), 2.79 (2H, s), 3.26-3.33 (4H, m), 3.99 (2H, d), 5.07 (2H, s), 7.28-7.44 (5H, m); m / z\ ES+[M+H]+418.3.
[0972] Intermediate 27b: tert-Butyl 4-tpiperidin-4-ylmethyl)piperazine-l-carboxylate
[0973] A mixture of tert-butyl 4-((l-((benzyloxy)carbonyl)piperidin-4-yl)methyl)piperazine-l -carboxy late (9.50 g, 22.75 mmol) and 10% Pd(OH)2 on activated charcoal (3.20 g, 2.28 mmol) in EtOH (40 mL) was stirred under an atmosphere of H2 at 1 atm and RT for 18h. The mixture was then filtered through celite washing through with EtOH. The filtrate was concentrated. The residue was dissolved in EtOH (40 mL) and 10% Pd(OH)2 on activated charcoal (3.20 g, 2.28 mmol) was added. The suspension was stirred under H2 at 1 atm and RT for 3 days. The mixture was then filtered through celite and washed through with EtOH (100 mL). The filtrate was concentrated to dryness to give crude product (5.61 g, 87 %) as a grey solid. A portion of the crude product (2.32 g) was purified by ion exchange chromatography (SCX column, eluting with IM NI L / MeOH ) to give the title compound (1.84 g, 79 %) as a grey oil; >H NMR: 0.83-0.99 (2H, m), 1.37 (9H, s), 1.45-1.54 (1H, m), 1.58 (2H, d), 2.07 (2H, d), 2.14-2.28 (4H, m), 2.40 (2H, td), 2.87 (2H, d), 3.2-3.35 (4H, m); m / z\ ES+[M+H]+ 284.2.
[0974] Intermediate 27c: tert- Butyl 4-((l-(4-(l-(4-cvano-3-(trifluoromethyl)phenyl)piperidin-4-yl)phenyl)- piperidin-4-vDmethvDpiperazine-l-carboxylate
[0975] A mixture of 4-(4-(4-bromophenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (350 mg, 0.86 mmol), tertbutyl 4-(piperidin-4-ylmethyl)piperazine-l -carboxylate (242 mg, 0.86 mmol), RuPhos G3 (53.6 mg, 0.06 mmol), RuPhos (29.9 mg, 0.06 mmol) sodium tert-butoxide (247 mg, 2.57 mmol) and anhydrous 1,4-dioxane (50 mL) was degassed, the flask filled with N2, and the mixture stirred at 100°C for Ih. The mixture was then cooled and concentrated to dryness. Water (10 mL) was added and the resulting mixture was extracted with EtOAc (3 x 20 mL). The combined organic solutions were dried (tSfeSOy) and concentrated. Purification by FSC (gradient: 0-100% EtOAc in heptane) gave the title compound (0.360 g, 69 %) as a pale yellow solid; *H NMR: 1.20 (2H, tt), 1.40 (9H, s), 1.53-1.67 (3H, m), 1.77 (2H, d), 1.84 (2H, d), 2.16 (2H, d), 2.26-2.31 (4H, m), 2.54-2.64 (2H, m), 2.68-2.77 (IH, m), 2.94-3.11 (2H, m), 3.31 (4H, d), 3.60 (2H, d), 4.17 (2H, d), 6.85 (2H, d), 7.07 (2H, d), 7.27 (IH, dd), 7.32 (IH, d), 7.81 (IH, d); m / z ES+[M+H]+= 611.9.
[0976] Intermediate 27d: Benzyl 4-(dibutoxymethyl)piperidine-l-carboxylate
[0977] 4-Methylbenzenesulfonic acid hydrate (0.100 g, 0.53 mmol) was added to 4-formyl-A-Cbz-piperidine (20.0 g, 80.88 mmol) in w-butanol (40 mL) at RT under air. The resulting solution was stirred at 50°C for Ih. (Reaction incomplete). MgSCL (10.6 g, 88.07 mmol) was added and the suspension was stirred at 50°C for a further Ih. The reaction was incomplete so the temperature was increased to 70°C and the mixture was stirred for a further 1 day. The mixture was then filtered, washing through with EtOAc (200 mL), where the filtrate was collected in a vessel containing 2M aq. K2CO3 (40 mL). The phases were separated. The organic solution was washed (2M aq. K2CO3 (2 x 40 mL) then sat. brine (2 x 20 mL)), dried (MgSCL) and concentrated. Purification by FSC (gradient: 0-30% EtOAc in heptane) gave the title compound (20.5 g, 67 %) as a colourless liquid; ‘HNMR: 0.88 (6H, t), 1.11 (2H, qd), 1.27-1.4 (4H, m), 1.47 (4H, dq), 1.65 (2H, d), 1.73 (IH, dtt), 2.75 (2H, s), 3.37 (2H, dt), 3.54 (2H, dt), 3.95-4.06 (2H, m), 4.16 (IH, d), 5.07 (2H, s), 7.25-7.44 (5H, m).
[0978] Intermediate 27e: 4-(Dibutoxymethyl)piperidine
[0979] A mixture of benzyl 4-(dibutoxymethyl)piperidine-l -carboxylate (20.5 g, 54.30 mmol) and 10% Pd(OH)2 on activated charcoal (3.8 g, 2.71 mmol) in EtOH (120 mL) was stirred under EE (1 atm) at RT for 3 days. The mixture was then filtered through celite and washed though with EtOEI (200 mL). The filtrate was concentrated to dryness to give the title compound (13.10 g, 99 %) as a colourless oil; *H NMR: 0.88 (6H, t), 1.07 (2H, qd), 1.26-1.4 (4H, m), 1.41-1.51 (4H, m), 1.51-1.65 (3H, m), 2.05 (lH, s), 2.31-2.46 (2H, m), 2.90 (2H, d), 3.36 (2H, dt), 3.52 (2H, dt), 4.10 (1H, d).
[0980] Intermediate 27f: 3-(5-(4-(Dibutoxymethyl)piperidin-l-yl)-l-oxoisoindolin-2-yl)piperidine-2,6-dione
[0981] Pd-PEPPSI-IHeptCl (0.23 g, 0.24 mmol) was added to a degassed mixture of 3-(5-bromo-l-oxoisoindolin-2- yl)piperidine-2, 6-dione (1.5 g, 4.64 mmol), 4-(dibutoxymethyl)piperidine (1.5 g, 6.16 mmol) and CS2CO3 (4.54 g, 13.93 mmol) in 1,4-dioxane (45 mL) at RT under N2. The resulting mixture was vacuum degassed, backfilling with N2 and then stirred at 100°C for 3h. After cooling, the mixture was diluted with DCM (75 mL) and 10% aq. AcOH (50 mL) and the phases were separated. The aqueous portion was extracted with DCM (75 mL). The combined organic layers were washed with sat. Nal ICO3 (50 mL), dried (MgSCL) and concentrated. The residue was partitioned between DCM (50 mL) and water (20 mL) and the aqueous portion was extracted with DCM (50 mL). The combined organic solutions were then dried (MgSO.4) and concentrated. Trituration with EtOAc (15 mL) gave a solid which was collected by filtration, washed sequentially with EtOAc (2 x 5 mL), EtOAc:Et2O (1 :1; 5 mL), and Et2O (5 mL) then dried under vacuum to give the title compound (1.659 g, 74 %) as a white solid; ‘HNMR: 0.89 (6H, t), 1.23-1.42 (6H, m), 1.43-1.56 (4H, m), 1.67-1.85 (3H, m), 1.96 (1H, ddd), 2.28-2.44 (1H, m), 2.55-2.64 (1H, m), 2.72-2.84 (2H, m), 2.90 (1H, ddd), 3.40 (2H, dt), 3.56 (2H, dt), 3.89 (2H, d), 4.09-4.25 (2H, m), 4.32 (1H, d), 5.04 (1H, dd), 7.04 (2H, d), 7.50 (1H, d), 10.91 (1H, s); m / z ES+[M+H]+= 486.0.
[0982] Example 27: 4-f4-[4-(4-f[4-(n-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihvdro- isoindol-5- yl1piperidin-4-yllmethyl)piperazin-l-yl1methyllpiperidin-l-yl)phenyl1piperidin-l-yll-2- (trifluoromethyl)benzonitrile
[0983] Intermediate 27c was reacted with Intermediate 27f using the general synthetic method illustrated by Example 1 to give the title compound (as a formate salt) after purification by HPLC (Column A, Eluent A). *H NMR: 1.09-1.27 (4H, m), 1.53-1.69 (3H, m), 1.77 (5H, d), 1.84 (2H, d), 1.92-2.01 (1H, m), 2.15 (4H, d), 2.28-2.42 (9H, m), 2.56-2.64 (3H, m), 2.74 (1H, d), 2.82 (2H, t), 2.86-2.95 (1H, m), 3.04 (2H, t), 3.60 (2H, d), 3.86 (2H, d), 4.11-4.26 (3H, m), 4.32 (1H, d), 5.04 (1H, dd), 6.85 (2H, d), 7.05 (4H, q), 7.27 (1H, dd), 7.32 (1H, d), 7.50 (1H, d), 7.81 (1H, d), 8.17 (1H, s), 10.91 (1H, s); m / z ES+[M+H]+ = 851.6. difluoropentyl 4-methylbenzenesulfonate
[0984] 4-Methylbenzenesulfonyl chloride (131 mg, 0.69 mmol) was added in one portion to 4-(4-(4-((3,3-difluoro-5- hydroxypentyl)oxy)phenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (190 mg, 0.41 mmol) and IAN (113 pL, 0.81 mmol) in DCM (2 mL) at RT and the solution was stirred for 2h. The reaction was incomplete and further 4-methylbenzenesulfonyl chloride (131 mg, 0.69 mmol) and IAN (113 pl, 0.81 mmol) were added in one portion and the solution was stirred at RT for a further 18h. The reaction was incomplete and further 4- methylbenzenesulfonyl chloride (131 mg, 0.69 mmol) and IAN (113 Lil,. 0.81 mmol) were added in one portion and the solution was stirred at RT for a further 3h. The mixture was then diluted with DCM (25 mL), washed (sat. NH4CI (10 mL), sat. Nal ICO;, (10 mL), water (20 mL) then sat. brine (10 mL)), dried with a phase separating cartridge and concentrated. Purification by FSC (gradient: 0-60% EtOAc in heptane) gave the title compound (0.147 g, 58%) as a yellow gum; m / z: ES+[M+H]+623.3 -
[0985] 4-Bromo-l-fluoro-2-nitrobenzene (11.69 mL, 93.91 mmol) was added to a stirred milky suspension of di- tertbutyl L-glutamate hydrochloride salt (50.00 g, 169.03 mmol) and EtaN (52.4 mL, 375.62 mmol) in THF (500 mL) at RT. The mixture was then stirred at 70°C for 72h. Water (500 mL) was then added and this mixture was extracted with EtOAc (2 x 500 mL). The combined organic solutions were then washed with brine (500 mL), passed through phase separating cartridge and concentrated. Purification by FSC (gradient: 0-20% EtOAc in heptane) gave the title compound (49.50 g, 115 %) as a yellow gum; *H NMR (CDCL) 1.44 (9H, s), 1.48 (9H, s), 2.16 (2H, q), 2.38 (2H, t), 4.22 (1H, q), 6.77 (1H, d), 7.50 (1H, dd), 8.34 (2H, d).
[0986] Intermediate 29b: di-tert-Butyl (2-amino-4-bromophenyl)-L-glutamate
[0987] Iron powder (26.20 g, 469.15 mmol) was added in one portion to di- tert-butyl (4-bromo-2-nitrophenyl)-L- glutamate (43.10 g, 93.83 mmol) and NH4CI (25.09 g, 469.15 mmol) in IPA (400 mL) and water (80 mL) at RT. The resulting mixture was stirred at 80 °C for 16h. After cooling the mixture was filtered through celite and washed through with EtOAc (500 mL). The dark red filtrate was washed with water (250 mL), sat. brine (250 mL), dried (MgSO.4) and concentrated. Purification by FSC (gradient 0-30% EtOAc in heptane) gave the title compound (36.1 g, 90 %) as an orange gum; >H NMR (CDC13) 1.44 (9H, s), 1.44 (9H, s), 1.89-2.17 (2H, m), 2.27-2.53 (2H, m), 3.53 (2H, s), 3.68-3.97 (2H, m), 6.48 (1H, d), 6.71-6.95 (2H, m); m / z\ ES+[M+H]+429.
[0988] Intermediate 29c: di-tert-Butyl (S)-2-(5-bromo-2-oxo-2,3-dihvdro-lH-benzo[d1imidazol-l-
[0989] CDI (14.30 g, 88.19 mmol) was added in one portion to di-tert-butyl (2-amino-4-bromophenyl)-L-glutamate (36.1 g, 83.99 mmol) in THF (500 mL) at RT. The resulting dark red solution was stirred at 60°C for 2h. The mixture was cooled to RT and concentrated. The residue was dissolved in EtOAc (500 mL). This solution was washed with water (500 mL) and brine (200 mL), dried (MgSCL) and concentrated to give the title compound (41.0 g, 107 %) as a beige solid; 'H NMR ^DClj) 1.40 (18H, d), 2.13-2.43 (3H, m), 2.46-2.64 (1H, m), 5.07 (1H, dd), 6.86 (1H, d), 7.17 (1H, dd), 7.23 (1H, d), 9.98 (1H, s) di-tert-Butyl (.S')-2-(5-bromo-2-oxo-2.3-dihvdro- l / 7-benzo| J|imidazol- 1 -yl)pentanedioate (38.0 g, 83.45 mmol) was dissolved in DMFDMA(333 mL) and the solution was stirred at 100°C for 16h then concentrated. Purification by FSC (gradient: 0-25% EtOAc in heptane) gave the title compound (35.0 g, 89 %) as a pale yellow gum that solidified on standing; >H NMR (CDC13) 1.39 (9H, s), 1.40 (9H, s), 2.09-2.41 (3H, m), 2.43- 2.63 (1H, m), 3.39 (3H, s), 5.06 (1H, dd), 6.85 (1H, d), 7.11 (1H, d), 7.17 (1H, dd).
[0990] Intermediate 29e: (S)-2-(5-Bromo-3-methyl-2-oxo-2,3-dihvdro-lH-benzo[d1imidazol-l-yl)pentanedioic
[0991] TFA (200 mL) was added to a stirred solution of di-tert-butyl (>S)-2-(5-bromo-3-methyl-2-oxo-2,3-dihydro-l / f- benzo| J|imidazol- 1 -vljpentanedioate (35.0 g, 74.57 mmol) in DCM (200 mL) at 0°C. This mixture was stirred for 15 mins then warned to RT and stirred for a further 3h. The mixture was then concentrated and the residue was azeotroped twice with toluene to give a yellow solid. This was then triturated in 3:1 heptaneMTBE overnight. A solid was collected by filtration and dried to give the title compound (25.2 g, 95 %) as a pale yellow solid; >H NMR: 2-2.44 (4H, m), 3.33 (3H, s), 5.04 (IH, dd), 7.05 (IH, d), 7.21 (IH, dd), 7.44 (IH, d), 12.16 (IH, s), 13.07 (IH, s);
[0992] Intermediate 29f: 3-(5-Bromo-3-methyl-2-oxo-2,3-dihvdro-l / / -benzo|< / |imidazol-l-yl)piperidine-2,6- dione
[0993] (N)-2-(5-Bromo-3-methyl-2-oxo-2,3-dihydro-l / f-benzo[<7|imidazol-l-yl)pentanedioic acid (1.0 g, 2.48 mmol) was dissolved in DCM (30 mL). DIPEA (2.163 mL, 12.42 mmol) and l-(bis(dimethylamino)methylene)-l / 7- [1.2.3 |triazolo|4.5-A |pvridine- 1 -ium 3-oxide hexafluorophosphate(V) (1.889 g, 4.97 mmol) was then added and the mixture was stirred for 10 mins at RT. 2,2,2-Trifluoroacetamide (0.281 g, 2.48 mmol) was then added and the mixture stirred for Ih. The mixture was then poured into 5% AcOH in water (200 mL). This mixture was extracted with DCM (2 x 150 mL) and the combined organic solutions were washed with sat. Nal ICO;, solution (200 mL) then passed through a phase separating cartridge and concentrated in vacuo to almost dryness (~75 mL). Purification by FSC (gradient: 0-80% EtOAc in heptane) gave crude product. The crude solid (0.8 g) was suspended in 1 :1 MTBE:heptane (10 mL) and triturated overnight. The resulting solid was collected by filtration and dried to give the title compound (0.70 g, 83 %) as a white solid; *H NMR (CDCI3) 2.11-2.33 (IH, m), 2.6-3.03 (3H, m), 3.42 (3H, s), 5.18 (IH, dd), 6.68 (IH, d), 7.1-7.24 (2H, m), 8.05 (IH, s); m / z: ES+[M+H]+338. Material has racemized in this step.
[0994] Intermediate 29g: tert-Butyl-4-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihvdro-l / 7-
[0995] (DiMeIHeptcl)Pd(cinnamyl)Cl (commercially available from Total Synthesis Ltd. Toronto, Canada, 0.031 g, 0.03 mmol) was added to 3-(5-bromo-3-methyl-2-oxo-2,3-dihydro-l / f-benzo[<7]imidazol-l-yl)piperidine-2,6- dione (0.100 g, 0.30 mmol), CS2CO3 (0.289 g, 0.89 mmol) and tert-butyl piperazine- 1 -carboxylate (0.138 g, 0.74 mmol) in 1,4-dioxane (4.5 mL) at RT under N2. The resulting suspension was stirred at 100°C for 6h. The mixture was then diluted with DCM (25 mL), washed (5% AcOH in water (20 mL), water (20 mL), sat. NaHCOa solution (20 mL) then sat. brine (20 mL)), dried (MgSCL) and concentrated. Trituration with EtOAc gave a solid which was collected by filtration, washed with Et3O and dried under vacuum to give the title compound (0.107 g, 82 %) as a cream solid; ‘H NMR: 1.43 (9H, s), 1.91-1.99 (IH, m), 2.54-2.65 (2H, m), 2.74-2.88 (IH, m), 3-3.07 (4H, m), 3.31 (3H, s), 3.45-3.51 (4H, m), 5.11-5.26 (IH, m), 6.65 (IH, dd), 6.87 (IH, d), 6.92 (IH, d); m / z: ES+[M+H]+444.2.
[0996] Example 29: 4-i4-[4-(4-i4-[l-(2,6-Dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihvdro- henzimidazol-5- yl1piperazin-l-yllbutoxy)phenyl1piperidin-l-yll-2-(trifluoromethyl)benzonitrile
[0997] Intermediate Ih was reacted with Intermediate 29g using the general synthetic method illustrated by Example 1 to give the title compound (as a formate salt) after purification by HPLC (Column A, Eluent A); *H NMR: 1.56-1.68 (4H, m), 1.69-1.79 (2H, m), 1.85 (2H, d), 1.94-2.04 (IH, m), 2.39 (2H, t), 2.52-2.54 (4H, m), 2.58- 2.65 (IH, m), 2.67-2.71 (IH, m), 2.72-2.82 (IH, m), 2.85-2.96 (IH, m), 3.00-3.12 (6H, m), 3.31 (5H, br), 3.97 (2H, t), 4.17 (2H, d), 5.29 (IH, dd), 6.62 (IH, dd), 6.81-6.91 (3H, m), 6.94 (IH, d), 7.16 (2H, d), 7.27 (IH, dd), 7.32 (IH, d), 7.81 (IH, d), 8.17 (IH, s), 11.04 (IH, s); rn z HS [M+H]+ = 743.9.
[0998] Intermediate 30a: 4-(4-(4-((lr,3r)-3-(2-Bromoethyl)cvclobutoxy)phenyl)piperidin-l-yl)-2-
[0999] (trifluoro-methvDbenzonitrile
[1000] A solution of PPh3(63.7 mg, 0.24 mmol) in THF (1 mL) was added dropwise to a stirred mixture of Irans- / - (4-(4-((ls,3r)-3-(2-hydroxyethyl)cyclobutoxy)phenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (Intermediate 5c) (54.0 mg, 0.12 mmol) and CBr i (81.0 mg, 0.24 mmol) in THF (1.0 mL) at 0°C. The resulting mixture was stirred at RT for 1 week. The mixture was then filtered, washed through with EtOAc (20 mL) and the filtrate was concentrated. Purification by FSC (gradient: 0-30% EtOAc in heptane) gave the title compound (0.034 g, 55%) as a colourless oil; >H NMR (CDC13) 1.75 (2H, qd), 1.97 (2H, d), 2.07 (2H, q), 2.14-2.23 (2H, m), 2.36 (2H, dddd), 2.54 (1H, ddq), 2.72 (1H, tt), 3.05 (2H, td), 3.36 (2H, t), 4.02 (2H, d), 4.72 (1H, t), 6.62-6.8 (2H, m), 6.98 (1H, dd), 7.04-7.14 (2H, m), 7.15 (1H, d), 7.61 (1H, d); m / z: ES+[M+H]+= 507.2.
[1001] Example 30: tr«M5-4-[4-(4-f[(ls,3r)-3-(2-f4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihvdro- isoindol- 5-' in-1-' in-l-yll-2-i
[1002] Intermediate 2c was reacted with Intermediate 30a using the general synthetic method illustrated by Example 5 to give the title compound (as a formate salt) after purification by HPLC (Column A, Eluent A). *H NMR: 1.56-1.69 (2H, m), 1.76 (2H, s), 1.85 (2H, d), 1.91-2.03 (1H, m), 2.16-2.20 (4H, m), 2.29 (1H, d), 2.36-2.44 (2H, m), 2.51-2.53 (4H, m), 2.60 (2H, d), 2.78 (1H, d), 2.86-2.96 (1H, m), 3.04 (2H, t), 4.20 (3H, dd), 4.34 (1H, d), 4.79 (1H, q), 5.05 (1H, dd), 6.75 (2H, d), 7.09 (2H, d), 7.15 (2H, d), 7.22-7.37 (2H, m), 7.54 (1H, d), 7.81 (1H, d), 10.92 (1H, s); 4H under solvent peak; m / z ES+[M+H]+ = 755.4.
[1003] Intermediate 31a: tert-Butyl 4-(4-hvdroxybutyl)piperidine-l-carboxylate
[1004] Di-tert-butyl carbonate (8.86 mL, 38.15 mmol) was added to 4-(piperidin-4-yl)butan-l-ol (4.00 g, 25.44 mmol) in THF (50 mL) and sat. NaiCO;, solution (50 mL) at RT and the mixture was stirred for 16h. The mixture was then diluted with EtOAc (300 mL), washed with sat. brine (200 mL), dried (Na2SO4) and concentrated. Purification by FSC (gradient: 0-50% petroleum ether in EtOAc) gave the title compound (5.30 g, 81 %) as a white liquid; ‘H NMR: 0.86-1.00 (2H, m), 1 .13-1.22 (2H, m), 1.25-1.33 (2H, m), 1.35-1.40 (12H, m), 1.57-1.65 (2H, m), 2.65 (2H, s), 3.34-3.42 (2H, m), 3.91 (2H, d), 4.31 (1H, t); m z\ ES+[M-tBu]+= 202.
[1005] Intermediate 31b: tert-Butvl 4-(4-(4-(l-(4-i lin-4-’
[1006] RockPhos Pd G3 (0.488 g, 0.58 mmol) was added to tert-butyl 4-(4-hydroxybutyl)piperidine-l -carboxylate (1.50 g, 5.83 mmol), 4-(4-(4-bromophenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (3.58 g, 8.74 mmol) and CS2CO3 (5.70 g, 17.48 mmol) in 1,4-dioxane (30 mL) at RT over 10 mins under Ni. The resulting mixture was stirred at 100°C for 16h. The mixture was then diluted with EtOAc (200 mL), washed with sat. brine (100 mL), dried (Na2SO4) and concentrated Purification by FSC (gradient: 0-15% EtOAc in petroleum ether) gave the title compound (1.50 g, 44 %) as a yellow liquid; >H NMR: 0.88-0.99 (2H, m), 1.22-1.28 (2H, m), 1.33- 1.45 (14H, m), 1.55-1.69 (6H, m), 1.79-1.88 (2H, m), 2.72-2.80 (1H, m), 2.98-3.08 (2H, m), 3.87-3.96 (4H, m), 4.16 (2H, d), 6.81-6.86 (2H, m), 7.11-7.17 (2H, m), 7.23-7.28 (1H, m), 7.32 (1H, d), 7.78-7.82 (1H, m); m / z\ ES+[M-tBu]+= 530.
[1007] Intermediate 31c: 4-(4-(4-(4-(PiDeridin-4-yl)butoxy)Dhenyl)Diperidin-l-yl)-2-
[1008] (trifluoromethvDbenzonitrile tert-Butyl 4-(4-(4-(l-(4-cyano-3-(trifluoromethyl)phenyl)piperidin-4-yl)phenoxy)butyl)piperidine-l- carboxylate (500 mg, 0.85 mmol) was added to DCM (2 mL) and HC1 in dioxane (7 mL) at RT and the mixture was stirred for 16h. Concentration under reduced pressure then gave the title compound which was used in the next step without further purification; *H NMR (300 MHz) 1.19-1.31 (4H, m), 1.32-1.54 (4H, m), 1.54-1.70 (3H, m), 1.73-1.84 (4H, m), 2.68-2.88 (3H, m), 3.02 (2H, t), 3.19 (2H, d), 3.90 (2H, t), 4.16 (2H, d), 6.82 (2H, d), 7.13 (2H, d), 7.21-7.29 (1H, m), 7.30 (1H, d), 7.79 (1H, d); m / z\ ES+[M+H]+= 486.
[1009] Example 31: 4-f4-[4-(4-n-[2-(2.6-DioxoDiDeridin-3-yl)-l-oxo-2.3-dihvdro- isoindol-5-yllDiperidin-4- yllbutoxy)phenyl1piperidin-l-yll-2-(trifluoromethyl)benzonitrile
[1010] Pd-PEPPSI-IPent (40.8 mg, 0.05 mmol) was added to 4-(4-(4-(4-(piperidin-4-yl)butoxy)phenyl)piperidin-l- yl)-2-(trifhioromethyl)benzonitrile (250 mg, 0.51 mmol), 3-(5-bromo-l-oxoisoindolin-2-yl)piperidine-2,6- dione (166 mg, 0.51 mmol) and CS2CO3 (503 mg, 1.54 mmol) in 1,4-dioxane (5 mL) at RT under N2. The resulting mixture was stirred at 100°C for 16h. The mixture was then diluted with DCM, washed (5% AcOH (aq), water, then sat. brine), dried (Na2SO4) and concentrated. Purification by flash C18-flash chromatography (gradient: 5-85% MeCN in water (0.1 % NH4HCO3)) gave material that was further purified by preparative SFC (Column: Viridis BEH 2-Ethylpyridine Prep OBD, 30* 150mm, 5 pm; Mobile Phase A: CO2, Mobile Phase B: MeOH (0.5% 2M NH3-MeOH)-HPLC; Flow rate:50 mL / min; Gradient:28% B; 254 nm; RT1 :4.25; Injection Volumn: 1 mL; Number Of Runs:5) to give the title compound (7 mg, 2 %) as a white solid; 'H NMR: 1.13-1.33 (5H, m), 1.40-1.55 (3H, m), 1.55-1.77 (6H, m), 1.81-1.91 (2H, m), 1.92-2.04 (1H, m), 2.30-2.42 (1H, m), 2.55-2.64 (1H, m), 2.71-2.96 (4H, m), 2.99-3.10 (2H, m), 3.86 (2H, d), 3.93 (2H, t), 4.13-4.26 (3H, m), 4.31 (1H, d), 4.98-5.07 (1H, m), 6.82-6.88 (2H, m), 7.00-7.07 (2H, m), 7.13-7.18 (2H, m), 7.24-7.30 (1H, m), 7.32 (1H, d), 7.47-7.52 (1H, m), 7.81 (1H, d); m / z ES+[M+H]+ = 728.4.
[1011] Example 32: 4-[4-(4-f[(lr,3s)-3-(2-f4-[2-(2,6-Dioxopiperidin-3-vD-l-oxo-2,3-dihvdro-l.H-isoindol-5-yl]-
[1012] Intermediate 2c was reacted with Intermediate 5d using the general synthetic method illustrated by Example 5 to give the title compound (as a formate salt) after purification by HPLC (Column A, Eluent A); *H NMR: 1.55-1.7 (6H, m), 1.85 (2H, d), 1.9-2.02 (2H, m), 2.25-2.31 (2H, m), 2.39 (2H, dd), 2.56-2.64 (3H, m), 2.75 (1H, d), 2.82-2.95 (1H, m), 3.04 (2H, t), 3.29 (8H, br), 4.11-4.27 (3H, m), 4.33 (1H, d), 4.51 (1H, p), 5.04 (1H, dd), 6.77 (2H, d), 7.06 (2H, d), 7.14 (2H, d), 7.27 (1H, dd), 7.32 (1H, d), 7.52 (1H, d), 7.81 (1H, d), 8.14 (1H, s), 10.92 (1H, s); m / z ES+[M+H]+ = 755.7.
[1013] Intermediate 33a: tert-Butyl-3-(2-(2.6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)-7-oxa-3.10-
[1014] Pd-PEPPSI-IHept.Cl (0.083 g, 0.09 mmol) was added to tert-butyl 7-oxa-3,10-diazaspiro[5.6]dodecane-10- carboxylate (0.603 g, 2.23 mmol), CS2CO3 (1.66 g, 5.11 mmol) and 3-(5-bromo-l-oxoisoindolin-2- yl)piperidine-2, 6-dione (0.550 g, 1.70 mmol) in 1,4-dioxane (12 mL) at RT under N2. The resulting suspension was stirred at 100°C for 20h. The mixture was then diluted with DCM (25 mL), washed (5% AcOH in water (10 mL), water (10 mL), and then sat. brine (10 mL)), dried (MgSCL) and concentrated. Purification by FSC (gradient 0-5% MeOH in DCM) gave the title compound (0.490 g, 56 %) as a yellow solid. *H NMR: 1.41 (9H, s), 1.49-1.6 (2H, m), 1.7-1.85 (4H, m), 1.91-2.02 (1H, m), 2.33-2.44 (1H, m), 2.55-2.64 (1H, m), 2.84- 2.96 (1H, m), 3.09-3.17 (2H, m), 3.38-3.47 (4H, m), 3.49-3.61 (2H, m), 3.62-3.69 (2H, m), 4.20 (1H, d), 4.32 (1H, d), 5.04 (1H, dd), 7-7.11 (2H, m), 7.50 (1H, d), 10.91 (1H, s); m / z ES+[M+H]+ = 513.3.
[1015] Example 33: 4-f4-[4-(4-f3-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihvdro-l / 7-isoindol-5-yl1-7-oxa-3,10- diazaspiro[5.61dodecan-10-yllbutoxy)phenyl1piperidin-l-yll-2-(trifluoromethyl)benzonitrile
[1016] Intermediate Ih was reacted with Intermediate 33a using the general synthetic method illustrated by Example
[1017] 1 to give the title compound (as a formate salt) after purification by HPLC (Column A, Eluent A). *H NMR: 1.43-1.53 (2H, m), 1.53-1.67 (4H, m), 1.67-1.81 (6H, m), 1.85 (2H, d), 1.91-2 (1H, m), 2.35-2.4 (1H, m), 2.41-2.47 (2H, m), 2.54-2.63 (4H, m), 2.77 (1H, t), 2.85-2.95 (1H, m), 3.05 (2H, t), 3.16 (2H, t), 3.30 (2H, s), 3.54 (2H, d), 3.62 (2H, d), 3.95 (2H, t), 4.18 (3H, dd), 4.32 (1H, d), 5.04 (1H, dd), 6.85 (2H, d), 7.04 (2H, d), 7.15 (2H, d), 7.27 (1H, dd), 7.33 (1H, d), 7.50 (1H, d), 7.81 (1H, d), 8.16 (1H, s), 10.91 (1H, s); m / z ES+[M+H]+ = 813.4.
[1018] Intermediate 34a: tert-Butyl 4-((methylsulfonyl)oxy)piperidine-l-carboxylate
[1019] Methanesulfonyl chloride (1.38 mL, 17.89 mmol) was added dropwise to a stirred solution of tert-butyl 4- hydroxypiperidine-1 -carboxylate (3.00 g, 14.91 mmol) and DIPEA (3.89 mL, 22.36 mmol) in DCM (55 mL) at 0°C. The mixture was then stirred at RT for 2h before being diluted with DCM (125 mL). This solution was washed with water (75 mL), citric acid solution (50 mL), brine (50 mL), then dried (MgSCL) and concentrated to give the title compound (4.69 g, 113 %) as a brown solid; *H NMR (CDCI3) 1.46 (9H, s), 1.81 (2H, dtd), 1.96 (2H, ddt), 3.03 (3H, s), 3.30 (2H, ddd), 3.64-3.76 (2H, m), 4.88 (1H, tt).
[1020] Intermediate 34b: Methyl 2-(bromomethyl)-4-((tert-butyldimethylsilyl)oxy)benzoate
[1021] AIBN (0.094 g, 0.57 mmol) was added to methyl 4-((tert-butyldimethylsilyl )oxy)-2-methylbenzoate (8 g, 28.53 mmol) and NBS (6.60 g, 37.08 mmol) in EtOAc (71 mL) at 80°C under N2. The resulting mixture was stirred at 80°C for 3h. The mixture was then poured into water (100 mL). This mixture was then extracted with EtOAc (3 x 50 mL). The combined organic solutions were washed with brine (50 mL), dried (MgSCL) and concentrated. Purification by FSC (gradient: 0-30% EtOAc in petroleum ether) gave the title compound (6.90 g, 67%) as a colourless liquid; ‘H NMR (CDCh) 0.22 (6H, s), 0.99 (9H, s), 2.15-2.24 (1H, m), 2.33 (1H, qd), 2.75-2.95 (2H, m), 4.22-4.46 (2H, m), 5.18 (1H, dd), 6.88 (1H, s), 6.89-6.96 (1H, m), 7.74 (1H, d), 8.02-8.19 (1H, m). i-l-oxoisoindolin-2-' >2, 6-dione
[1022] DIPEA (9.89 mL, 56.77 mmol) was added to a stirred solution of methyl 2-(bromomethyl)-4-((tert-butyl- dimethylsilyl)oxy)benzoate (6.80 g, 18.92 mmol) and 3-aminopiperidine-2, 6-dione hydrochloride salt (3.11 g, 18.92 mmol) in MeCN (60 mL) at RT under N2 and the mixture was stirred for 25h. The mixture was then diluted with water (50 mL). This mixture was then extracted with EtOAc (25 mL x 3) and the combined organic solutions were dried (MgSOy) and concentrated to give the title compound (2.00 g, 28 %); *H NMR (CDClj) 0.22-0.25 (6H, m), 0.98-0.99 (9H, m), 3.87-3.92 (3H, m), 4.93 (2H, s), 6.76-6.82 (1H, m), 6.93 (1H, d), 7.91 (1H, d).
[1023] Intermediate 34d: 3-(5-Hvdroxy-l-oxoisoindolin-2-yl)piperidine-2,6-dione
[1024] A stirred solution of 3-(5-((tert-butyldimethylsilyl)oxy)-l-oxoisoindolin-2-yl)piperidine-2,6-dione (1.50 g, 4.01 mmol) in 1,4-dioxane (10 mL) was treated with 4M HC1 (5.56 mL, 160.21 mmol) under N2. The resulting slurry was stirred at RT for 18h. The mixture was then concentrated under reduced. The residue was then dissolved with hot MeCN before being allowed to cool to RT, then to 0°C. A solid was collected by filtration and washed with cold MeCN and dried in a vacuum desiccator for 18h to give the title compound (1.16 g, 111 %) as a black solid; m / z (ES-) [M-H]' = 259.
[1025] Intermediate 34e: terZ-Butyl-4-((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-5-yl)oxy)piperidine-l-
[1026] K2CO3 (0.320 g, 2.31 mmol) was added in one portion to a stirred solution of tert-butyl 4-((methylsulfonyl)- oxy)piperidine-l -carboxylate (0.644 g, 2.31 mmol) and 3-(5-hydroxy-l-oxoisoindolin-2-yl)piperidine-2,6- dione (0.500 g, 1.92 mmol) in DMF (10 mL) at RT under N2. The resulting solution was stirred for 18h at 100°C. The mixture was then diluted with water (50 mL). This mixture was then extracted with EtOAc (3 x 30mL) and the combined organic solutions were washed with brine (75 mL), dried (MgSOy) and concentrated. The residue (500mg) was dissolved into 4.5 mL 7:2 DMSOMeOH (111 mg / mL), then purified by preparative HPLC (Column A, Eluent A) to give the title compound (0.461 g, 54%) as a white solid; 'HNMR: 1.42 (9H, s), 1.56 (2H, d), 1.91-2.02 (3H, m), 2.40 (1H, td), 2.55-2.65 (1H, m), 2.8-2.98 (1H, m), 3.20 (2H, t), 3.68 (2H, dt), 4.27 (1H, d), 4.39 (1H, d), 4.70 (1H, dt), 5.07 (1H, dd), 7.09 (1H, dd), 7.22 (1H, d), 7.63 (1H, d), 10.94 (1H, s); m / z (ES-) [M-H]' = 442.2.
[1027] Example 34: 4-(4-f4-[4-(4-f[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihvdro-l / f-isoindol-5- yl1oxylpiperidin-l-vDbutoxy1phenyl|piperidin-l-vD-2-(trifluoromethvDbenzonitrile
[1028] Intermediate Ih was reacted with Intermediate 34e using the general synthetic method illustrated by Example 1 to give the title compound after purification by HPLC (Column A, Eluent A). 'H NMR: 1.54-1.75 (8H, m), 1.85 (2H, d), 1.92-2.05 (3H, m), 2.21-2.32 (2H, m), 2.35-2.41 (3H, m), 2.56-2.65 (IH, m), 2.7-2.82 (3H, m), 2.84-2.95 (IH, m), 3.05 (3H, t), 3.96 (2H, t), 4.17 (2H, d), 4.26 (IH, d), 4.38 (IH, d), 4.51 (IH, dt), 5.07 (IH, dd), 6.81-6.91 (2H, m), 7.06 (IH, dd), 7.13-7.22 (3H, m), 7.27 (IH, dd), 7.32 (IH, d), 7.61 (IH, d), 7.81 (IH, d), 8.15 (IH, s), 10.94 (IH, s); Wz ES+[M+H]+ = 744.4.
[1029] Intermediate 35a: Benzyl 4-(3-fluoro-4-hvdroxyphenyl)-3,6-dihvdropyridine-l(2 / D-carboxylate
[1030] Pd(dppf)2Ch-DCM (0.824 g, 1.01 mmol) was added to 2-fluoro-4-iodophenol (2.40 g, 10.08 mmol), benzyl 4- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-l(2 / / )-carboxylate (5.19 g, 15.13 mmol) and K2CO3 (4.18 g, 30.25 mmol) in 1 ,4-dioxane (1.6 mL) and water (0.4 mL) at RT under N2. The resulting mixture was stirred at 80°C for 16h. The mixture was then diluted with EtOAc, washed with water then sat. brine, dried (Na2SC>4) and concentrated. Purification by FSC (gradient: 0-30% EtOAc in petroleum ether) gave the title compound (2.20 g, 67%) as a yellow solid; >H NMR (300 MHz) 2.45 (2H, s), 3.58 (2H, d), 4.05 (2H, d), 5.11 (2H, s), 6.06 (1H, s), 6.90 (1H, t), 7.07 (1H, dd), 7.21 (1H, dd), 7.29-7.42 (5H, m), 9.85 (1H, s); m / z ES+[M+H]+= 328.
[1031] Intermediate 35b: tert-Butyl 4-(3-fluoro-4-hvdroxyphenyl)piperidine-l-carboxylate
[1032] 10% Pd-on-C (1.365 g, 1.28 mmol) was added to di-tert-butyl carbonate (1.520 g, 7.06 mmol) and benzyl 4- (3-fluoro-4-hydroxyphenyl)-3,6-dihydropyridine-l(2 / f)-carboxylate (2.100 g, 6.42 mmol) in MeOH (10 mL) at RT under H2. The resulting mixture was stirred at 80°C for 16h. The mixture was then filtered through celite and the filtrate was concentrated. Purification by FSC (gradient: 0-30% EtOAc in petroleum ether) gave the title compound (1.00 g, 53 %) as a white solid; ‘HNMR: 1.35-1.48 (HH, m), 1.70 (2H, d), 2.57 (IH, tt), 2.76 (2H, s), 3.99-4.10 (2H, m), 6.83-6.86 (2H, m), 6.97-7.02 (IH, m), 9.56 (IH, s); m / z ES+[MH-tBu]+= 240.1.
[1033] Intermediate 35c: 2-Fluoro-4-(piperidin-4-yl)phenol tert-Butyl 4-(3-fluoro-4-hydroxyphenyl)piperidine-l -carboxylate (500 mg, 1.69 mmol) was added to 4M HC1 in 1 ,4-dioxane (8 mL, 32.00 mmol) at RT and the mixture was stirred for 2h. Concentration under reduced pressure then gave the title compound as a hydrochloride salt (0.430 g, 130 %) as a white solid; *H NMR (300 MHz) 1.66-1.96 (4H, m), 2.72 (1H, tt), 2.91 (2H, q), 3.29 (2H, d), 6.82 (1H, dd), 6.89 (1H, d), 6.94 (1H, dd), 8.85 (OH, s), 9.72 (1H, s); m / z ES+[M+H]+= 196.0.
[1034] DIPEA (1.923 mL, 11.01 mmol) was added to 2-fluoro-4-(piperidin-4-yl)phenol (430 mg, 2.20 mmol) and 4- fhioro-2-(trifhioromethyl)benzonitrile (417 mg, 2.20 mmol) in DMSO (2 mL) at RT. The resulting solution was stirred at 60°C for 2h. The mixture was then poured into water (20 mL). This mixture was then extracted with EtOAc (3 x 250 mL) and the combined organic solutions were dried (Na2SO4) and concentrated.
[1035] Purification by FSC (gradient: 0-30% EtOAc in petroleum ether) gave the title compound (0.507 g, 63%) as a white solid; ‘H NMR: 1.59 (2H, qd), 1.78-1.87 (2H, m), 2.73 (1H, tt), 3.02 (2H, td), 4.16 (2H, dt), 6.84-6.89 (2H, m), 7.02 (1H, dd), 7.26 (1H, dd), 7.31 (1H, d), 7.80 (1H, d), 9.58 (1H, s); m / z ES+[M+H]+= 365.
[1036] Intermediate 35e: 4-(4-(4-(4-Bromobutoxy)-3-fluorophenyl)piperidin-l-yl)-2-(trifluoromethyl)- benzonitrile
[1037] K2CO3 (228 mg, 1.65 mmol) was added to 4-(4-(3-fluoro-4-hydroxyphenyl)piperidin-l-yl)-2-(trifluoro- methyl)benzonitrile (200 mg, 0.55 mmol) and 1 ,4-dibromobutane (593 mg, 2.74 mmol) inDMF (2 mL) at RT under air and the mixture was stirred for 2h. The mixture was then poured into water (20 mL). This mixture was extracted with EtOAc (3 x 20 mL) and the combined organic solutions were dried (TS^SCL) and concentrated. Purification by flash Cl 8-flash chromatography (gradient: 0-100% MeCN in water) gave the title compound (0.210 g, 77 %) as a white solid; >H NMR (300 MHz) 1.62 (2H, qd), 1.78-1 .92 (4H, m), 1.92- 2.04 (2H, m), 2.79 (1H, t), 3.03 (2H, dd), 3.61 (2H, t), 4.05 (2H, t), 4.18 (2H, d), 7.01 (1H, dd), 7.07 (1H, d), 7.13 (1H, dd), 7.27 (1H, dd), 7.33 (1H, d), 7.82 (1H, d); m / z ES+[M+H]+= 499. lZT-isoindol-5-yllpiperazin-l-
[1038] Intermediate 2c was reacted with Intermediate 35e using the general synthetic method illustrated by Example 5 to give the title compound after purification by preparative TLC (eluent: DCM:MeOH;10:l); *H NMR: (300 MHz) 1.23-1.28 (2H, m), 1.54-1.89 (8H, m), 1.89-2.02 (lH, m), 2.30-2.48 (4H, m), 2.53-2.65 (2H, m), 2.70- 2.83 (1H, m), 2.81-2.97 (1H, m), 3.03 (2H, t), 3.10-3.29 (4H, m), 4.06 (2H, t), 4.13-4.27 (3H, m), 4.34 (1H, d), 5.06 (1H, dd), 6.97-7.18 (5H, m), 7.23-7.35 (2H, m), 7.54 (1H, d), 7.82 (1H, d), 10.95 (1H, s); Wz ES+[M+H]+ = 747.4. in-4-'
[1039] RockPhos Pd G3 (291 mg, 0.35 mmol) was added to methyl 3 -(hydroxymethyl)cyclobutane-l -carboxylate (500 mg, 3.47 mmol), CS2CO3 (3.39 g, 10.40 mmol) and 4-(4-(4-bromophenyl)piperidin-l-yl)-2- (trifluoromethyl)-benzonitrile (1.42 g, 3.47 mmol) in 1,4-dioxane (5 mL) at RT under N2. The resulting mixture was stirred at 100°C for 16h then concentrated. Purification by FSC (gradient: 0-20% EtOAc in petroleum ether) gave the title compound (1.20 g, 73%) as a pale yellow solid; *H NMR (300 MHz) 1.51-1.68 (2H, m), 1.82 (2H, d), 1.95-2.10 (2H, m), 2.20-2.37 (2H, m), 2.56-2.82 (2H, m), 2.94-3.10 (2H, m), 3.37-3.52 (1H, m), 3.59 (3H, d), 3.85 (1H, d), 3.96 (1H, d), 4.15 (2H, d), 6.83 (2H, t), 7.13 (2H, dd), 7.25 (1H, dd), 7.30 (1H, d), 7.79 (1H, d); m / z ES+, [M+H]+ = 473.4.
[1040] Intermediates 36b and 36c: 4-1
[1041] Methyl 3-((4-(l-(4-cyano-3-(trifluoromethyl)phenyl)piperidin-4-yl)phenoxy)methyl)cyclobutane-l- carboxylate (1.10 g, 2.33 mmol) was added to NaBH.4 (0.264 g, 6.98 mmol) in MeOH (10 mL) at RT and the mixture was stirred for 16h. After concentration under reduced pressure the mixture was poured into water (100 mL). This mixture was extracted with EtOAc (250 mL x 3), dried (NaiSO i) and concentrated. Purification by FSC (gradient: 0-10% EtOAc in petroleum ether) gave the title compounds (700 mg) as a mixture of cisltrans isomers. Further purification by preparative Prep-SFC (Column: CHIRAL ART Amylose- SA S, 3*25cm, 5pm; Mobile Phase A:CO2, Mobile Phase BMeOH (0.5% 2MNH3-MeOH)-HPLC; Flow rate:6.1 mL / min; Gradient:40% B; 220 nm; 36b RTE9.47; 36c RT2:10.97; Injection Volumn:1.5 mL; Number Of Runs:33) gave 36b (0.123 g, 12 %) and 36c (0.154 g, 15 %) as pale yellow solids.
[1042] Intermediate 36b: ‘H NMR (CDCI3, 300 MHz) 1.76 (2H, qd), 1.90-2.06 (6H, m), 2.54 (1H, dt), 2.67-2.81 (2H, m), 3.06 (2H, td), 3.69 (2H, d), 3.97 (2H, d), 4.03 (2H, d), 6.84-6.92 (2H, m), 6.99 (1H, dd), 7.08-7.20 (3H, m), 7.62 (1H, d); m / z ES+, [M+H]+ = 445.2.
[1043] Intermediate 36c: 'H NMR ^DCh, 300 MHz) 1.59-1.86 (4H, m), 1.93-2.08 (2H, m), 2.14-2.29 (2H, m), 2.37-2.56 (1H, m), 2.60-2.80 (2H, m), 2.98-3.13 (2H, m), 3.60 (2H, d), 3.87 (2H, d), 4.02 (2H, d), 6.80-6.91 (2H, m), 6.94-7.04 (1H, m), 7.07-7.21 (3H, m), 7.61 (1H, d); Wz ES+, [M+H]+ = 445.2
[1044] Intermediate 36d: 4-(4-(4-(((lr,3r)-3-(Bromomethyl)cvclobutyl)methoxy)phenyl)piperidin-l-yl)-2-
[1045] (trifluoromethvDbenzonitrile
[1046] CBr i (74.6 mg, 0.22 mmol) was added to PPh3(59.0 mg, 0.22 mmol) and 4-(4-(4-(((lr,3r)-3-(hydroxymethyl)- cyclobutyl)methoxy)phenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (50 mg, 0.11 mmol) in DCM (1 mL) at RT and the mixture was stirred for 2h. After concentration under reduced pressure, purification by preparative TLC (eluent: petroleum ether: EtOAc = 5:1) gave the title compound (0.050 g, 88 %) as a colourless gum; >H NMR (300 MHz) 1.60 (2H, qd), 1.77-2.01 (6H, m), 2.56-2.80 (3H, m), 2.98-3.13 (2H, m), 3.63 (2H, d), 3.95 (2H, d), 4.16 (2H, d), 6.81-6.89 (2H, m), 7.09-7.18 (2H, m), 7.25 (1H, dd), 7.31 (1H, d), 7.80 (1H, d); m / z ES+, [M+H]+ = 507.
[1047] Example 36: 4-[4-(4-f[(lr,3r)-3-(f4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihvdro-l / 7-isoindol-5-yl1- piperazin-l-yllmethyl)cvclobutyl1methoxylphenyl)piperidin-l-yl1-2-(trifluoromethyl)benzonitrile
[1048] Intermediate 2c was reacted with Intermediate 36d using the general synthetic method illustrated by Example 5 to give the title compound after purification by preparative TLC (eluent: DCMMeOH, 20:1); 'H NMR: (300 MHz) 1.53-1.71 (2H, m), 1.79-2.09 (7H, m), 2.24-2.48 (5H, m), 2.53-2.98 (5H, m), 3.05 (2H, t), 3.29 (6H, d), 3.51 (1H, s), 3.99 (2H, d), 4.12-4.24 (2H, m), 4.27-4.38 (1H, m), 5.05 (1H, dd), 6.87 (2H, d), 7.05 (2H, d), 7.16 (2H, d), 7.27 (1H, dd), 7.33 (1H, d), 7.50 (1H, t), 7.82 (1H, d), 10.94 (1H, s); m / z ES+[M+H]+ = 755.4.
[1049] Intermediate 37a: 4-(4-(4-(4-(Dimethoxymethyl)piperidin-l-yl)phenyl)piperidin-l-yl)-2-(trifluoro- methvDbenzonitrile
[1050] 4-(4-(4-Bromophenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (1.00 g, 2.44 mmol), 4-(dimethoxy- methyl)piperidine (0.467 g, 2.93 mmol), RuPhos G3 (0.153 g, 0.18 mmol), RuPhos (0.086 g, 0.18 mmol) sodium tert-butoxide (0.704 g, 7.33 mmol) and anhydrous 1,4-dioxane (24.4 mL) were added to a flask. The mixture was degassed, the flask filled with Ni. The mixture was then stirred at 100°C overnight, then concentrated after cooling to RT. Water (10 mL) was added and the resulting mixture was extracted with EtOAc (3 x 20 mL). The combined organic solutions were dried (T^SCh) and concentrated. Purification by FSC (gradient: 0-100% EtOAc in heptane) gave the title compound (0.393 g, 33%) as a pale yellow solid; *H NMR (CDClj) 1.45 (2H, qd), 1.67-1.8 (3H, m), 1.8-1.89 (2H, m), 1.97 (2H, d), 2.55-2.77 (3H, m), 3.05 (2H, td), 3.37 (6H, s), 3.67 (2H, d), 4.01 (2H, d), 4.08 (1H, d), 6.88-6.92 (2H, m), 6.98 (1H, dd), 7.06-7.12 (2H, m), 7.15 (1H, d), 7.61 (1H, d); m / z\ ES+[M+H]+488.8.
[1051] Example 37: 4-[4-(4-f4-[(4-f[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihvdro-l / 7-isoindol-5-yl1oxyl- piperidin-l-yl)methyl1piperidin-l-yllphenyl)piperidin-l-yl1-2-(trifluoromethyl)benzonitrile
[1052] Intermediate 34e was reacted with Intermediate 37a using the general synthetic method illustrated by Example 1 to give the title compound after purification by HPLC (Column A, Eluent A); *H NMR: (CDCI3) 1.42-1.59 (2H, m), 1.75 (2H, qd), 1.97 (5H, dd), 2.09-2.19 (2H, m), 2.22 (1H, ddq), 2.28-2.4 (1H, m), 2.4-2.5 (2H, m), 2.71 (3H, td), 2.77-2.86 (1H, m), 2.92 (3H, dd), 2.99-3.16 (4H, m), 3.41 (2H, d), 3.65 (2H, d), 4.01 (2H, d), 4.30 (1H, d), 4.45 (1H, d), 4.72 (1H, s), 5.20 (1H, dd), 6.89 (2H, dd), 6.96 (2H, dd), 6.98-7.04 (2H, m), 7.10 (2H, d), 7.15 (1H, d), 7.57-7.63 (1H, m), 7.82 (1H, d), 8.30 (2H, s); m / z ES+[M+H]+ = 769.0.
[1053] PdChCdppf) (118 mg, 0.16 mmol) was added to tert-butyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,6- dilwdropvridine- 1 ( 2 / 7)-carboxvlate (500 mg, 1.62 mmol), 4-bromo-2-fluorophenol (340 mg, 1.78 mmol) and K2CO3 (670 mg, 4.85 mmol) in 1 ,4-dioxane (8 mL) and water (2 mL) at RT under N2. The resulting solution was stirred at 80°C for 4h. The mixture was then filtered through celite and the filtrate was concentrated. Purification by FCC (gradient: 0-10% EtOAc in petroleum ether) gave the title compound (0.40 g, 84 %) as a colourless oil; *H NMR (300 MHz) 1.40 (9H, s), 2.35 (2H, s), 3.43-3.52 (2H, m), 3.93 (2H, d), 5.83 (1H, s), 6.46-6.61 (2H, m), 7.06-7.18 (1H, m), 9.86 (1H, s); m / z\ ES+[M-tBu]+238.
[1054] Intermediate 38b: tert-Butyl 4-(2-fluoro-4-hvdroxyphenyl)piperidine-l-carboxylate
[1055] 10% Pd-on-C (1.451 g, 1.36 mmol) was added to tert-butyl 4-(2-fluoro-4-hydroxyphenyl)-3,6- dihydropyridine- 1 (277)-carboxylate (2.00 g, 6.82 mmol) in MeOH (10 mL) at RT under H2. The resulting mixture was stirred at 80°C for 16h. The mixture was then filtered through celite and the filtrate was concentrated. Purification by flash Cl 8-flash chromatography (gradient: 0-70% MeCN in water(0.1% formic acid)) gave the title compound (1.20 g, 60 %) as a white solid; 'H NMR: 1.42 (9H, s), 1.40-1.55 (2H, m), 1.63- 1.72 (2H, m), 2.71-2.92 (3H, m), 3.99-4.13 (2H, m), 6.51 (1H, dd), 6.56 (1H, dd), 7.08 (1H, t), 9.65 (1H, s); m / z\ ES+[M-tBu]+ 240. Intermediate 38c: 3-Fluoro-4-(piperidin-4-'
[1056] A mixture of HC1 in 1,4-dioxane (18.8 mL, 8.00 mmol) and tert-butyl 4-(2-fluoro-4-hydroxyphenyl)- piperidine-1 -carboxylate (600 mg, 2.05 mmol) was stirred at RT for 2h. Concentration under reduced pressure then gave the title compound as a hydrochloride salt (0.580 g, 145 %) as a white solid; *H NMR (300 MHz) 1.72-1.97 (4H, m), 2.97 (3H, dq), 3.29 (2H, d), 6.49-6.62 (2H, m), 7.02 (1H, t), 8.92 (1H, br), 9.83 (1H, s); m / z\ ES+[M+H]+ 196.
[1057] Intermediate 38d: 4-[4-t2-fluoro-4-hvdroxyphenyl)piperidin-l-yll-2-ttritluoromethyl)benzonitrile
[1058] DIPEA (3.81 mL, 21.80 mmol) was added to 3-fluoro-4-(piperidin-4-yl)phenol hydrochloride salt (1.01 g, 4.36 mmol) and 4-fluoro-2-(trifhioromethyl)benzonitrile (0.989 g, 5.23 mmol) in DMSO (10 mL) at RT under air and the mixture was stirred for 18h then poured into water (20 mL). This mixture was stirred at RT for 0.5h and then filtered. The collected solid was washed with water (20 mL) and 5% AcOH / water (20 mL) and dried under vacuum to give the title compound (1.51 g, 95 %) as a yellow solid; *H NMR: 1.67 (2H, qd), 1.80 (2H, d), 2.94-3.01 (1H, m), 3.03-3.18 (2H, m), 4.17 (2H, d), 6.45-6.63 (2H, m), 7.08 (1H, t), 7.19-7.38 (2H, m), 7.81 (1H, d), 9.65 (1H, s); m / z\ ES+[M+H]+ 365.2.
[1059] Intermediate 38e: 4-(4-(4-(3-(l,3-Dioxolan-2-yl)propoxy)-2-fluorophenyl)piperidin-l-yl)-2-(trifluoro-
[1060] 2-(3-Bromopropyl)-l,3-dioxolane (0.613 mL, 4.53 mmol) was added in one portion to 4-(4-(2-fluoro-4- hydroxyphenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (1.50 g, 4.12 mmol) and K2CO3 (1.707 g, 12.35 mmol) in MeCN (10 mL) at RT under N2. The resulting suspension was stirred at 80°C for 5h. After cooling the mixture was filtered and water (150 mL) was added to the filtrate. A white precipitate was then collected by filtration to give the title compound (1.85 g, 94 %) as a yellow solid; 'H NMR: 1.62-1.84 (8H, m), 3.03- 3.12 (3H, m), 3.75-3.8 (2H, m), 3.86-3.9 (2H, m), 3.98 (2H, t), 4.18 (2H, d), 4.85 (1H, t), 6.7-6.8 (2H, m), 7.20 (1H, t), 7.27 (1H, dd), 7.32 (1H, s), 7.81 (1H, d); m / z\ ES+[M+H]+ 479.4.
[1061] Example 38: 4-f4-[4-(4-f4-[2-(2.6-Dioxopiperidin-3-yl)-l-oxo-2.3-dihvdro-lEI-isoindol-5-yllpiperazin-l- yllbutoxy)-2-fluorophenyl1piperidin-l-yll-2-(trifluoromethyl) benzonitrile
[1062] Intermediate 2b was reacted with Intermediate 38e using the general synthetic method illustrated by Example 1 to give the title compound after purification by EIPLC (Column A, Eluent A, Basic Work-Up A); 'El NMR: (300 MHz) 1.21-1.32 (1H, m), 1 .56-1.86 (8H, m), 1.91-2.03 (1H, m), 2.26-2.49 (4H, m), 2.52-2.65 (3H, m), 2.84-2.98 (1H, m), 3.07 (3H, t), 3.20-3.33 (4H, m), 4.00 (2H, t), 4.12-4.28 (3H, m), 4.34 (1H, d), 5.05 (1H, dd), 6.70-6.84 (2H, m), 7.07 (2H, d), 7.20 (1H, t), 7.27 (1H, d), 7.33 (1H, d), 7.53 (1H, d), 7.82 (1H, d), 10.95 (1H, s); m / z ES+[M+H]+ = 747.5.
[1063] Intermediate 39a: 4-(4-(4-(((lr,3r)-3-(Bromomethyl)cvclobutyl)methoxy)phenyl)piperidin-l-yl)-2-
[1064] (trifluoromethvDbenzonitrile
[1065] CBr i (74.6 mg, 0.22 mmol) was added to PPha (59.0 mg, 0.22 mmol) and 4-(4-(4-(((ls,3s)-3-(hydroxyl- methyl)cyclobutyl)methoxy)phenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (50 mg, 0.11 mmol) in DCM (1 mL) at RT and the mixture was stirred for 2h then concentrated. Purification by preparative TLC (eluent EtOAc: petroleum ether = 1 :5) gave the title (0.050 g, 88 %) as a colourless gum; 'H NMR: 1.51-1.70 (4H, m), 1.85 (2H, d), 2.13-2.24 (2H, m), 2.53-2.64 (2H, m), 2.71-2.83 (1H, m), 3.05 (2H, dd), 3.56 (2H, d), 3.88 (2H, d), 4.18 (2H, d), 6.85 (2H, d), 7.15 (2H, d), 7.27 (1H, dd), 7.33 (1H, d), 7.82 (1H, d); m / z ES+, [M+H]+= 507.
[1066] Example 39: 4-[4-(4-n(ls,3s)-3-(f4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihvdro- isoindol-5-yl1- piperazin-l-yllmethyl)cvclobutyllmethoxylphenyl)piperidin-l-yll-2-(trifluoromethyl)benzonitrile
[1067] Intermediate 2c was reacted with Intermediate 39a using the general synthetic method illustrated by Example 5 to give the title compound after purification by preparative TLC (eluent: DCM:MeOH, 20:1); 'H NMR: (300 MHz) 1.43-1.75 (4H, m), 1.85 (2H, d), 1.91-2.10 (1H, m), 2.12-2.27 (2H, m), 2.31-2.44 (3H, m), 2.50 (4H, q), 2.52-2.67 (3H, m), 2.77-2.98 (2H, m), 2.99-3.11 (2H, m), 3.22-3.31 (4H, m), 3.86 (2H, d), 4.12-4.25 (3H, m), 4.33 (1H, d), 5.05 (1H, dd), 6.84 (2H, d), 7.05 (2H, d), 7.15 (2H, d), 7.27 (1H, dd), 7.33 (1H, d), 7.52 (1H, d), 7.82 (1H, d), 10.94 (1H, s); m / z ES+[M+H]+ = 755.4.
[1068] Intermediate 40a: tert-Butyl 4-(4-(l-(4-cvano-3-(tritluoromethyl)rihenyl)riirieridin-4-yl)rihenoxy)-
[1069] DIAD (337 Lil 1.73 mmol) was added to 4-(4-(4-hydroxyphenyl)piperidin-l-yl)-2-(trifluoromethyl)- benzonitrile (Example 1g) (300 mg, 0.87 mmol), tert-butyl 4-hydroxypiperidine- 1 -carboxylate (209 mg, 1.04 mmol) and PPha (454 mg, 1.73 mmol) in DCM (1 mL) at 0°C. The resulting mixture was stirred at RT for 16h then concentrated. Purification by flash C18-flash chromatography (gradient: 0-100% MeCN in water (0.1% formic acid)) gave the title compound (0.100 g 22%) as a white solid; *H NMR: 1.40 (9H, s), 1.50 (2H, ddt), 1.62 (2H, qd), 1.78-1.93 (4H, m), 2.76 (lH, tt), 3.04 (2H, td), 3.13-3.21 (2H, m), 3.57-3.71 (2H, m), 4.17 (2H, d), 4.49 (1H, tt), 6.89 (2H, d), 7.15 (2H, d), 7.26 (1H, dd), 7.32 (1H, d), 7.81 (1H, d).
[1070] Intermediate 40b: 3-(5-(4-(Dimethoxymethyl)DiDeridin-l-yl)-l-oxoisoindolin-2-yl)Diperidine-2.6-dione
[1071] Pd-PEPPSI-IPent (0.355 g, 0.45 mmol) was added to 3-(5-bromo-l-oxoisoindolin-2-yl)piperidine-2, 6-dione (1.45 g, 4.49 mmol), 4-(dimethoxymethyl)piperidine (1.00 g, 6.28 mmol) and CS2CO3 (4.38 g, 13.46 mmol) in 1,4-dioxane (45 mL) at RT under N2. The resulting suspension was vacuum degassed, backfilling with N2 and stirred at 90°C for 4.5h. The mixture was then allowed to stand at RT for 16h. The mixture was then diluted with DCM (75 mL) and 10% aq. AcOH (150 mL) and the layers were separated. The aqueous layer was extracted with DCM (75 mL x 2). The combined organic solutions were washed with sat. brine (60 mL), dried (MgSCh) and concentrated. Purification by FSC (gradient: 0-8% EtOH in EtOAc) gave the title compound (0.800 g, 44 %) as an off-white solid; ‘H NMR: 1.24-1.39 (2H, m), 1.71 (2H, d), 1 .76-1.9 (1H, m), 1.9-2.04 (1H, m), 2.26-2.43 (1H, m), 2.58 (1H, td), 2.73-3.02 (3H, m), 3.27 (1H, s), 3.28 (6H, s), 3.89 (2H, d), 4.20 (1H, d), 4.32 (1H, d), 5.04 (1H, dd), 7.04 (2H, d), 7.50 (1H, d), 10.92 (1H, s); m / z ES+, [M+H]+= 402. dol-5-yllpiperidin-4-
[1072] Intermediate 40a was reacted with Intermediate 40b using the general synthetic method illustrated by Example 1 to give the title compound after purification by preparative SFC (Column: DAICEL DCpak P4VP, 20mm*250mm, 5|im; Mobile Phase A:CC>2, Mobile Phase BMeOH— HPLC; Flow rate:50 mL / min;
[1073] Gradient:45% B; 254 nm; RT1 :5.67; Injection Volumn: 1 mL; Number Of Runs:5); *H NMR: (300 MHz) 1.09- 1.21 (2H, m), 1.52-1.68 (4H, m), 1.70-2.02 (8H, m), 2.10-2.44 (5H, m), 2.54-3.14 (9H, m), 3.87 (2H, d), 4.12- 4.25 (3H, m), 4.26-4.39 (2H, m), 5.05 (1H, dd), 6.82-6.93 (2H, m), 7.04 (2H, d), 7.12-7.18 (2H, m), 7.25-7.35 (2H, m), 7.50 (1H, d), 7.82 (1H, d), 10.94 (1H, s); m / z ES+[M+H]+ = 769.4. i-3,6-di
[1074] PdC12(dppf) (7.39 g, 10.10 mmol) was added to 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-3,6-dihydro- 2H-pyridine-l -carboxylic acid benzyl ester (3.47 g, 10.10 mmol), 4-bromo-l-iodo-2-methylbenzene (3.00 g, 10.10 mmol) and K2CO3 (4.19 g, 30.31 mmol) in 1,4-dioxane (20 mL) and water (5 mL) at RT under N2. The resulting solution was stirred at 80°C for 4h. The mixture was then diluted with EtOAc (50 mL). This solution was washed with water (20 mL x 3) then sat. brine (20 mL x 2), dried (Na2SO4) and concentrated. Purification by FSC (gradient: 0-30% EtOAc in petroleum ether) gave the title compound (2.00 g, 51%) as a pale yellow solid; ‘H NMR (300 MHz) 2.21 (3H, s), 2.21-2.33 (2H, m), 3.59 (2H, d), 4.01 (2H, d), 5.11 (2H, s), 5.58 (1H, s), 7.02 (1H, d), 7.25-7.36 (2H, m), 7.33-7.43 (5H, m); m / z ES+[M+H]+ = 388. i-2-methylphenyl)-3,6-
[1075] Rockphos Pd G3 (0.217 g, 0.26 mmol) was added to benzyl 4-(4-bromo-2-methylphenyl)-3,6-dihydro- pyridine-l(277)-carboxylate (1.00 g, 2.59 mmol), 4-((tert-butyldimethylsilyl)oxy)butan-l-ol (0.794 g, 3.88 mmol) and CS2CO3 (2.53 g, 7.77 mmol) in 1,4-dioxane (1 mL) at RT under N2. The resulting solution was stirred at 100°C for 12h and then concentrated. Purification by flash C18-flash chromatography (gradient: 0- 100% MeCN in water) gave the title compound (0.700 g, 53 %) as a yellow solid; *H NMR (300 MHz) 0.02 (6H, s), 0.84 (9H, d), 1.49-1.64 (2H, m), 1.66-1.78 (2H, m), 2.17 (3H, s), 2.22-2.36 (2H, m), 3.31 (2H, s), 3.62 (2H, t), 3.92 (2H, t), 4.01 (2H, q), 5.11 (2H, s), 5.50 (1H, s), 6.67 (1H, dd), 6.72 (1H, d), 6.95 (1H, d), 7.35- 7.39 (5H, m); m / z ES+[M+H]+ = 510.
[1076] A mixture of benzyl 4-(4-(4-((tert-butyldimethylsilyl)oxy)butoxy)-2-methylphenyl)-3,6-dihydropyridine- l(277)-carboxylate (600 mg, 1.18 mmol) and platinum (IV) oxide hydrate (60 mg, 0.24 mmol) in EtOAc (10 mL) was stirred under H2 (20 atm) at 80°C for 1 Oh. The mixture was then filtered through celite pad and the filtrate was concentrated to give the title compound (460 mg, 103%); m / z ES+[M+H]+ = 378. idin-l-vl)-2-
[1077] CS2CO3 (518 mg, 1.59 mmol) was added to 4-(4-(4-(( tert- butyldimethylsilyl )oxy)butoxy)-2-methylphenyl )- piperidine (200 mg, 0.53 mmol) and 4-fhioro-2-(trifhioromethyl)benzonitrile (150 mg, 0.79 mmol) in DMSO
[1078] (5 mL) at RT under air. The resulting solution was stirred at 60°C for 2h and then concentrated. Purification by flash C18-flash chromatography (gradient: 10-100% MeCN in water) gave the title compound (0.125 g, 43%) as a white solid; >H NMR (CD3OD, 300 MHz) 0.82 (6H, s), 1.65 (9H, s), 2.30-2.45 (4H, m), 2.44-2.60 (4H, m), 3.09 (3H, s), 3.74 (1H, t), 3.87 (2H, t), 4.42 (2H, t), 4.71 (2H, t), 4.98 (2H, d), 7.47 (1H, dd), 7.51 (1H, d), 7.84 (1H, d), 8.06 (1H, dd), 8.12 (1H, d), 8.61 (1H, d); Wz ES+[M+H]+ = 547.
[1079] Intermediate 41e: 4-(4-(4-(4- in-l-yD-2-i benzonitrile
[1080] 4-(4-(4-(4-((tert-Butyldimethylsilyl)oxy)butoxy)-2-methylphenyl)piperidin-l-yl)-2- (trifluoromethyl)benzonitrile (90 mg, 0.16 mmol) was added to tetra-w-butylammonium fluoride (86 mg, 0.33 mmol) in THF (2 mL) at RT and the mixture was stirred for 16h, then concentrated. The residue was diluted with DCM (250 mL). This solution was washed with water (30 mL) then sat. brine (50 mL), dried (Na2SO4) and concentrated to give the title compound (0.085 g, 119 %); 'H NMR: 1.51-1.58 (2H, m), 1.61 (2H, dd), 1.71 (2H, dd), 1.77 (2H, d), 2.31 (3H, s), 2.95 (1H, ddd), 3.08 (2H, t), 3.40-3.50 (2H, m), 3.91 (2H, t), 4.19 (2H, d), 4.43 (1H, t), 6.69 (1H, dd), 6.73 (1H, d), 7.05 (1H, d), 7.27 (1H, dd), 7.33 (1H, d), 7.82 (1H, d); m / z ES+[M+H]+= 433.2.
[1081] Intermediate 41f: 4-(4-(4-(4-Bromobutoxy)-2-methylphenyl)piperidin-l-yl)-2-(trifluoromethyl)- benzonitrile
[1082] 4-(4-(4-(4-Hydroxybutoxy)-2-methylphenyl)piperidin-l-yl)-2-(trifluoromethyl)benzonitrile (80.0 mg, 0.18 mmol) was added to ITh;, (97.0 mg, 0.37 mmol) and CBr i (123 mg, 0.37 mmol) in DCM (2 mL) at RT and the mixture was stirred for 3h, then concentrated. Purification by FSC (gradient: 0-30% EtOAc in petroleum ether) gave the title compound (0.075 g, 82 %) as a colourless gum; *H NMR (300 MHz) 1.59 (2H, qd), 1.68- 1.85 (4H, m), 1.93 (2H, dtd), 2.29 (3H, s), 2.88-2.99 (1H, m), 3.06 (2H, t), 3.58 (2H, t), 3.93 (2H, t), 4.17 (2H, d), 6.68 (1H, dd), 6.72 (1H, d), 7.04 (1H, d), 7.25 (1H, dd), 7.31 (1H, d), 7.80 (1H, d); rn z HS [M+H]+ = 495.2. ZT-isoindol-5-yllpiperazin-l-
[1083] Intermediate 2c was reacted with Intermediate 41 f using the general synthetic method illustrated by Example 5 to give the title compound after purification by preparative TLC (eluent: DCMMeOH, 10:1); *H NMR: 1.54- 1.67 (4H, m), 1.69-1.78 (4H, m), 1.92-2.01 (1H, m), 2.31 (3H, s), 2.31-2.44 (3H, m), 2.54-2.62 (1H, m), 2.84- 2.98 (2H, m), 3.07 (2H, t), 3.23-3.31 (8H, m), 3.95 (2H, t), 4.14-4.25 (3H, m), 4.33 (1H, d), 5.04 (1H, dd), 6.70 (1H, dd), 6.74 (1H, d), 7.02-7.08 (3H, m), 7.26 (1H, dd), 7.32 (1H, d), 7.52 (1H, d), 7.81 (1H, d), 10.93 (1H, s); m / z ES+[M+H]+ = 743.6. isoindol-5-
[1084] Intermediate 2b was reacted with Intermediate 3 c using the general synthetic method illustrated by Example 1 to give the title compound after purification by preparative SFC (Column: Triart Diol-NP, 20*250mm, 5|im; Mobile Phase A:CC>2, Mobile Phase B:IPA (0.2% Et2NH); Flow rate:50 mL / min; Gradient:40% B); *H NMR: 0.79-0.88 (2H, m), 0.97-1.08 (2H, m), 1.15-1.28 (3H, m), 1.49-1.74 (3H, m), 1.80 (4H, d), 1.96 (1H, d), 2.01- 2.12 (1H, m), 2.21 (2H, d), 2.28-2.43 (1H, m), 2.52-2.67 (5H, m), 2.82-2.97 (3H, m), 3.23-3.32 (6H, m), 3.61 (2H, d), 4.02 (2H, d), 4.20 (1H, d), 4.33 (1H, d), 5.00-5.09 (1H, m), 6.45 (1H, d), 6.81-6.89 (3H, m), 7.02-7.10 (4H, m), 7.44-7.56 (2H, m), 10.95 (1H, s); m / z ES+[M+H]+ = 726.5.
[1085] Example 43: 2-Cvclopropyl-4-f4-[4-(4-f4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihvdro-l / T-isoindol-5- in-1-'
[1086] Intermediate 2c was reacted with Intermediate 14b using the general synthetic method illustrated by Example 5 to give the title compound after purification by flash Cl 8-flash chromatography (gradient 0-37% MeCN in water) and further purification by preparative Prep-SFC (Column: GreenSep Basic; Mobile Phase A:CO2, Mobile Phase BMeOH (8mmol / L NI E.MeOH )— EIPLC; Flow rate:50 mL / min; Gradient:50% B); *H NMR: (300 MHz) 0.79-0.88 (2H, m), 1.00-1.09 (2H, m), 1.60 (2H, qd), 1.71-1.88 (6H, m), 1.92-2.14 (2H, m), 2.32- 2.48 (2H, m), 2.56-2.78 (2H, m), 2.83-2.97 (4H, m), 3.09-3.24 (5H, m), 3.49-3.73 (2H, m), 3.92-4.10 (5H, m), 4.19-4.40 (2H, m), 5.07 (1H, dd), 6.46 (1H, d), 6.83-6.90 (3H, m), 7.11-7.19 (4H, m), 7.48 (1H, d), 7.59 (1H, d), 10.96 (1H, s); m / z ES+[M+H]+ = 701.4. Intermediate 44a: 2-Hvdrazineyl-4-iodopyridine
[1087] Hydrazine monohydrate (1.23 g, 24.66 mmol) was added to 2-fluoro-4-iodopyridine (5.50 g, 24.66 mmol) in EtOH (50 mL) at RT under air and the mixture was stirred for 2 days. Water was then added and a solid collected by filtration to give the title compound (4.30 g, 74 %) as a pale yellow solid; *H NMR (300 MHz) 4.15 (2H, s), 6.85 (1H, dd), 7.11 (1H, d), 7.58 (1H, s), 7.65 (1H, d); m / z ES+[M+H]+ = 236.
[1088] Intermediate 44b: 7-Iodo-[l,2,41triazolo[4,3-a1pyridin-3(2 / D-one
[1089] CDI (4.45 g, 27.44 mmol) was added to 2-hydrazineyl-4-iodopyridine (4.30 g, 18.30 mmol) in MeCN (40 mL) at RT under air. The resulting solution was stirred at 60°C for 17h. The mixture was then filtered (with suction) and the solid was washed with MeCN to give the title compound (4.40 g, 92 %) as a pale yellow solid; *H NMR (300 MHz) 6.74 (1H, dd), 7.58 (1H, dd), 7.75 (1H, t), 12.47 (1H, s); m / z ES+[M+H]+ = 262.
[1090] Intermediate 44c: tert- Butyl 4-(3-oxo-2,3-dihvdro-[l,2,41triazolo[4,3-a1pyridin-7-yl)piperazine-l- carboxylate
[1091] RuPhos Pd G3 (0.481 g, 0.57 mmol) was added to 7-iodo-[l,2,4]triazolo[4,3-a]pyridin-3(2 / / )-one (1.5g, 5.75 mmol), tert-butyl piperazine- 1 -carboxylate (2.14 g, 11.49 mmol) and sodium 2-methylpropan-2-olate (1.66 g, 17.24 mmol) in / BuOH (10 mL) at RT under N2. The resulting solution was stirred at 100°C for 3h then concentrated. Purification by FSC (gradient: 0-10% MeOH in DCM) gave the title compound (1.50 g, 82 %) as a yellow solid; >H NMR (300 MHz) 1.40 (9H, s), 3.20 (4H, dd), 3.41 (4H, t), 6.11 (1H, d), 6.58 (1H, dd), 7.63 (1H, d); m / z ES+[M+H]+ = 320.
[1092] Intermediate 44d: tert-Butyl 4-(2-(2, 6-dioxopiperidin-3-yl )-3-oxo-2,3-dih vdro-[l, 2, 4ltriazolo [4,3- al pyridin-7-yl)piperazine-l -carboxylate NaH (0.095 g, 3.95 mmol)(60%) was added to tert-butyl 4-(3-oxo-2,3-dihydro-[l,2,4]triazolo[4,3-a]pyridin-7- yl)piperazine-l -carboxylate (1.05 g, 3.29 mmol) in DMF (10 mL) at RT under N2. The resulting solution was stirred at 60°C for 0.5h. 3-Bromopiperidine-2, 6-dione (0.631 g, 3.29 mmol) was then added and the solution was stirred at 60°C for lOh and then concentrated. Purification by flash C-18 chromatography (gradient: 10- 80% MeCN in water) gave the title compound (0.600 g, 42 %) as a green solid; *H NMR (300 MHz) 1.40 (9H, s), 2.04-2.17 (1H, m), 2.48-2.62 (1H, m), 2.59-2.68 (1H, m), 2.87 (1H, ddd), 3.20-3.26 (4H, m), 3.37-3.45 (4H, m), 5.22 (1H, dd), 6.13 (1H, d), 6.66 (1H, dd), 7.72 (1H, d), 11.03 (1H, s); Wz ES+[M+H]+ = 431.
[1093] Intermediate 44e: 3-(3-Oxo-7-(piperazin-l-yl)-|l,2,4|triazolo|4,3-a|pyridin-2(3 / / )-yl)piperidine-2,6- dione tert-Butyl-4-(2-(2,6-dioxopiperidin-3-yl)-3-oxo-2,3-dihydro-[l,2,4]triazolo[4,3-a]pyridin-7-yl)piperazine-l- carboxylate (151 mg, 0.35 mmol) was added to HC1 in 1 ,4-dioxane (3 mL, 12.00 mmol) at RT and the mixture was stirred for 2h. Concentration under reduced pressure then gave the title compound (0.120 g, 104 %) as a white solid; ‘H NMR (300 MHz) 2.06-2.16 (1H, m), 2.38-2.45 (1H, m), 2.61 (1H, dt), 2.88 (1H, ddd), 3.18 (4H, s), 3.50 (4H, s), 5.24 (1H, dd), 6.28 (1H, d), 6.67 (1H, dd), 7.78 (1H, d), 9.10 (1H, s), 11.04 (1H, s); m / z ES+[M+H]+ = 331.1.
[1094] Example 44: 4-f4-[4-(3-f4-[2-(2,6-Dioxopiperidin-3-yl)-3-oxo-2,3-dihvdro[l,2,41triazolo[4,3-«1pyridin-7- yl1piperazin-l-yllpropoxy)phenyl1piperidin-l-yll-2-(trifluoromethyl)benzonitrile
[1095] Intermediate 13a was reacted with Intermediate 44e using the general synthetic method illustrated by Example 12 to give the title compound after purification by preparative TLC (eluent: DCMMeOH, 10:1); *H NMR: 1.21-1.30 (5H, m), 1.61 (2H, qd), 1.79-1.99 (4H, m), 2.08-2.17 (1H, m), 2.62 (1H, dt), 2.77 (1H, ddt), 2.88 (1H, ddd), 3.04 (2H, td), 3.10-3.19 (1H, m), 3.19-3.28 (4H, m), 3.56-3.67 (1H, m), 3.99 (2H, t), 4.17 (2H, d), 5.23 (1H, dd), 6.11 (1H, d), 6.69 (1H, dd), 6.86 (2H, d), 7.15 (2H, d), 7.27 (1H, dd), 7.32 (1H, d), 7.71 (1H, d), 7.81 (1H, d), 11.03 (1H, s); Wz ES+[M+H]+ = 717.4.
[1096] Example 45: 4-(4-f4-[4-(2-f4-[2-(2.6-Dioxopiperidin-3-yl)-l-oxo-2.3-dihvdro-l / T-isoindol-5-yl1piperazin- l-yllethyl)piperidin-l-yl1phenyllpiperidin-l-yl)-2-(trifluoromethyl) benzonitrile
[1097] Intermediate 2c was reacted with Intermediate 15f using the general synthetic method illustrated by Example 2 to give the title compound after purification by preparative TLC (eluent: DCM:MeOH, 10: 1 ): 'H NMR: (300 MHz) 1.17-1.35 (2H, m), 1.45 (3H, s), 1.62 (2H, t), 1.80 (4H, dd), 1.90-2.02 (1H, m), 2.29-2.45 (4H, m), 2.53- 2.79 (6H, m), 2.91 (1H, ddd), 3.04 (2H, t), 3.24-3.31 (5H, m), 3.61 (2H, d), 4.12-4.25 (3H, m), 4.34 (1H, d), 5.05 (1H, dd), 6.86 (2H, d), 7.03-7.13 (4H, m), 7.27 (1H, dd), 7.33 (1H, d), 7.53 (1H, d), 7.81 (1H, d), 10.95 (1H, s); m / z ES+[M+H]+ = 768.5.
[1098] Example 46: 4-(4-f4-[4-(f4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihvdro-lE7-isoindol-5-yl1piperazin-l-
[1099] Intermediate 2c was reacted with Intermediate 6d using the general synthetic method illustrated by Example 2 to give the title compound after purification by HPLC (Column A, Eluent A, Basic Work-Up A); *H NMR: 1.19-1.27 (4H, m), 1.72 (3H, dd), 1.83 (4H, t), 1.93-2.01 (1H, m), 2.23 (2H, d), 2.39 (2H, td), 2.51-2.54 (4H, m), 2.58 (1H, dd), 2.64 (2H, d), 2.81-2.97 (1H, m), 3.04 (2H, t), 3.28-3.31 (4H, m), 3.63 (2H, d), 3.72 (2H, d), 4.22 (1H, d), 4.34 (1H, d), 5.05 (1H, dd), 6.88 (2H, d), 7.03-7.14 (4H, m), 7.46 (1H, t), 7.53 (1H, d), 7.80 (1H, d), 10.92 (1H, s); m / z ES+[M+H]+ = 772.4.
[1100] Example 47: 4-[4-(4-f4-[(4-f2-[-2,6-Dioxopiperidin-3-yl1-3-oxo-2,3-dihvdro[l,2,41triazolo[4,3-«1-pyridin-
[1101] 7-yllpiperazin-l-yl)methyl1piperidin-l-yllphenyl)piperidin-l-yl1-2-(trifluoromethyl)benzonitrile
[1102] Intermediate 4c was reacted with Intermediate 44e using the general synthetic method illustrated by Example 2 to give the title compound after purification by flash Cl 8-flash chromatography (gradient: 0-40% MeCN in water (0.1% formic acid)) to give white solid which was further purified by preparative TLC (eluent: DCM:MeOH, 10:1); ‘HNMR: 1.10-1.29 (4H, m), 1.52-1.69 (3H, m), 1.81 (4H, t), 2.09-2.18 (1H, m), 2.21 (2H, d), 2.41-2.49 (4H, m), 2.61 (3H, t), 2.89 (1H, ddd), 2.98-3.10 (2H, m), 3.23-3.28 (4H, m), 3.61 (2H, d), 4.17 (2H, d), 5.23 (1H, dd), 6.11 (1H, d), 6.69 (1H, dd), 6.82-6.90 (2H, m), 7.07 (2H, d), 7.26 (1H, dd), 7.32 (1H, d), 7.71 (1H, d), 7.81 (1H, d), 11.02 (1H, s); m / z ES+[M+H]+ = 756.4.
[1103] Intermediate 48a: tert-Butyl (.S,)-3-methyl-4-(4-((( / ?.S,)-tetrahvdro-2 / / -py ran-2-yl)oxy)phenyl)piperazine- 1-carboxylate
[1104] 2-(4-Bromophenoxy)tetrahydro-2 / f-pyran (1.00 g, 3.89 mmol), tert-butyl (S)-3-methylpiperazine- 1 - carboxylate (1.17 g, 5.83 mmol), RuPhos (0.091 g, 0.19 mmol), RuPhos Pd G3 (0.163 g, 0.19 mmol) and potassium tert-butoxide (0.873 g, 7.78 mmol) were stirred in 1,4-dioxane (20 mL) and the mixture was degassed by bubbling N2. The mixture was then heated to 90°C for 2h. After cooling the mixture was partitioned between ...
Claims
CLAIMS1. A compound of Formula (I) :or a pharmaceutically acceptable salt thereof, wherein:X1is C & 0, 1 or 2 of X2, X3& X4is / are N, and are otherwise C; orX3& X4are both C and are substituted by -X5=X6-X7=XS- with Xsattached to X3and with Xsattached to Xs, where 1 or 2 of X1, X2, Xs, X6, X7& Xsis / are N, and are otherwise C:P is 1 or 2 and X1is C attached to R1when X3& X4are not substituted by -X5=X6-X7=X8-; and otherwise p is 0, 1 or 2: where: each R1is a substituent on any C atom at X1, X2, X3& X4, (or at X1, X2, Xs, X6, X7& Xswhen X3& X4are substituted by -X5=X6- X7=X8— ), and is independently selected from F, Cl, C _;,alkvl and Ci-aalkoxy, wherein said C i-aalkyl and C i-aalkoxy may be independently optionally substituted by one or more F; n is 0, 1 or 2; m is 0 or 1 ;Q is CH or N when n & m are both other than 0 and otherwise Q is CH;R2aand R2bare substituents on the same or different C atoms other than at Q, each independently selected from H, F and Ci-aalkyl, or R2a& R2btogether form a -(CH2)r- group where r is 1 , 2 or 3 ;0, 1 or 2 of Y1, Y2, Y3& Y4is / are N, and are otherwise C; each R3is a substituent on any C atom at Y1, Y2, Y3& Y4, and is independently selected from F, Cl, CN, C _;,alkvl and Ci-aalkoxy, wherein said Ci-aalkyl and C i-aalkoxy may be independently optionally substituted by one or more F; q is 0, 1 or 2;Linker is a saturated or a partially or fully unsaturated framework comprising C and H atoms and at least one heteroatom, wherein said framework has end points of attachment ‘a’ and‘b’ and a minimum length of from 6 to 26 atoms between ‘a’ and ‘b’ ; wherein said framework may include one or more straight and / or branched chains and / or rings and is optionally substituted on any available C atom(s) by one or more F; and W is an E3 ubiquitin ligase cereblon binder unit.
2. The compound of Formula (I), or pharmaceutically acceptable salt thereof, according to claim 1 wherein the Linker has the Formula: a -QA-QB-QC- b wherein:‘a’ and ‘b’ represent the end points of attachment;QAis -G-QH- or -G-(Ci.5alkylene)-;QBis a direct bond, -QB1-QB2-QB3- or Cj.vilkvlene optionally substituted by one or more F (e.g. 1 or 2); where:QB1& QB3each independently represent a direct bond or C ^alkylene;QB2is QH, -O-CH2CH2-O-, -O- or -N(RJ)- where RJis H or Ci.3alkyl;Qcis -QH-G- or -(Ci-5alkylene)-G-; each G is independently a direct bond, -CH2-, -O-, or -N(RG)- where RGis H or Ci.3alkyl; each QHis independently a 4-12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group; where the values of QA, QBand Qcare selected so that the Linker does not contain any N-N or N-O bonds.
3. The compound of Formula (I), or pharmaceutically acceptable salt thereof, according to claim 2 wherein QB2is QH, -O-CH2CH2-O- or -N(RJ)- where RJis Ci-jalkyl.
4. The compound of Formula (I), or pharmaceutically acceptable salt thereof, according to claim 2 or claim 3 wherein Qcis -QH-G- or -(Ci-2alkylene)-G-.
5. The compound of Formula (I), or pharmaceutically acceptable salt thereof, according to any one of claims 2 to 4, wherein each QHis independently selected from piperazin- 1,4-diyl, azetidin-l,3-diyl, piperidin-l,4-diyl, 1 ,4-diazepan- 1,4-diyl, 12-oxa-3,9-diazaspiro[5.6]dodecan-3,9-diyl, pyrrolidin-1,3- diyl, 3,9-diazaspiro[5.5]undecan-3,9-diyl, 2,5-diazabicyclo[2.
2. l]heptan-2,5-diyl, 1 , 3, 3a, 4, 6,6a- hexahydropyrrolo[3,4-c]pyrrol-2,5-diyl, 3.6-dihvdro-2 / / -pvridin- 1 .4-divl and 9-azaspiro[5.5]undecan- 3,9-diyl.
6. The compound of Formula (I), or pharmaceutically acceptable salt thereof, according to claim 1 , wherein the Linker is selected from any of Linkers 1 to 46 or 1 to 48:The compound of Formula (I), or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 6, wherein W is W1 which is: -Z-(RA)h where Z is:wherein: represents a single covalent bond or a double covalent bond;0, 1 or 2 of XA, XB, Xc, XD, XE& XFis / are N, where XE& XEare not both N, and are otherwise C; 1 of XG, XH& XJis C(O);1 ofXG, XH& XJis N-(2,6-dioxopiperidin-3-yl) (Y); and1 ofXG, XH& XJis selected from C(RT)2, -CH2CH2-, C(O), N(Ci.3alkyl), -O- and -N=, wherein each RTis selected from H, F, Me or together with the carbon of C(RT)2forms a cycloprop- 1 , 1 -diyl group ; where XG, XH& XJare selected such that there are not two C(O) groups present at adjacent positions, and that the N-(2,6-dioxopiperidin-3-yl) is not at an adjacent position to either N(Ci-3alkyl) or O: each RAis independently a substituent on any available C atom at XA, XB, Xcor XDselected from F, Cl, Ci-jalkyl, Ci-salkoxy wherein said Ci-salkyl and Ci-salkoxy is independently optionally substituted by one or more F; h is 0, 1 or 2; and wherein the Linker is attached to any C atom at XA, XB, Xcor XD. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, according to claim 7 where each RAis a substituent on any available C at XA, XB, Xcor XDselected from F, Cl andC i-aalkoxy optionally substituted by one or more F. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, according to claim 7 or statement 22 where XG-XH-XJis:(i) XG-NY-C(O) where XGis -CH2-, -CH2CH2-, =N- or C(O);(ii) XG-C(O)-NY where XGis -O- or N(Ci-3alkyl); or(iii) C(O)-NY-CH2. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 6 where W is any one of groups 1 to 21 :
11. The compound of Formula (I), or a pharmaceutically acceptable salt thereof, according to any one ofclaims 1 to 6, wherein W is W2 which isZAis:wherein:* represents a single covalent bond or a double covalent bond;1 of XA2, XB2, XC2& XD2is C and covalently bound to Y ;0, 1 or 2 of XA2, XB2, XC2, XD2, XE2& XE2is / are N (where XE2& XE2are not both N) and are otherwise C;1 or 2 of XG2, XH2& XJ2is / are N; and are otherwise C; each RAAis a substituent on any available C or N atom of Z - in each case independently selected from RAAIoptionally substituted by one or more RAA2: where RAAis further selected from RAA2when RAAis a substituent on an available C atom of ZA; each RAAIis independently Ci.4alkyl, C2-3alkenyl, C2-3alkynyl,Ci-salkoxyCi-salkyl, carboxyCi-salkyl, Cj-ycarbocyclyl or a 4-6 membered heterocyclyl; each RAA2is independently selected from F, Cl, Br, CN, NH2, Chalky 1,O(Ci-3alkyl), NH(Ci-3alkyl) and N(Ci-3alkyl)2; wherein said Ci-salkyls are optionally substituted by one or more F; v is 0, 1 or 2;Y is N-(2,6-dioxopiperidin-3-yl).
12. The compound or salt thereof according to claim 11, wherein1 of XA2& XB2is C and covalently bound to Y and the other of XA2& XB2is C;0 or 1 of XC2& XD2is N and is / are otherwise C;1 of XG2& XJ2is N and the other of XG2& XJ2is C; andXH2XE2& XF2are all C.
13. The compound or salt thereof according to claim 11, wherein W is W2-1wherein:XKand XLare either N-linker and CH or NMe and C-linker respectively;1 ofXMand X° is N-(2,6-dioxopiperidin-3-yl) (Y);0 or 1 of XMand XNis C-F;XN may be N if XMis not C-F ; the remainder of XN, XMand X° are CH.
14. The compound or salt thereore according to any one of claims 1 to 6, wherein W represents any of the groups 22 to 26 shown below:
15. The compound or salt thereof, according to any one of claims 1 to 14 wherein R2aand R2bare substituents on the same or different C atoms adjacent Q.
16. The compound or salt thereof according to any one of claims 1 to 15 wherein R2aand R2bare substituents on the same or different C atoms, each independently selected from H and Ci-aalkyl.
17. The compound or salt thereof according to any one of claims 1 to 16 wherein p is 1 ; X3& X4are not substituted by -X5=X6-X7=X8-; X1, X2, X3& X4are all C and R1is a substituent on X1and is CFs.
18. The compound or salt thereof according to any one of claims 1 to 16 wherein p is 2; X3& X4are not substituted by -X5=X6-X7=X8-; X1, X2, X3& X4are all C; one R1substituent is on X1and is CFs, and the other R1substituent is on X2and is F or ethyl.
19. The compound of salt thereof according to any one of claims 1 to 18 wherein n is 1 , m is 1 , Q is CH, R2ais H and R2bis H.
20. The compound of salt thereof according to any one of claims 1 to 19 wherein Y1, Y2, Y3& Y4are all C.
21. The compound of salt thereof according to any one of claims 1 to 20 wherein q is 0.
22. The compound of salt thereof according to any one of claims 1 to 20, wherein q is 1 and R3is attached to C at Y1, and R3is selected from F, CN and Me.
23. The compound of salt thereof according to any one of claims 1 to 21 , wherein q is 2 and each R3group is F, which are attached to C at Y1and Y3.
24. The compound or salt thereof according to claim 1 which is of Formula (VI):or a pharmaceutically acceptable salt thereof, wherein:RZ1is H or F;RZ2is H or F;RZ3is H or F;Lzis a linker selected from 1, 3, 45 and 47:where Y is N-(2,6-dioxopiperidin-3-yl).
25. The compound or salt thereof according to claim 1 which is of Formula (VI-1):or a pharmaceutically acceptable salt thereof, wherein:RZ1is H or F;Lzis a linker selected from 1 and 3:and Wzis selected from 1, 2 and 10:where Y is N-(2,6-dioxopiperidin-3-yl).
26. The compound or salt thereof according to claim 1 which is of Formula (VI- 2):or a pharmaceutically acceptable salt thereof,wherein:RZ1isHorF;RZ2isHorF;RZ3is H or F; Lzis a linker selected from 3, 45 and 47 :and Wzis selected from 1, 3, 16, 22, 23, 24 and 26:where Y is N-(2,6-dioxopiperidin-3-yl).
27. A pharmaceutical composition, which comprises a compound of Formula (I) or a pharmaceutically acceptable salt thereof according to one of claims 1 to 26, in association with a pharmaceutically acceptable excipient.
28. A compound of Formula (I) or a pharmaceutically acceptable salt thereof according to one of claims 1 to 26 or a pharmaceutical composition according to claim 24, for use in the prevention or treatment of tumour types that are sensitive to degradation of androgen receptors or for use in the treatment of prostate cancer (for example castrate-resistant prostate cancer (CRPC), for example metastatic CRPC)).
